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ABSTRACT 
Polycystic ovary syndrome (PCOS) is the most common form of infertility 
among women of reproductive age. Despite the prevalence of PCOS, the underlying 
mechanisms behind how PCOS arises and causes infertility remain poorly understood. 
While primarily considered a disorder of the ovary, a growing body of evidence suggests 
that PCOS is associated with dysfunctional neuroendocrine circuitry in the hypothalamus 
that orchestrates gonadotrophin hormone secretion. Women with PCOS frequently 
exhibit rapid pulsatile luteinizing hormone (LH) secretion. While LH secretion is tightly 
regulated by ovarian steroid hormonal feedback in fertile women, women with PCOS are 
unresponsive to these hormones. Elevated LH secretion likely reflects dysfunctions to 
the gonadotropin-releasing hormone (GnRH) neuronal network in the hypothalamus that 
gates LH secretion and integrates steroid hormone feedback. As GnRH neurons 
themselves do not express the receptors necessary for feedback to occur, research has 
sought to identify alterations to GnRH neural afferents that may arise in PCOS.  
Prior work within our lab has utilized a prenatal androgen (PNA) treated mouse 
model of PCOS to identify enhancement of excitatory GABAergic inputs to GnRH 
neurons. In particular, GABA neurons in the hypothalamic arcuate nucleus (ARN) have 
been identified with enhanced input to GnRH neurons, and reduced sensitivity to an 
ovarian steroid hormone, progesterone. Neuropeptide Y (NPY) neurons compose a large 
proportion of GABA neurons within the ARN, and are known to play an important role 
in restraint of LH secretion via inhibition of GnRH neurons. Interestingly, plasma NPY 
is often reduced in women with PCOS, indicating impairment of its neural secretion. The 
overarching aim of work presented in this thesis was therefore to determine whether 
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NPY neurons within the ARN also exhibit PNA-induced alterations, which may advance 
our understanding of how unrestrained LH secretion occurs in PCOS. 
Initially, the proportion of NPY neurons that are GABAergic within the ARN was 
assessed by pairing immunohistochemical (IHC) labelling of NPY with transgenic 
reporter identification of GABA neurons, in both PNA-treated mice and fertile controls. 
Additionally, the molecular identity of ARN GABA neurons was further dissected to 
assess whether they express other peptides known to regulate GnRH neurons. This work 
established that ARN NPY neurons compose approximately one-third of ARN 
GABAergic neurons, a far larger proportion than any other neural phenotype examined, 
and demonstrated that the vast majority (> 93%) of ARN NPY neurons are GABAergic. 
While fertile male mice were observed to have a larger population of ARN NPY neurons 
compared with both fertile (p = 0.0006) and PNA-treated females (p = 0.0192), no 
differences were found between female groups, indicating the size of this population is 
not masculinized by PNA-treatment.  
To investigate remodelling of NPY neurons in the ARN specifically, the validity 
of an agouti-related peptide (AgRP)-Cre mouse line was characterised as AgRP is highly 
co-expressed with NPY, and exclusively expressed in the ARN. After crossing AgRP-
Cre mice onto a Cre-dependant tGFP reporter it was demonstrated that within the ARN, 
GFP reporter was highly specific and effective at identifying NPY neurons. Additionally, 
GFP expression was overwhelmingly confined to the ARN only. Whole brain mapping 
of axon-associated tGFP expression revealed that this reporter was highly effective for 
visualising distal axons. In order to assess whether ARN NPY neurons projecting to 
GnRH neurons could be targeted more specifically, a fluorescent retrograde tracer was 
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injected into the preoptic area where the majority of GnRH neurons reside. This revealed 
that approximately 10% of ARN NPY neurons project to the area where GnRH neurons 
are located, and that these neurons are scattered throughout the ARN rather than 
composing an anatomically defined population. These experiments demonstrated that 
AgRP-tGFP mice are an appropriate model for further dissection of ARN NPY neurons.  
Using this model, the hypothesis that PNA exposure leads to remodelling of ARN 
NPY sensitivity to steroid hormones, and their projections to GnRH neurons was 
addressed. Interestingly, ARN NPY neurons did not express the progesterone receptor or 
estrogen receptor a. However, a greater proportion of ARN NPY neurons expressed 
androgen receptor (AR) in PNA mice compared with fertile controls (p = 0.045). When 
close appositions between ARN NPY axons and GnRH neurons was examined, 
indicating putative innervation, it was revealed that there were no differences in the close 
appositions onto GnRH neurons in the PNA-treated mouse. Overall, these results suggest 
that ARN NPY neurons are not remodelled in the same way as ARN GABA neurons, but 
are subject to their own distinct alterations in PNA-treated mice in the form of elevated 
androgen sensitivity. 
The role of leptin, a major regulator of ARN NPY neurons and permissive cue in 
fertility, was then examined in PNA-treated mice compared to fertile controls. Plasma 
leptin was measured in fed and fasted states, and there were no differences in leptin levels 
in PNA-treated mice. Interestingly, fasting reduced plasma leptin in PNA-treated mice 
similar to controls, contrasting previous findings indicating derangements to fasted leptin 
levels. Furthermore, leptin responsiveness indicated by induction of pSTAT3 was not 
different in PNA-treated mice. These results indicate that leptin signalling in the ARN is 
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normal in PNA-treated mice and leptin acting within this region is not likely to contribute 
to altered GnRH neuron activity.  
While ARN NPY neurons and circuitry were found to be largely unaffected by 
PNA-treatment, a sensitive NanoString assay for gene expression revealed evidence for 
potential reductions in downstream signalling within hypothalamic regions important for 
GnRH neural regulation. Expression of the NPY Y1 receptor was downregulated in the 
rostral periventricular region of the third ventricle, a region important for generating the 
preovulatory LH surge. Additionally, a sizable reduction in leptin receptor gene 
expression was observed in the preoptic area in the vicinity of GnRH neurons, an area in 
which leptin signalling plays a role in regulating LH secretion. 
Taken together these results do not support the hypothesis that alterations within 
ARN NPY-to-GnRH neuron circuitry plays a major role underpinning neuroendocrine 
disruption in PNA-treated mice and PCOS. While ARN NPY neurons do not appear to 
compose a subset of ARN GABA neurons that are remodelled following PNA-treatment, 
elevated androgen sensitivity was identified. As androgens disrupt negative feedback in 
PCOS, this opens up the possibility that androgens act via ARN NPY neurons to disrupt 
appropriate response by other steroid hormone sensitive afferent populations. 
Differences in NPY receptor expression were discovered in hypothalamic regions 
important for regulation of GnRH neurons, and potentially indicates altered NPY 
signalling within the GnRH afferent network. These findings establish a platform upon 
which future research will elucidate the importance of these circuit alterations in 




The journey that I have gone through in order to complete this thesis has 
undoubtedly been the most difficult undertaking in my life so far, and I owe deep 
gratitude to everyone who has helped and guided me along the way – without all of you 
this would not have been possible. First and foremost, I have to extend my heartfelt 
thanks to my supervisor and mentor, Dr Rebecca Campbell. From those very first 
undergraduate lectures through to now you have been an inspiration both as a scientist 
and as a person. Owing to both your kindness and wisdom I have achieved what at times 
felt like an insurmountable task, and I feel truly blessed to have worked with you. 
I sincerely thank all past and present Campbell Lab members for not only 
knowledge and guidance, but also shared laughs and banter. I must especially thank Mel 
Prescott for being the glue that keeps the lab together and running smoothly. I would also 
like to thank Dr Elodie Desroziers, Dr Eulalia Coutinho, Dr Joe Yip, Dr Aleisha Moore, 
Dr Mauro da Silva, Dr Chris Coyle, Georgina Abbott, Bradley Jamieson, Sarah Holland, 
Aisha Sati and Amy Ruddenklau for all the help and shared good times. My gratitude 
also goes out to my past and present advisory committee members, Dr Ruth Empson, Dr 
Greg Anderson, and Dr Allan Herbison; your input and advice has been invaluable. Ruth, 
your kindness in particular has been greatly appreciated through the more difficult 
periods over this journey. 
I, of course, need to also extend my love and gratitude to all the friends who were 
with me from the start and those I have made along the way, in no particular order, Lex, 
Dean, Ian, Hannah, Brandon, Alisa, Tony, Felix, Xander, Aaron, Gorman, India, 
 vii 
Kristina, Coyle, Georgina, Aleisha, Bradley, Jule, and Libby – thank you all for your 
support over the years!  
Lastly I need to give my love to my family, I could not have done this without 
any of you and know that you’re there celebrating right alongside me.   
 viii 
TABLE OF CONTENTS 
A B S T R A C T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  I I 	
A C K N O W L E D G E M E N T S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  V I 	
TABLE OF CONTENTS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  V I I I 	
LIST OF FIGURES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  X I V 	
LIST OF TABLES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  X V I I 	
LIST O F ABBREVIATIONS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  X V I I I 	
1 	 LITERATURE REV IEW  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 	
1.1	 Preface ............................................................................................................. 2	
1.2	 Polycystic ovary syndrome ............................................................................ 3	
1.2.1	 Definition and prevalence ....................................................................... 3	
1.2.1.1	 Hyperandrogenism ........................................................................................... 5	
1.2.1.2	 Ovulatory dysfunction and polycystic ovarian morphology ............................ 7	
1.2.1.3	 Neuroendocrine abnormalities ........................................................................ 8	
1.2.2	 Aetiology ................................................................................................ 12	
1.2.2.1	 Genetic heritability ........................................................................................ 12	
1.2.2.2	 Link to metabolic syndrome ........................................................................... 13	
1.2.2.3	 Early androgen exposure ............................................................................... 14	
1.2.3	 Animal models of PCOS ....................................................................... 15	
1.2.3.1	 Non-Human Primate ...................................................................................... 16	
1.2.3.2	 Rodent ............................................................................................................ 17	
1.3	 The hypothalamic-pituitary-gonadal axis ................................................. 22	
1.3.1	 Overview ................................................................................................ 22	
1.3.2	 The gonadotrophin-releasing hormone neuron .................................. 22	
1.3.2.1	 Distribution and development ........................................................................ 22	
1.3.2.2	 Morphology .................................................................................................... 25	
1.3.2.3	 Pulsatile GnRH release at the median eminence drives gonadotrophin 
secretion 27	
1.3.3	 Gonadal steroid hormone mediated feedback ...................................... 28	
1.3.3.1	 Estradiol ......................................................................................................... 31	
1.3.3.2	 Progesterone .................................................................................................. 32	
1.3.3.3	 Androgens ...................................................................................................... 33	
1.3.4	 Neural mediation of GnRH neurons .................................................... 35	
 ix 
1.3.4.1	 Glutamate ....................................................................................................... 35	
1.3.4.2	 Kisspeptin ....................................................................................................... 38	
1.3.4.3	 GABA ............................................................................................................. 41	
1.3.4.4	 Neuropeptide Y, a potential integrator of reproductive and metabolic cues . 45	
1.4	 The PNA mouse elucidates circuit alterations that may underpin 
neuroendocrine derangement in PCOS ..................................................................... 53	
1.5	 Summary, aims and hypotheses ................................................................. 56	
2 	 GENERAL METHODS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58 	
2.1	 Animals ......................................................................................................... 59	
2.2	 Prenatal androgen exposure ....................................................................... 59	
2.3	 Estrous cycle monitoring ............................................................................. 60	
2.4	 Blood sampling ............................................................................................. 60	
2.5	 Stereotaxic surgery ...................................................................................... 61	
2.6	 Tissue collection and preparation .............................................................. 62	
2.6.1	 Unfixed frozen brain tissue .................................................................. 62	
2.6.2	 Fixed brain tissue .................................................................................. 63	
2.7	 Immunohistochemistry ................................................................................ 64	
2.7.1	 Generic single and double-label fluorescent immunohistochemistry . 64	
2.7.2	 Single-label chromogenic GFP immunohistochemistry ..................... 64	
2.7.3	 Antibody controls .................................................................................. 65	
2.8	 RNA purification .......................................................................................... 65	
2.9	 Microscopy and image analysis .................................................................. 66	
2.9.1	 Anatomical division of the arcuate nucleus ......................................... 67	
2.10	 Statistical analysis ........................................................................................ 69	
3 	 D E F I N I N G  T H E  MOLECULAR IDENTITY O F 
A R C U A T E  N U C L E U S  G A B A N E U R O N S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  70 	
3.1	 Introduction .................................................................................................. 71	
3.2	 Methods ......................................................................................................... 74	
3.2.1	 Animals .................................................................................................. 74	
3.2.1.1	 Prenatal androgen treatment ......................................................................... 74	
3.2.2	 Intracerebroventricular colchicine injections and tissue collection ... 74	
3.2.3	 Single-label immunohistochemistry ..................................................... 75	
3.2.4	 Confocal microscopy ............................................................................. 76	
3.2.5	 Analysis ................................................................................................. 77	
 x 
3.2.5.1	 Image analysis ............................................................................................... 77	
3.2.5.2	 Statistical analysis ......................................................................................... 77	
3.3	 Results ........................................................................................................... 78	
3.3.1	 Identifying ARN GABA neurons and co-expressed neurotransmitters
 78	
3.3.2	 Kisspeptin and β-endorphin are not highly co-expressed in ARN 
GABA neurons .............................................................................................................. 81	
3.3.3	 GABA and NPY are highly co-expressed in the ARN ......................... 82	
3.3.4	 Co-localization of both TH-ir and nNOS-ir in ARN GABA neurons is 
sexually dimorphic ........................................................................................................ 83	
3.4	 Discussion ..................................................................................................... 86	
3.4.1	 Kisspeptin and β-endorphin are predominantly not GABAergic ........ 87	
3.4.2	 Sexually dimorphic co-localisation of TH and GABA ........................ 89	
3.4.3	 Identification of GABAergic nNOS neurons in the hypothalamus .... 90	
3.4.4	 Abundant co-expression of NPY and GABA in the ARN ................... 91	
4 	 V A L I D A T I O N  O F  T H E  A GR P- C R E  M O U S E  F O R  
GENETIC TARGETING OF  A R N  N P Y  N E U R O N S . . . . . . . . . . . . . . . . . .  93 	
4.1	 Introduction .................................................................................................. 94	
4.2	 Methods ......................................................................................................... 95	
4.2.1	 Animals .................................................................................................. 95	
4.2.2	 Experiment 1: Assessing the specificity of tGFP reporter .................. 95	
4.2.2.1	 Intracerebroventricular injection of colchicine ............................................. 95	
4.2.2.2	 Double-label fluorescent immunohistochemistry .......................................... 96	
4.2.2.3	 Image acquisition and analysis ...................................................................... 96	
4.2.3	 Experiment 2: Mapping of ARN NPY axon projections throughout the 
brain using tGFP .......................................................................................................... 97	
4.2.3.1	 Single label chromogenic immunohistochemistry ......................................... 97	
4.2.3.2	 Mapping of ARN NPY fibre projections ......................................................... 98	
4.2.4	 Experiment 3: Assessing the distribution and proportion of ARN NPY 
neurons projecting to the preoptic area ....................................................................... 98	
4.2.4.1	 Injection of fluorescent RetroBeads into the preoptic area ........................... 98	
4.2.4.2	 Single label fluorescent immunohistochemistry ........................................... 100	
4.2.4.3	 Image acquisition and analysis .................................................................... 100	
4.2.5	 Descriptive statistics ............................................................................ 101	
4.3	 Results ......................................................................................................... 102	
 xi 
4.3.1	 Validation of AgRP-τGFP specificity ................................................. 102	
4.3.2	 ARN NPY projections throughout the brain ...................................... 105	
4.3.3	 Distribution of ARN NPY neurons projecting to the rPOA .............. 115	
4.4	 Discussion ................................................................................................... 118	
4.4.1	 Axon-localised τGFP demonstrates ARN NPY neurons project widely 
throughout the brain, including to GnRH neuron afferent regions ......................... 119	
4.4.2	 ARN NPY neurons projecting to the rostral preoptic area are scattered 
throughout the ARN ................................................................................................... 121	
4.4.3	 Summary ............................................................................................. 122	
5 	 EXAMINING ALTERATION S  T O  T H E  A R N  N P Y- TO-
GNRH NEURAL CIRCUIT I N  P N A  M I C E . . . . . . . . . . . . . . . . . . . . . . . . . . .  123 	
5.1	 Introduction ................................................................................................ 124	
5.1.1	 Aims and hypotheses ........................................................................... 127	
5.2	 Methods ....................................................................................................... 128	
5.2.1	 Animals ................................................................................................ 128	
5.2.2	 Experiment 1: Assessing steroid hormone receptor expression in ARN 
NPY neurons 128	
5.2.2.1	 Double label fluorescent immunohistochemistry ......................................... 128	
5.2.2.2	 Image acquisition and analysis .................................................................... 129	
5.2.3	 Experiment 2: Assessing putative innervation of GnRH neurons by 
ARN NPY neurons ...................................................................................................... 129	
5.2.3.1	 Double-label fluorescent immunohistochemistry ........................................ 129	
5.2.3.2	 Image acquisition ......................................................................................... 130	
5.2.3.3	 Image analysis ............................................................................................. 130	
5.2.4	 Statistical analysis ............................................................................... 131	
5.3	 Results ......................................................................................................... 133	
5.3.1	 Assessing steroid hormone receptor expression in ARN NPY neurons 
in PNA mice 133	
5.3.1.1	 Progesterone receptor ................................................................................. 133	
5.3.1.2	 Estrogen receptor alpha .............................................................................. 135	
5.3.1.3	 Androgen receptor ....................................................................................... 137	
5.3.2	 Examining putative ARN NPY innervation to GnRH neurons in PNA 
mice 141	
5.4	 Discussion ................................................................................................... 144	
5.4.1	 ARN NPY neurons do not express nuclear estrogen or progesterone 
receptors 144	
 xii 
5.4.2	 A greater proportion of ARN NPY neurons express androgen 
receptors in PNA mice ................................................................................................ 146	
5.4.3	 The ARN NPY to GnRH neuron circuit does not appear to be 
remodelled by PNA treatment ..................................................................................... 148	
5.4.4	 Summary ............................................................................................. 150	
6 	 A S S E S S I N G  A R N  N P Y  N EU R O N  L E P T I N  S E N S I T I VI T Y  
I N  T H E  P N A  M O U S E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  152 	
6.1	 Introduction ................................................................................................ 153	
6.2	 Methods ....................................................................................................... 156	
6.2.1	 Animals ................................................................................................ 156	
6.2.2	 Leptin treatment .................................................................................. 156	
6.2.3	 Leptin ELISA ...................................................................................... 157	
6.2.4	 Immunohistochemistry ....................................................................... 158	
6.2.5	 Image acquisition and analysis .......................................................... 158	
6.2.6	 Statistical analysis ............................................................................... 159	
6.3	 Results ......................................................................................................... 160	
6.3.1	 Comparison of body weight and plasma leptin concentration .......... 160	
6.3.2	 Comparison of ARN NPY neuron leptin responsiveness using 
induction of pSTAT3 ................................................................................................... 161	
6.4	 Discussion ................................................................................................... 165	
7 	 D I S C O V E R I N G  A L T E R A T IONS IN  HYPOTHALAMIC 
GENE E X P R E S S I O N  I N  T H E  P N A MOUSE  . . . . . . . . . . . . . . . . . . . . . . . . .  168 	
7.1	 Introduction ................................................................................................ 169	
7.2	 Methods ....................................................................................................... 172	
7.2.1	 Animals ................................................................................................ 172	
7.2.2	 Tissue and RNA sample collection ..................................................... 172	
7.2.3	 NanoString design and assay ............................................................. 174	
7.2.4	 Differential gene expression analysis ................................................. 175	
7.3	 Results ......................................................................................................... 179	
7.3.1	 Differential gene expression in the rostral preoptic area .................. 179	
7.3.2	 Differential gene expression in the rostral periventricular area of the 
3rd ventricle 179	
7.3.3	 Differential gene expression in the arcuate nucleus ......................... 179	
7.4	 Discussion ................................................................................................... 181	
7.4.1	 NPY Y1 receptor gene transcription is down regulated in the RP3V of 
PNA mice 181	
 xiii 
7.4.2	 Leptin receptor expression is reduced in the rPOA of PNA mice ..... 183	
7.4.3	 Expression of the cytokine Tnf is reduced in the ARN of PNA mice 184	
7.4.4	 Gene expression in KNDy neurons appears to be unaltered in the ARN 
of PNA mice 185	
7.4.5	 Summary ............................................................................................. 186	
8 	 FINAL DISCUSSION  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  187 	
8.1	 Background and summary of findings ..................................................... 188	
8.2	 Implications of findings ............................................................................. 196	
8.2.1	 The remodelling of ARN GABA circuits is not stereotyped following 
prenatal androgen exposure ....................................................................................... 196	
8.2.2	 The ARN GABA neurons that undergo remodelling in PNA-treated 
mice have not yet been identified ................................................................................ 197	
8.2.3	 Further insight into the possible mechanism of androgen blockade of 
progesterone negative feedback .................................................................................. 199	
8.3	 Future directions ........................................................................................ 202	
8.3.1	 Assessment of androgen actions in ARN NPY neurons and blockade 
in PNA-treated mice .................................................................................................... 202	
8.3.2	 Mapping of circuit changes within the wider GnRH neuronal network 
in PNA-treated mice .................................................................................................... 204	
8.3.3	 Assessing the role of ARN NPY neurons on fertility in female mice 
using chronic inhibition ............................................................................................. 207	
8.4	 Clinical relevance of ARN NPY circuitry in PCOS ................................ 209	
8.5	 Concluding remarks .................................................................................. 211	
R E F E R E N C E S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  212 	
A P P E N D I X  I :  P R I M A R Y  A N T I B O D Y  I N F O R M A T I O N A N D  
V A L I D A T I O N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  255 	
A P P E N D I X  I I :  D E F I N I NG SUBPOPULATIONS OF A R C U A T E  
N U C L E U S  G A B A  N E U R O N S I N  M A L E ,  F E M A L E ,  A N D 
PRENATALLY ANDROGENI ZED FEMALE MICE –  FULL 
MANUSCRIPT  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  257 	
A P P E N D I X  I I I :  N A N O S TR I N G  A S S A Y  Q U A L I T Y  CONTROL
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  271 	
	 	
 xiv 
LIST OF FIGURES 
Figure 1.1 PCOS clinical phenotypes and severity of manifestation.   5 
Figure 1.2. LH secretion is increased in women with PCOS.    11 
Figure 1.3. GnRH neurons are scattered through the rostral forebrain of the adult 
mouse.           24 
Figure 1.4. GnRH and LH pulses occur concurrently.     28 
Figure 1.5. Profile of circulating steroid hormones and gonadotropins over the 
human menstrual and rodent estrous cycles.      30 
Figure 1.6. Intracellular chloride concentration determines depolarization and 
hyperpolarization following GABAA receptor activation.    45 
Figure 2.1. Anatomical divisions of the rostral, middle, and caudal ARN. 68 
Figure 3.1. Co-labelling of phenotypic markers with VGAT-tdTomato expression 
throughout the ARN.         79 
Figure 3.2. Average number of neurotransmitter- or enzyme-immunoreactive cells 
across the ARN.          80 
Figure 3.3. Percentage of co-localization of kisspeptin and β-endorphin with 
VGAT in male and female mice.        82 
Figure 3.4. Percentage of co-localization of NPY and TH with VGAT in males as 
well as VEH-treated and PNA-treated females.      85 
Figure 3.5. Summary of neuropeptides and enzymes co-localised with GABA in 
the ARN.           87 
Figure 4.1. Evaluation of RetroBead injection needle placement.   100 
Figure 4.2. NPY and GFP are highly co-localised in the ARN of AgRP-tGFP mice.        
           103 
Figure 4.3. Negligible expression of GFP outside of the ARN does not co-localise 
with NPY.           104 
Figure 4.4. Distribution of tGFP reporter expression in ARN NPY neural 
projections throughout the brain.       107 
Figure 4.5. The expression of tGFP reporter in select nuclei.   110 
Figure 4.6. A subset of ARN NPY neurons project to the preoptic area.  116 
Figure 4.7. Distribution of ARN neurons projecting to the rPOA.   117 
 xv 
Figure 5.1. Alterations in ARN NPY neurons may lead to LH hypersecretion. 127 
Figure 5.2. PR-immunoreactivity and GFP expressing NPY neurons within the 
ARN of VEH- and PNA-treated mice.       134 
Figure 5.3. Fewer cells express PR within the ARN of PNA mice, while PR 
expression is absent from NPY neurons.       135 
Figure 5.4. Distribution of ERa and NPY expression in the ARN.   136 
Figure 5.5. ERa co-expression within NPY neurons is virtually absent in both 
VEH- and PNA-treated mice.        137 
Figure 5.6. Distribution of AR and NPY expression within the ARN of VEH- and 
PNA-treated mice.          139 
Figure 5.7. Expression of AR within NPY neurons is elevated in PNA-treated 
mice.            140 
Figure 5.8. ARN NPY fibres appose GnRH neurons in the rostral preoptic area 
and anterior hypothalamic area, but not in the medial septum.    142 
Figure 5.9. Close appositions made by ARN NPY neurons onto GnRH neurons is 
not different between VEH- and PNA-treated mice.     143 
Figure 6.1. Dysregulation of leptin signalling in PCOS may cause LH 
hypersecretion.          154 
Figure 6.2. Body weight and plasma leptin concentrations are not different 
between VEH- and PNA-treated mice.       161 
Figure 6.3. ARN NPY neurons are co-localised with pSTAT3 VEH- and PNA-
treated mice administered exogenous leptin.      163 
Figure 6.4. ARN NPY neuron responsiveness to leptin is not altered PNA-treated 
mice.            164 
Figure 7.1. Location of tissue dissected for RNA purification.    173 
Figure 7.2. Overview of NanoString methodology.     175 
Figure 7.3. Relative expression of leptin receptor, Y1 receptor, and tumor necrosis 
factor genes are altered in regions of the hypothalamus in PNA mice.   180 
Figure 8.1. Summary of GnRH regulatory signal remodelling in the PNA-treated 
mouse.           194 
Figure 8.2. Possible mechanisms of androgen blockade of progesterone signalling 
in the ARN of PNA-treated mice.        202 
 xvi 
Figure 8.3. Possible rewiring of ARN NPY neural inputs to kisspeptin neurons 
may increase GnRH neuron activity in PNA-treated mice.    206	 	
 xvii 
LIST OF TABLES 
Table 1.1. Summary of rodent PCOS models.     19 
Table 4.1. Co-expression of GFP and NPY and total cell counts in the ARN of 
AgRP-τGFP mice.          102 
Table 4.2. List of brain regions containing projections from ARN NPY neurons.                                           
           112 
Table 7.1. Genes of interest and target sequences for NanoString capture and 
reporter probes.          177 
Table 8.1. Comparison of ARN GABA and ARN NPY alterations in PNA-treated 
mice.            195	 	
 xviii 
LIST OF ABBREVIATIONS 
3V    Third ventricle 
A4    Androstenedione  
AA    Anterior amygdaloid area 
ac   Anterior commissure 
AC    Anterior commissure nucleus 
Acb    Nucleus accumbens 
ACo    Anterior cortical nucleus of the amygdala  
ADP    Anterodorsal preoptic nucleus  
AchSh    Nucleus accumbens, shell 
AgRP    Agouti-related peptide/protein 
AHiAL  Amygdalohippocampal area, anterolateral part 
AM    Anteromedial thalamic nucleus 
AMPA   α-Amino-3-hydroxyl-5-methyl-4-isoxazole-propionate  
AP    Anteroposterior 
Aq   Cerebral aqueduct 
AR    Androgen receptor 
ARKO   Androgen receptor knockout 
ARN   Arcuate nucleus 
   rARN  rostral arcuate nucleus 
 xix 
   mARN  middle arcuate nucleus 
   cARN  caudal arcuate nucleus 
AVPV    Anteroventral periventricular nucleus 
B   Basal nucleus 
BAC   Bed nucleus of the anterior commissure 
BAOT   Bed nucleus of the accessory olfactory tract 
BAT   Brown adipose tissue 
BLA   Basolateral nucleus of the amygdala, anterior 
BMA   Basomedial nucleus of the amygdala, anterior 
BMP   Basomedial nucleus of the amygdala, posterior 
BNST   Bed nucleus of the stria terminalis 
BSA   Bovine serum albumin 
cc   Corpus callosum  
CeC   Central amygdaloid nucleus, capsular part  
CeMAD  Central amygdaloid nucleus, anterodorsal 
CeMAV  Central amygdaloid nucleus, anteroventral  
Cg1   Cingulate cortex, area 1 
Cg2   Cingulate cortex, area 2 
CM   Central medial thalamic nucleus 
CNO   Clozapine-N-oxide 
cp   Cerebral peduncle, basal part 
 xx 
CPO   Central periolivary nucleus 
Cre   Cre recombinase 
CREB   Cyclic-AMP response element binding protein 
CxA   Cortex-amygdala transition zone 
d   Day 
DAB   3,3’- diaminobenzidine  
DAT   Dopamine transporter 
DHEA   Dihydroepiandrosterone 
DHT   Dihydrotestosterone 
DLG   Dorsal lateral geniculate nucleus 
DMH   Dorsomedial hypothalamic nucleus 
DP   Dorsal peduncular cortex 
DpG   Deep grey layer of the superior colliculus  
DpMe   Deep mesencephalic nucleus 
DR   Dorsal raphe nucleus 
DTM   Dorsal tuberomammillary nucleus 
DV   Dorsoventral 
E   Embryonic day 
E1   Estrone 
E2   Estradiol 
ECIC   External cortex of the inferior colliculus 
 xxi 
EDTA   Ethylenediamine tetraacetic acid 
ELISA   Enzyme-linked immunosorbent assay  
ERa   Estrogen receptor alpha 
ERb   Estrogen receptor beta 
EW   Edinger-Westphal nucleus 
FSH   Follicle stimulating hormone 
GABA   g-Aminobutyric acid 
GAD   Glutamic acid decarboxylase 
GFP   Green fluorescent protein  
GnRH   Gonadotropin-releasing hormone 
GPCR   G-protein coupled receptor 
GrDG   Granular layer of the dentate gyrus 
GWAS  Genome-wide association study 
h   Hour 
HDB   Horizontal limb of the diagonal band of Broca  
HPG   Hypothalamic-pituitary-gonadal (axis) 
IAM   Interanteromedial thalamic nucleus 
i.c.v.   Intracerebroventricular 
IF   Interfascicular nucleus 
IGL   Intergeniculate leaf 
IHC   Immunohistochemistry 
 xxii 
IL   Infralimbic cortex 
ILL   Intermediate nucleus of the lateral lemniscus 
IM   Intercalated amygdaloid nucleus 
IMD   Intermediodorsal thalamic nucleus 
InG   Intermediate grey layer of the superior colliculus  
i.p.   Intraperitoneal 
IP   Interpeduncular nucleus 
IPAC Interstitial nucleus of the posterior limb of the anterior 
commissure   
ir   Immunoreactivity 
IRES   Internal ribosomal entry site 
KF   Kölliker-Fuse nucleus 
KNDy   Kisspeptin-Neurokinin B-Dynorphin 
KO   Knockout 
LA   Lateroanterior hypothalamic area 
Ld   Lambdoid septal zone 
LH   Luteinizing hormone 
LHA   Lateral hypothalamic area 
LHb   Lateral habenular nucleus 
LM   Lateral mammillary nucleus 
LOT   Lateral olfactory tract nucleus 
 xxiii 
LPO   Lateral preoptic area 
LSD   Lateral septum, dorsal 
LSI   Lateral septum, intermediate 
LSO   Lateral superior olive 
LSV   Lateral septum, ventral 
M2   2nd motor cortex 
MCLH   Magnocellular nucleus of the lateral hypothalamus 
MCPO   Magnocellular preoptic nucleus 
MD   Mediodorsal thalamic nucleus 
MDC   Mediodorsal thalamic nucleus, central part 
MDM   Mediodorsal thalamic nucleus, medial part 
ME   Median eminence 
MeAD   Medial amygdaloid nucleus, anteroventral 
MePD   Medial amygdaloid nucleus, posterodorsal 
MePV   Medial amygdaloid nucleus, posteroventral 
MHb   Medial habenular nucleus 
min   Minute 
MiTg   Microcellular tegmental nucleus  
ML   Mediolateral / Medial mammillary nucleus, lateral part 
MM   Medial mammillary nucleus, medial part 
MnPO   Median preoptic nucleus 
 xxiv 
MnR   Median raphe nucleus 
Mo5   Motor trigeminal nucleus 
MPA   Medial preoptic area 
MPO   Medial preoptic nucleus  
NDS   Normal donkey serum 
NGS   Normal goat serum 
NKB   Neurokinin B 
NMDA  N-methyl-D-aspartic acid  
nNOS   Neuronal nitric oxide synthase 
NPY   Neuropeptide Y 
NTS   Nucleus tractus solitarius 
OCT   Optimal cutting temperature (compound) 
Op   Optic nerve layer of the superior colliculus 
ot    Optic tract 
OVLT   Organum vasculosum of the lamina terminalis 
OVX   Ovariectomized  
ox   Optic chiasm 
P   Postnatal day 
P4   Progesterone  
PAG   Periaqueductal grey 
PBN   Parabrachial nucleus 
 xxv 
PCOS   Polycystic ovary syndrome  
PeN   Periventricular nucleus 
PH   Posterior hypothalamic area 
Pir   Piriform cortex 
PLCo   Posterolateral cortical amygdaloid nucleus 
PMCo   Posteromedial cortical amygdaloid nucleus 
PMD   Premammillary nucleus, dorsal 
PMV   Premammillary nucleus, ventral 
Pn   Pontine nucleus 
PnV   Pontine nucleus, ventral part  
PNA   Prenatal androgen/Prenatal androgen exposure 
PnO   Pontine reticular nucleus, oral part 
Po   Posterior thalamic nuclear group 
PR   Progesterone receptor 
Pr5   Principal sensory trigeminal nucleus 
PrC   Precommissural nucleus  
PSCs   Post-synaptic currents 
pSTAT3 Phosphorylated signal transducer and activator of 
transcription 3 
PT   Paratenial thalamic nucleus 
PV   Paraventricular thalamic nucleus 
 xxvi 
QC   Quality control 
RCF   Relative centrifugal force 
RCh   Retrochiasmatic zone  
Re   Reuniens thalamic nucleus 
Rh   Rhomboid thalamic nucleus 
RIA   Radioimmunoassay 
RLi   Rostral linear raphe nucleus 
RMC   Red nucleus, magnocellular part 
RMg   Raphe magnus nucleus 
RP3V   Rostral periventricular area of the third ventricle 
RPO   Rostral periolivary region  
RR   Retrorubral nucleus 
Rt   Reticular thalamic nucleus 
RtTg   Reticulotegmental nucleus  
S1   Primary somatosensory cortex  
s.c.   Subcutaneous 
SCh   Suprachiasmatic nucleus  
SFi   Septofimbrial nucleus 
SHBG   Sex hormone binding globulin 
SHy   Septohypothalamic nucleus 
SI   Substantia innominata  
 xxvii 
SNC   Substantia nigra, compact 
SNR   Substantia nigra reticular 
SON   Supraoptic nucleus 
sox   Supraoptic decussation  
SPa   Subparaventricular zone of the hypothalamus  
SPO   Superior paraovulatory nucleus 
STh   Subthalamic nucleus 
Sub   Submedius thalamic nucleus  
SubI   Subincertal nucleus 
SuMM   Supramammillary nucleus, medial 
T   Testosterone 
TH   Tyrosine hydroxylase 
TIDA   Tuberoinfundibular dopamine neurons 
TNFα   Tumor necrosis factor alpha 
Tu   Olfactory tubercle 
Tz   Nucleus of the trapezoid body 
VDB   Vertical limb of the diagonal band of Broca 
VEn   Ventral endopiriform nucleus 
VGAT   Vesicular GABA transporter 
VGLUT  Vesicular glutamate transporter 
VLGMC  Ventral lateral geniculate nucleus, magnocellular part 
 xxviii 
VLL   Ventral nucleus of the lateral lemniscus 
VM   Resting membrane potential 
VMH   Ventromedial hypothalamic nucleus  
VMPO   Ventromedial preoptic nucleus  
VP   Ventral pallidum 
VPL   Ventral posterolateral thalamic nucleus 
VPM   Ventral posteromedial thalamic nucleus 
VPO   Ventral periolivary nucleus 
VRe   Ventral reuniens thalamic nucleus  
VTA   Ventral tegmental area 
VTM   Ventral tuberomammillary nucleus 
ZI   Zona incerta 
ZL   Zona limitans 
	 	 CHAPTER ONE 
 1 
1 LITERATURE REVIEW 
  
	 	 CHAPTER ONE 
 2 
1.1 Preface 
Polycystic ovary syndrome (PCOS) is the most common form of infertility in 
women, affecting 5-20% of women of reproductive age (Lizneva et al., 2016; Zawadski 
and Dunaif, 1992). While this affects a similar proportion of the population as diabetes 
mellitus, PCOS research receives a fraction of the research funding by comparison 
(Rodgers et al., 2019), limiting our present understanding and treatment of this disorder 
despite its prevalence. Currently, there is no cure for PCOS. Interventions tend to be 
broad lifestyle changes, or the off-label application of pharmaceuticals that deal with the 
management of symptoms rather than the root of the disorder. This is unsurprising, given 
our lack of understanding of the aetiology and pathophysiology of PCOS, and highlights 
the need for research into this disorder. 
The following review will aim to define and describe the key features of PCOS, 
including evidence that this disorder may have neuroendocrine origins stemming from 
androgen excess. It will critically assess current animal models used to study the 
underlying pathophysiology of PCOS, and key insights drawn from the use of these 
models. The neural regulation of fertility will be outlined, highlighting critical neural 
circuits that integrate and generate the complex hormonal milieu that is crucial for 
maintaining fertility. Finally, known alterations to GABAergic circuits that are thought 
to be important for generating PCOS will be outlined, and a case will be made for 
neuropeptide Y (NPY) neurons composing a subset of GABA neurons that may be 
altered in PCOS. 
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1.2 Polycystic ovary syndrome 
1.2.1 Definition and prevalence 
While not a recognised disorder by the World Health Organisation until the late 
20th Century, a seminal paper by Stein and Leventhal in 1935 described what we know 
as PCOS today (Stein and Leventhal, 1935). Their description includes what would still 
be considered key features of the disorder, such as amenorrhea and chronic anovulation 
leading to infertility, hirsutism, as well as the eponymous enlarged cystic ovaries. 
However, it also included what would now be considered secondary symptoms or 
features of the disorder, such as obesity (Stein and Leventhal, 1935). Given the 
heterogeneity of presentation, it seems likely this is a reason why PCOS was not 
recognised in an official capacity for nearly 60 years after this initial description, when 
it was finally included in the 10th revision of the International Statistical Classification of 
diseases and related health problems (ICD-10) in 1990 (Organization, 2004). 
The first effort to definitively characterise PCOS for investigators and clinicians 
arose from a conference sponsored by the National Institutes of Health (NIH)/National 
Institute of Child Health and Human Development in 1990 (Zawadski and Dunaif, 1992). 
Recommendations from this conference outlined the so-called ‘NIH criteria’ where, in 
the absence of other related disorders, PCOS was defined by the presence of both 1) 
clinical signs of hyperandrogenism (such as hirsutism) or hyperandrogenaemia and 2) 
ovulatory dysfunction in the form of chronic oligo- or anovulation. The restrictive nature 
of these criteria led to reporting of prevalence rates through the 1990s that are lower than 
what is commonly reported today, typically ranging from 4% to 8% depending upon the 
sample population (Knochenhauer et al., 1998; Michelmore et al., 1999). 
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A second, broader definition of PCOS was laid out in another conference held in 
Rotterdam, Netherlands in May of 2003, a joint effort by the European Society for 
Human Reproduction and Embryology and the American Society for Reproductive 
Medicine (Group, 2004). As the initial NIH criteria was largely based upon anecdote and 
opinions of clinicians, this workshop aimed to define PCOS criteria using an evidence-
based approach. The conclusion was that the definition should be broadened to the 
presence of two out of three clinical features: 1) oligo- or anovulation, 2) clinical and/or 
biochemical signs of hyperandrogenism, 3) polycystic ovarian morphology; additionally, 
these features must be present at the exclusion of other aetiologies. The exclusion of other 
aetiologies is important as there are a range of other conditions that may mimic features 
of PCOS. Hyperandrogenism may also be caused by congenital adrenal hyperplasia, 
Cushing’s syndrome, or androgen secreting tumours, and anovulation could result from 
raised prolactin or diminished luteinizing hormone (LH), for example.  
A third set of criteria was defined by a special Androgen Excess/PCOS Society 
task force (AE-PCOS) (Azziz et al., 2009). They sought to refine the definition of PCOS 
even further, acting as something of a middle ground between the NIH and Rotterdam 
criteria. These criteria consider hyperandrogenism a necessary feature, defining PCOS 
as 1) hyperandrogenism AND 2) oligo/anovulation AND/OR polycystic ovaries. It is 
worth noting that the definition of PCOS is still a contentious issue and is subject to 
change over the coming years as our understanding of the disorder evolves. At present, 
the 2003 Rotterdam criteria allows for greater flexibility in diagnosis and includes 
women that would be excluded under the other two criteria; however, care must be taken 
comparing research and findings in hyperandrogenic women and normoandrogenic 
women included under these guidelines. For the sake of this review and following thesis, 
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the PCOS definition that will be used is the 2003 Rotterdam criteria, as it covers the 
broadest range of phenotypes, and is also the most widely utilised and cited by clinicians 
and researchers. 
The three cardinal features of PCOS have allowed categorization of four 
phenotypes that lie in a spectrum of severity (outlined in Figure 1.1) and often predicts 
long term outcomes and the presence of co-morbidities such as insulin resistance. 
Phenotype A, or severe PCOS, is characterised by the presence of all three cardinal 
features and represents 61% of affected women. Women with phenotype B, 
‘hyperandrogenism and chronic anovulation’ do not have polycystic ovaries, and 
represents a further 7% of PCOS patients. This phenotype is considered more severe 
along with phenotype A. Phenotypes C, ‘ovulatory PCOS’, and D ‘mild PCOS’, are 
considered more mild forms of the disorder and each represent 16% of affected women 
respectively (Dewailly et al., 2006). The following sections will outline each of these 
cardinal features and how they are detected and defined, as well as their biological 
mechanisms that lead to the pathophysiology of PCOS.  
 
Figure 1.1 PCOS clinical phenotypes and severity of manifestation. The Rotterdam criteria defines 
PCOS by the presence of two of more cardinal features, the combination of which can be utilised to 
categorise the phenotype in order of severity. 
1.2.1.1 Hyperandrogenism 
Elevated androgen levels are the longest standing and most consistently used 
feature of PCOS in the clinical setting regardless of diagnostic guideline used. Even so, 
Cardinal PCOS features
Phenotype Hyperandrogenism PCO Oligo-/anovulation
A   
B   
C   
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detecting hyperandrogenism is not necessarily straightforward. Hyperandrogenism can 
be detected by either clinical or biochemical signs. Hirsutism, the presence of course 
terminal hair in a ‘male’ distribution (Escobar-Morreale et al., 2012), is frequently used 
as the primary clinical indicator of elevated androgens. This arises as a result of the 
conversion of testosterone (T) to dihydrotestosterone (DHT) in the pilosebaceous unit of 
hair follicles (Martin et al., 2018), which is exacerbated in a high androgen environment 
such as PCOS. Typically, this is assessed by clinicians using semi-qualitative scoring 
methods, such as the modified Ferrimen-Gallway score (Ferriman and Gallwey, 1961) in 
which the body is divided into 11 areas and graded 0-4 on severity. Hirsutism is present 
in approximately 60%-70% of women with PCOS (Chang et al., 2005; Conway et al., 
1989), compared to 7-8% among women in an unselected population (Knochenhauer et 
al., 1998). However, it should be noted that this can vary depending on ethnicity, in 
particular hirsutism is rarely present women of east Asian decent (Carmina et al., 1992). 
This has led to the suggestion that some kind of consideration of population should be 
accounted for when scoring the degree of hirsutism (DeUgarte et al., 2006). While 
hirsutism appears to predict elevated blood androgens reasonably well (Conway et al., 
1989), it still ultimately relies on the subjective nature of scoring methods that also may 
be confounded in cases where women have previously received treatment for hirsutism, 
and can often be distressing for women subjected to examination. Another clinical 
indicator that is used is the presence of acne, however there is debate over how well this 
reflects actual androgen levels (Falsetti et al., 2002). 
Biochemical signs involve the measurement of blood serum androgens in order 
to detect hyperandrogenaemia. While free T levels may be detected directly by 
radioimmunoassay (RIA), these measurements are unreliable and tend not to be used in 
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clinical settings (Miller et al., 2004; Vermeulen et al., 1999). A more commonly used 
method is to measure both total T and sex hormone binding globulin (SHBG) and 
calculate free or bioavailable T from these measurements (Miller et al., 2004; Vermeulen 
et al., 1999). A free or total T concentration above the 95th percentile of a control range 
from eumenorreheic women has been considered the cut-off for hyperandrogenaemia in 
past cross-sectional studies (Chang et al., 2005; Knochenhauer et al., 1998). While it 
might be tempting to assume that this method is reliable, it has been shown that in as 
many as 40% of patients, serum analysis fails to detect biochemical hyperandrogenism 
(Chang et al., 2005). This suggests that definitions of PCOS that require 
hyperandrogenism to be present (NIH and AE-PCOS) may be under-sampling the true 
prevalence of PCOS, and that the Rotterdam criteria may be more a more appropriate 
definition until more accurate tests or reference ranges are developed. 
1.2.1.2 Ovulatory dysfunction and polycystic ovarian morphology  
Ovulatory dysfunction in PCOS presents as disruptions to the menstrual cycle 
and is intrinsically tied to the presentation of polycystic ovaries that many women with 
PCOS possess. Disruptions to ovulation present as oligo- or amenorrhea, both of which 
are sufficient to be considered a diagnostic sign of PCOS under more recent definitions 
(Azziz et al., 2009; Group, 2004), and are present in as many as 80% of women with 
PCOS [mean percentage from 20 cross-sectional studies outlined in (Azziz et al., 2009)]. 
Oligomenorrhea is diagnosed when menstrual cycles are in excess of 35 days, or when 
menstruation occurs fewer than eight times a year, whereas amenorrhea is absence of 
menstruation for more than three months, in the absence of pregnancy (Norman et al., 
2007). It should be emphasised that menstrual history is merely a clinical sign to detect 
anovulation, and thus can lead to a high rate of false negatives. One report has found that 
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16% of women with PCOS may present with normal menstrual cycles, but in reality are 
not ovulating (Chang et al., 2005). If PCOS is suspected in a woman with normal 
menstrual cycles, serum progesterone (P4) levels of lower than 3-4 ng/mL during the 
mid-luteal phase of the cycle may be a more direct, biochemical marker for detecting 
anovulation (Legro et al., 2007).  
The other sign of ovarian dysregulation is polycystic ovarian morphology on 
examination via ultrasound, which is considered a diagnostic feature in more recent 
criteria (Azziz et al., 2009; Group, 2004). This is performed transabdominally or 
transvaginally, and is defined as the presence of 12 or more follicles measuring 2-9 mm 
in diameter, or an ovarian volume of greater than 10 cm3 (Balen et al., 2003). In PCOS, 
this accumulation of visible follicles and ovary volume is due to arrested growth of antral 
follicles before they reach 10 mm and an apparent failure of a dominant follicle to emerge 
(Franks et al., 2008a). This arrest of follicular growth has been proposed to occur as a 
result of hyperinsulinaemia, as well as elevated LH secretion (Robinson et al., 1993; 
Willis et al., 1996). Additionally, follicular recruitment in women with PCOS is far 
greater then in fertile women, and this may be a result of hyperandrogenism as androgens 
are a key stimulator of early follicle growth, prior to gonadotropin-dependent processes. 
1.2.1.3 Neuroendocrine abnormalities 
While not considered a defining feature, a large proportion of women with PCOS 
exhibit abnormalities in the hypothalamic-pituitary-gonadal (HPG) axis that facilitates 
communication and feedback between the brain and ovary (this axis and its components 
will be outlined in further detail in section 1.3). This becomes apparent when 
gonadotropin levels are measured. Derangement to LH levels is found in 40-50% of 
women with PCOS (Balen et al., 1995; Franks, 1989), and may present in the form of 
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elevated mean LH levels, or an increased frequency of LH pulses  (Waldstreicher et al., 
1988; Yoo et al., 2006b) (Figure 1.2). Interestingly, this rise in LH pulse frequency may 
precede, or at least be an early indicator, of ovulatory dysfunction in early puberty, as it 
can be detected in hyperandrogenic girls prior to menarche (Apter et al., 1994). When 
the ratio of LH to follicle stimulating hormone (FSH) is considered, it becomes apparent 
that the vast majority of women (94%) with PCOS have alterations to the neuroendocrine 
component of fertility (Taylor et al., 1997), which may not be appreciated when LH alone 
is considered. Given the role of gonadotropins, these alterations will drive, or contribute 
to, the abnormalities and folliculogenesis and steroidogenesis that occur at the ovary. 
Increased LH/FSH ratios have been shown to have broad detrimental effects on fertility 
in women, leading to a reduction in mature oocytes and fertilization rates, a lowered rate 
of pregnancy, and a greater risk of miscarriage (Balen et al., 1993; Tarlatzis et al., 1995).  
These abnormal gonadotropin levels are almost certainly due to alterations in the 
neural component of the HPG axis. Briefly, the output from the brain to the anterior 
pituitary gland is composed of a small population of gonadotropin-releasing hormone 
(GnRH) secreting neurons, that are the final common pathway from a vast neural network 
that integrate a range of signals, including gonadal steroid hormones. GnRH is secreted 
in a pulsatile pattern that drives LH pulsatility (detailed in section 1.3.2.3), as well as 
secretion of FSH. As LH pulses are directly driven by GnRH pulses, these can be 
measured in circulation as a readout of GnRH activity. Rodent studies have determined 
that higher GnRH pulsatility favours synthesis of LH within gonadotropin cells of the 
pituitary, while slower pulse frequency favours FSH synthesis (Dalkin et al., 1989). The 
rate of GnRH secretion in fertile women is variable across the menstrual cycle, and is 
crucial for coordinating folliculogenesis and ovulation, however this is tonically raised 
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in PCOS patients, as indicated by the increase in LH pulse frequency. To exacerbate this, 
the pituitary gland appears to become hypersensitive to GnRH, as administration of a 
GnRH receptor agonist, will raise serum LH to a greater degree in women with PCOS 
than in fertile women (Ehrmann et al., 1992). These abnormalities to gonadotropin 
secretion may denote alterations to steroid hormone negative-feedback to the neural 
network that acts as the GnRH neuron pulse generator. Notably, women with PCOS 
demonstrate insensitivity to progesterone (P4) in the presence of estradiol (E2) (Daniels 
and Berga, 1997; Pastor et al., 1998), which is thought to contribute to persistently 
elevated LH secretion. Elevated androgens appear to have a role in this, as blockade of 
the androgen receptor (AR) with flutamide restores P4-mediated negative-feedback in 
women with PCOS (Eagleson et al., 2000). More specific details regarding the GnRH 
neural network alterations that have been elucidated with animal studies will be outlined 
in section 1.4. 
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Figure 1.2. LH secretion is increased in women with PCOS. Two secretion profiles of serum LH 
concentration taken over 24h from a fertile 17-year-old woman (above) and a 17-year-old woman with 
PCOS. The profile from the fertile woman displays typical episodic secretion, with a pulse occurring once 
every 1-2 hours. The pulse frequency in the woman with PCOS is vastly more rapid, and the basal LH 
concentration is notably higher. Horizontal black bars represent the sleep phase, where pulse frequency 
slows in the fertile woman, but is unchanged in the woman with PCOS. Figure is adapted from (Yoo et al., 
2006b). 
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1.2.2 Aetiology  
1.2.2.1 Genetic heritability 
Initially misinterpreted as an autosomal dominant genetic disorder (Govind et al., 
1999), PCOS is currently recognised as a complex, polygenic syndrome where genes and 
environment determine susceptibility. Twin studies comparing monozygotic and 
dizygotic twin pairs concluded that 72% of the variance in the pathogenesis of PCOS 
could be put down to genetic influences, and that co-morbidities such as blood insulin 
and BMI are highly influenced by genetics (Jahanfar et al., 1995; Vink et al., 2006). 
Family based studies lend further evidence of genetic influence by highlighting the strong 
familial clustering that occurs between women with PCOS. In a study of sisters of women 
with PCOS, 22% were found to fulfil the diagnostic criteria for PCOS themselves, and a 
further 24% displayed hyperandrogenism with no associated amenorrhea (Legro et al., 
1998a). Familial clustering of hyperandrogenism in fertile first-degree relatives is well 
documented (Franks et al., 2008b; Kahsar-Miller et al., 2001; Legro et al., 1998a), and 
may itself contribute to clustering of PCOS within families as early androgen excess is a 
possible heritable risk factor (outlined in section 1.2.2.3). Similar to hyperandrogenism, 
features of metabolic syndrome are also more common in first-degree relatives of PCOS, 
such as dyslipidaemia, insulin resistance, obesity, and type 2 diabetes (Sam et al., 2005; 
Sam et al., 2006). Interestingly, male relatives of women with PCOS are also more 
susceptible to metabolic syndrome and have higher rates of obesity than the general 
population (Baillargeon and Carpentier, 2007; Coviello et al., 2009).  
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1.2.2.2 Link to metabolic syndrome 
Women with PCOS have greater rates of hallmark features of metabolic 
syndrome than the general population. The prevalence of insulin resistance is between 
50-70% in women with PCOS depending upon the definition of PCOS utilised (Azziz et 
al., 2004; DeUgarte et al., 2005; Dunaif et al., 1989). Obesity affects approximately 50% 
of women with PCOS (Legro et al., 1998b), however in countries such as the United 
States this has been reported to be as high as 80% (Ehrmann et al., 1999). Notably, while 
being commonly associated among the general population, insulin resistance in woman 
with PCOS seems to arise independently of obesity (Dunaif et al., 1989). Insulin 
resistance in turn is associated with hyperinsulinaemia in what is frequently ascribed to 
compensatory mechanisms (Shanik et al., 2008). This raised insulin has been implicated 
as a source of hyperandrogenism in women with PCOS. Insulin acts upon theca cells in 
developing follicles in concert with LH to stimulate androgen production (Diamanti-
Kandarakis et al., 2008; Nestler, 1997), while directly increasing theca cell proliferation 
(Duleba et al., 1998). Additionally, insulin decreases hepatic secretion of SHBG, which 
acts to sequester free androgens (Nestler et al., 1991). Thus, insulin has a well-established 
role in acting upon two pathways to increase the levels of total as well as bioavailable 
androgens.  
The potential pathophysiological role of obesity on the primary features PCOS is 
somewhat less clear. On one hand, obesity has been linked to increased androgens and 
lowered SHBG in women with or without PCOS (Bjorntorp, 1993; Lim et al., 2013; 
Lovejoy et al., 1996), and weight loss in PCOS women may help restore appropriate 
androgen levels while improving menstrual cycles and fertility (Crosignani et al., 2003; 
Kiddy et al., 1992). On the other hand, the use of androgen blockers reduces fat mass 
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(Gambineri et al., 2006), so it is unclear whether hyperandrogenaemia leads to increased 
obesity or vice versa. Whatever the case, increased adiposity at least exacerbates the 
features of PCOS, and whether it is a causative factor or not is still to be deciphered.  
1.2.2.3 Early androgen exposure 
Exposure to androgens in utero has been proposed as a potential factor to the 
development of PCOS along with genetic predisposition. In humans, one of the most 
apparent clinical examples is in women with adrenal virilising disorders such as 21-
hydroxylase deficiency or androgen secretion carcinomas that increase adrenal androgen 
secretion perinatally (Barnes et al., 1994). This leads to PCOS-like features in 
adolescence and adulthood, including cystic ovaries, increased gonadotropin secretion, 
and increased ovarian androgen secretion, even when the primary source of androgen 
elevation is treated (Barnes et al., 1994). This study in particular is notable, as it is an 
early study in which it was hypothesised that androgen excess leads to prenatal 
programming of hypothalamic-pituitary communication. Women with PCOS display 
significantly elevated serum androgens during pregnancy compared with reproductively 
healthy controls (Sir-Petermann et al., 2002). This may be associated with an increase in 
androgen exposure to the developing fetus, as T levels in umbilical cord blood from 
female offspring have been reported as higher in infants born to mothers with PCOS 
(Barry et al., 2010). One study has reported that androgen levels in amniotic fluid are 
elevated in women with PCOS with female fetuses (Palomba et al., 2012); another 
reported that placental levels of the enzyme 3β-hydroxysteroid dehydrogenase type 1 was 
increased while P450 aromatase was reduced, which would lead to elevated androgen 
production and reduced aromatization to estrogens. (Maliqueo et al., 2013). The 
possibility that maternal androgens may lead to subsequent increases in fetal androgens 
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would provide some explanation toward the familial clustering of PCOS and 
hyperandrogenism without anovulation that occurs in first-degree relative of women with 
PCOS (Franks et al., 2008b; Kahsar-Miller et al., 2001; Legro et al., 1998a). 
Direct links between in utero exposure to androgens have been difficult to 
elucidate in humans, however, a vast body of work in genetically similar non-human 
primates as well as rodents have contributed greatly to our understanding of early 
androgens and prenatal programming. These findings will be discussed in the following 
section.  
1.2.3 Animal models of PCOS 
Due to the technical and ethical limitations on studies in human patients, much 
of the research into the pathophysiology of PCOS employs the use of animal models. 
This permits the collection and research of tissue not readily obtainable from women 
with PCOS, and allows for the breadth of understanding that comes with the ability to 
perform genetic manipulation. As naturally occurring PCOS typically only occurs in 
humans and possibly in certain non-human primates (Abbott et al., 2017), the animal 
models utilised generally have a ‘PCOS-like’ phenotype induced. Induction of PCOS-
like features is frequently conducted by environmental insults such as prenatal androgen 
exposure (PNA). The following section will outline commonly used animal models in 
non-human primates and rodents, and discuss how well they recapitulate features of 
PCOS. Important findings elucidated in the PNA-treated mouse are discussed further in 
section 1.4. 
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1.2.3.1 Non-Human Primate 
Due to their genetic and phenotypic similarities to humans, non-human primates 
provide useful and potentially very translatable models of PCOS. Importantly, they 
possess a menstrual cycle with distinct follicular and luteal phases that are similar to 
those in humans [outlined within (Stouffer and Hennebold, 2015)]. Arguably, prenatal 
testosterone propionate (TP) exposure in female rhesus macaques most closely matches 
human PCOS. Two different paradigms are commonly used where mothers are injected 
with 10-15 mg of TP daily during early (days 40-80) (Abbott et al., 2008; Dumesic et al., 
1997; Eisner et al., 2002) or late (days 94-140) (Dumesic et al., 1997) gestation. An 
impressive set of experiments conducted by Abbott and colleagues measured serum 
gonadal hormone levels in fetal and infant monkeys following early gestational TP 
exposure (Abbott et al., 2008). They demonstrated that fetal serum androgen levels 
returned to basal levels once exogenous TP application had ceased, and that serum 
estrone (E1) and E2 levels were not elevated during gestation, suggesting that this 
protocol would not lead to masculinization of female offspring. Serum estrogens did not 
rise in infancy, whereas androstenedione (A4), a metabolic precursor to T, rose in TP 
treated females, suggesting the preprograming of endogenous hyperandrogenism. 
In adulthood, prenatal TP-treated monkeys display a degree of heterogeneity in 
the presence and severity of their phenotypes in a manner that is similar to PCOS patients. 
Regardless of whether the early or late gestational treatment window is used, 
approximately 45% of TP treated monkeys will exhibit a phenotype similar to that of the 
two most severe phenotypes in PCOS women (outlined in Figure 1.1) (Abbott et al., 
2009), and a further 11% of late-gestation treated monkeys will display an ovulatory 
PCOS-like phenotype. Overall, once monkeys reach adulthood, this treatment paradigm 
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appears to recapitulate almost all of the ovarian, endocrine, and neuroendocrine features 
found in PCOS patients. This includes hyperandrogenism stemming from both ovarian 
(Eisner et al., 2002) and adrenal origin (Zhou et al., 2005), intermittent or halted 
menstrual cycles (Dumesic et al., 1997), polycystic ovaries (Abbott et al., 1998), 
unhealthy oocytes (Dumesic et al., 2002), and increased LH secretion (Dumesic et al., 
1997; Dumesic et al., 2002) with diminished steroid hormone negative feedback 
[outlined in (Abbott et al., 2005)]. Many of the metabolic features of PCOS are also 
replicated, such as increased adiposity (Eisner et al., 2003), hyperlipidaemia (Zhou et al., 
2007), and type 2 diabetes (Dumesic et al., 2005). Interestingly, relatively recent 
evidence suggests that PCOS may occur naturally in rhesus macaques (Abbott et al., 
2017). Pooling three separate lab colonies, Abbot and colleagues identified a subset of 
monkeys with naturally elevated T levels and LH hypersecretion among other endocrine 
derangements. While these monkeys have reduced fecundity, they do not display 
menstrual irregularities, and the presence of polycystic ovarian morphology has not yet 
been determined; at the author’s own admission, future studies will therefore be needed 
to establish whether this is a true PCOS phenotype (Abbott et al., 2017). 
1.2.3.2 Rodent 
Due to the ability to generate large sample sizes, as well as their amenability to 
genetic manipulation, rodent models have been extremely useful in researching the 
potential mechanisms of the aetiology and pathophysiology of PCOS. These models, 
however, do not always faithfully replicate typical PCOS, or may introduce aberrant 
features that do not reflect the condition in humans. Moreover, depending on the 
treatment utilised, the resulting phenotype may range from metabolically healthy, to 
possessing some metabolic abnormalities, to exhibiting the full recapitulation of 
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metabolic syndrome. The following table outlines rodent models of PCOS that have been 
reported using hormonal insult prenatally or in early life, and indicates whether they: do 
not replicate PCOS features (grey), replicate PCOS with metabolic features (yellow), 
replicate lean PCOS (green), or replicate features of PCOS but with extraneous 
abnormalities (red). 
Among the androgen excess models of PCOS in mice, prenatal and postnatal 
DHT-treatment models are the only that most fully recapitulate the features of PCOS 
without inducing other abnormalities. The PNA mouse in particular has proven a useful 
tool for exploring intrinsic pathophysiology in a PCOS-like state without the 
confounding factors associated with metabolic disruptions seen in postnatally DHT-
treated models. 
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Table 1.1. Summary of rodent PCOS models. 
Grey = PCOS features not replicated, yellow = replicates PCOS with metabolic features, green = replicates 
lean PCOS, red = replicates PCOS but with extraneous abnormalities. 
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1.3 The hypothalamic-pituitary-gonadal axis 
1.3.1 Overview 
As touched on earlier, reproductive abnormalities that occur in PCOS ultimately 
reflect a breakdown in the complex network of communication that drives fertility, called 
the HPG axis. Hormones and other cues are detected by a vast network of neurons in the 
hypothalamus that relay this information to a small population of GnRH neurons. These 
neurons release GnRH in a pulsatile manner into portal vasculature where it acts at the 
anterior pituitary gland to drive pulsatile LH release, as well as stimulate the secretion of 
FSH. These gonadotropins act upon the ovary driving follicular development, ovulation 
and steroidogenesis. The ovarian hormones E2 and P4 are released, along with lower 
levels of androgens. This creates a steroid hormone milieu that relays back to the 
hypothalamus, completing and facilitating a tightly controlled classic feedback loop that 
helps to co-ordinated these complex events. The following sections will discuss aspects 
of this axis, followed by how this axis may be disrupted in PCOS. 
1.3.2 The gonadotrophin-releasing hormone neuron 
1.3.2.1 Distribution and development 
The neural network that controls the HPG axis is akin to a funnel. A wide range 
of information from the periphery is initially sensed, and then relayed by a vast neural 
network, which is all integrated by one small population of 800-2000 neurons that act as 
the sole reproductive output from the brain, the GnRH neurons. While most neural 
populations reside in discrete nuclei, or are organised into highly structured layers, GnRH 
neurons exist in a highly scattered distribution, through a rostro-caudal continuum in the 
rostral forebrain extending from the olfactory bulb to the median eminence (ME) in what 
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is sometimes referred to as an ‘inverted Y’ pattern (Herbison, 2015; Silverman et al., 
1994). The GnRH neural somata in the adult mouse reside in three broad anatomical 
zones along this axis that are commonly referred to as, the medial septum (MS), rostral 
preoptic area (rPOA) and anterior hypothalamic area (AHA) (Figure 1.3).  
This unique distribution likely results from the origin and migration of GnRH 
neurons into the brain during embryonic development. GnRH neurons originate in the 
olfactory placode, where they begin to express GnRH mRNA between embryonic days 
(E) 9.5 and 10.5 in mice (Wray et al., 1989a). From here, the neurons migrate into the 
forebrain via the nasal septum at around E12, and continue to migrate caudally until E16, 
at which time most GnRH neurons are in their mature distribution (Schwanzel-Fukuda 
and Pfaff, 1989; Wray et al., 1989a; Wray et al., 1989b). In the much longer human 
gestation period, GnRH immunoreactivity is present in the olfactory pit in 4-week-old 
embryos (Schwanzel-Fukuda et al., 1996), and their migration is complete at 20 weeks 
(Boehm et al., 1994). The pool of GnRH neurons at the beginning of their migration at 
E12 in mice is initially around 2000 cells, which is then reduced to approximately 800 in 
the mature brain (Wu et al., 1997), likely as a result of the remaining neurons failing to 
migrate from the olfactory placode. A complete failure to migrate leads to Kallmann 
syndrome, a form of congenital hypogonadotropic hypogonadism that is frequently 
associated with anosmia (Dodé and Hardelin, 2009).  
In adulthood, 50-70% of GnRH neurons are hypophysiotropic, extending 
projections toward the ME to ultimately regulate gonadotropic hormone secretion 
(Merchenthaler et al., 1989; Silverman et al., 1994). More recent morphological work 
has revealed that a sizable portion of GnRH neurons extend axons that appear to be 
projecting elsewhere. As many as 50% of neurons in a subset within the rPOA that reside 
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close to the organum vasculosum of the lamina terminalis (OVLT) project elsewhere 
(Herde and Herbison, 2015), suggesting possible extra-hypophysiotropic roles for these 
neurons. Interestingly, there is evidence that GnRH neurons in these three regions may 
extend their projections to different areas of the brain from one another, hinting at the 
possibility of anatomically distinct GnRH neuron subpopulations [unpublished results 
from (Marshall, 2014)].  
 
Figure 1.3. GnRH neurons are scattered through the rostral forebrain of the adult mouse. The rostro-
caudal distribution of GnRH neuron cell bodies is shown in a schematic of the adult mouse brain in the 
sagittal plane. Photomicrographs show examples of the distribution of GnRH neurons and their projections 
in the coronal plane (A-E). Sparse cell bodies are found as rostral as the olfactory bulb, and become more 
numerous towards the medial septum (MS, blue region) where they are bundled into two vertically aligned 
columns (A). The largest subset of GnRH neurons are found within the rostral preoptic area (rPOA, pink 
region) where the distribution begins to bifurcate into an ‘inverted Y’ pattern (B, C). Cell bodies are then 
found in two bilateral tracts in the anterior hypothalamic area (AHA, yellow region), that run superior to 
the left- and right-most aspects of the optic chiasm (D). Hypophysiotropic GnRH neurons in all regions 
extend their projections towards the median eminence (ME, purple region) where dense bundles of 
projections are found (E). Scale bars = 100 µm. 3V, third ventricle; ac, anterior commissure; AHA, anterior 
hypothalamic area; cc, corpus callosum; fx, fornix; ME, median eminence; MS, medial septum; OVLT, 
organum vasculosum of the lamina terminalis; pit, pituitary gland; rPOA, rostral preoptic area. Diagram 
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1.3.2.2 Morphology 
Our understanding of this population of neurons has historically been very 
limited, due in part to their unusual distribution, as well as limitations in visualisation 
techniques. Technological advances over the past two decades has allowed gradual 
elucidation of the unique features of these cells. Early structural studies utilising basic 
immunolabelling initially undersold GnRH neurons as relatively simple structures, being 
ovoid cells with uni- or bipolar dendrites that possess very little arborisation (Barry et 
al., 1973; King et al., 1982; Krisch, 1980), and that extend these projections, at most, 
200-300 µm (Jennes et al., 1985).  
In the past decade, a substantial amount of work has been carried out to further 
characterise GnRH neuron morphology in full, particularly the extent of the dendrites 
and their characteristics. The transgenic GnRH-GFP mouse (Spergel et al., 1999), often 
coupled with the use of low-weight molecular dyes such as biocytin and neurobiotin that 
fill the entire cytoplasm of the cell, or viral delivery of membrane-docked fluorophores, 
allow far greater resolution than immunolabelling of GnRH peptide alone. Usage of these 
‘cell-filling’ techniques has consistently revealed that GnRH neuron dendrites are vast, 
projecting thousands of microns from their soma to the ME (Campbell et al., 2005; Herde 
et al., 2011; Herde et al., 2013; Moore et al., 2018b; Roberts et al., 2006). These dendrites 
are decorated with synaptic spines, most densely within 50 µm of the soma, but are also 
present at very distal portions indicating that these neurons possess an incredibly long 
input zone (Campbell et al., 2005). At more proximal regions, GnRH neural dendrites in 
the rPOA have the tendency to vertically bundle, and ultrastructure has revealed that 
these bundles facilitate shared synapses between one afferent neuron input and multiple 
GnRH neuron dendrites (Campbell et al., 2009). Further evidence of shared synapses 
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between dendrites has even been demonstrated 4000 µm distally from the soma, just 
proximal to the ME (Moore et al., 2018b). These bundling properties are thought to 
facilitate co-ordinated GnRH neural activity, allowing pulses or surges to occur, even 
among such a scattered population of cells.  
GnRH neuron dendrites possess qualities that make them highly unique. They 
have unusual electrical properties, possessing the capability to initiate as well as 
propagate action potentials (Iremonger and Herbison, 2012; Roberts et al., 2008). 
Electrophysiology and immunolabelling have identified a spike initiation site 100 µm 
distal to the soma (Herde et al., 2013; Iremonger and Herbison, 2012), though notably 
this is not present in all GnRH neurons (10-50% depending upon region), where a more 
typical axon is instead present (Herde and Herbison, 2015). Morphologically, GnRH 
neuron dendrites often branch heavily has they approach ‘leaky’ circumventricular areas, 
presumably to increase surface area, and thus create a larger interface with capillaries in 
these areas. Many GnRH neurons in the rPOA extend one dendrite toward the 
immediately ventral OVLT, where they transition into highly branched structures, 
possibly to facilitate ‘sampling’ of blood-borne signalling molecules outside of the 
blood-brain barrier (Herde et al., 2011; Herde and Herbison, 2015). Neurobiotin cell-
filling with special tissue preparations has allowed complete reconstruction of GnRH 
neurons in that AHA, finding that they extend one or two dendrites which, just proximal 
to the ME, transition into axons (Herde et al., 2013). This finding has also been 
demonstrated more recently in GnRH neurons originating in the rPOA, and is supported 
with ultrastructural evidence (Moore et al., 2018b). Additionally, GnRH neuron 
projections possess both axon-like and dendrite-like electrical properties, where they 
respond to localized ‘puffs’ of glutamate and GABA, and also propagate action potentials 
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(Iremonger and Herbison, 2012). This blended dendritic/axonal morphology and 
electrical activity is, to our knowledge, wholly unique to GnRH neurons within the 
mammalian brain, and has led to these processes being referred to a ‘dendrons’, reflecting 
these blended properties (Herde et al., 2013). 
1.3.2.3 Pulsatile GnRH release at the median eminence drives gonadotrophin 
secretion 
Appropriate patterns of GnRH release at the median eminence are critical for 
maintaining gonadotrophin release from the anterior pituitary. LH secretion from the 
anterior pituitary occurs in a pulsatile manner, a pattern that is highly conserved across a 
wide range of mammalian species, from rodents (Gay and Sheth, 1972) through to sheep 
(Butler et al., 1972), as well as both non-human primates (Dierschke et al., 1970) and 
humans (Nankin and Troen, 1971). Continuous application of GnRH in rhesus monkeys 
with hypothalamic lesions is not sufficient to drive LH secretion, instead requiring 
intermittent administration (Belchetz et al., 1978), indicating pulsatile GnRH secretion 
is necessary for LH secretion. Simultaneous sampling of portal vasculature and 
peripheral blood has revealed that pulses of LH occur in a manner where they are 
invariably preceded or accompanied by a pulse of GnRH (Clarke and Cummins, 1982; 
Levine et al., 1982; Moenter et al., 1992) (Figure 1.4). The rate of GnRH pulse frequency 
leads to differential release of gonadotrophins, where higher rates lead to greater LH 
secretion, while slower rates favour FSH release (Wildt et al., 1981).  
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Figure 1.4. GnRH and LH pulses occur concurrently. GnRH neurons (red cells) scattered throughout 
the hypothalamus extend their projections to the median eminence and secrete GnRH peptide (green) in a 
pulsatile manner. Pulses of GnRH act on gonadotrophs (green cells) in the anterior pituitary to elicit 
pulsatile LH secretion (blue). Graphs show simultaneous blood sampling (10 min intervals) from portal 
vasculature and the periphery, conducted in an ovariectomised ewe over four hours. Radioimmunoassay 
in blood samples reveals pulses of GnRH (green trace) occur just prior to, or at the same time as LH pulses 
(blue trace). Graphs are adapted from (Levine et al., 1982). 
1.3.3 Gonadal steroid hormone mediated feedback 
In mammalian species, including humans, dynamic levels of gonadal steroid 
hormones play a critical role in modulating activity of the GnRH neural network, acting 
as feedback messengers between the gonads and hypothalamus (Figure 1.5) (Karsch, 
1987). In males, this action appears to be a straightforward homeostatic negative 
feedback in which tonically secreted levels of T act to suppress GnRH neural activity 
and subsequent gonadotropin output (Plant, 1982; Tilbrook and Clarke, 1995). This is 
also the case for the majority of the ovulatory cycle in females, where E2 in the early 
follicular stage, and P4 in the luteal phase keep LH secretion relatively low (Karsch, 
1987). During the mid-to-late follicular phase, however, E2 levels rise and evoke a switch 
to positive feedback upon the GnRH neural network (Yamaji et al., 1971). During 
positive feedback, a sustained release of high GnRH secretion drives the preovulatory 
LH surge that triggers ovulation (Clarke and Cummins, 1985; Moenter et al., 1991). In 
rodents, along with E2, there is a preovulatory rise in P4 during positive feedback that is 
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required to drive the full amplitude of the LH surge [integrated model outlined in 
(Herbison, 2015)]. In humans, P4 terminates the LH surge (Dierschke et al., 1973), and 
sustained levels are secreted over the course of the luteal phase to maintain negative 
feedback and decrease LH secretion over this period (Gibson et al., 1991; Goodman et 
al., 1981).  
The following sections will discuss what is known about estrogen, progesterone, 
and androgen-mediated feedback on the GnRH neuronal network, and how these 
hormones are necessary for maintaining fertility.  
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Figure 1.5. Profile of circulating steroid hormones and gonadotropins over the human menstrual 
and rodent estrous cycles. Ovarian steroid hormones and gonadotropins are dynamic over the menstrual 
(top) and estrous (bottom) cycles; schematic representations of typical levels are shown above. In the 
human follicular phase, all hormones are suppressed by negative feedback (red area), however in the 3-4 
days approaching ovulation, feedback by estradiol switches to positive (green area), thus driving rising 
levels of estradiol, and an eventual surge in luteinizing hormone just prior to ovulation (dashed red line). 
Following ovulation, rising levels of progesterone drive a switch back to negative feedback, which are 
maintained through the luteal phases, along with a smaller rise of estradiol. Over the rodent estrous cycle 
this is similar, with a few key differences. Over the day of proestrus, rising estradiol levels delineate a shift 
to positive feedback, which is followed by a rise in progesterone, as they both exert positive feedback 
actions. On the afternoon of proestrus a surge of luteinizing hormone occurs, and negative feedback is 
restored by briefly maintained high level of progesterone. Bottom figure is adapted from real measurements 
presented in (Levine, 2015).  
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1.3.3.1 Estradiol 
E2 can act upon GnRH neurons both directly and indirectly, with indirect actions 
being the predominant mode of feedback and acting via neural afferents to maintain 
fertility. GnRH neurons themselves do not express the nuclear estrogen receptor alpha 
(ERa) (Herbison and Pape, 2001), but have been shown to express cytoplasmic estrogen 
receptor beta (ERb) in a number of species including rodents and humans (Hrabovszky 
et al., 2007; Hrabovszky et al., 2000; Skynner et al., 1999). Actions mediated by ERb are 
transduced via a non-genomic pathway, as E2 exerts a rapid hyperpolarising action 
directly upon GnRH neurons, faster than gene transcription can occur (Lagrange et al., 
1995). Supporting this, GnRH mRNA expression is unaltered in ERb genetic knockout 
(KO) mice, suggesting this receptor does not act upon gene transcription (Dorling et al., 
2003). One way in which non-genomic ERb mediated inhibition may occur is via second 
messengers that phosphorylate cyclic-AMP response element binding protein (CREB) in 
GnRH neurons (Ábrahám et al., 2003; Cheong et al., 2012). ERb-CREB signalling in 
GnRH neurons has been shown to suppress intracellular calcium oscillations and 
activating ATP-dependent potassium channels (Romano and Herbison, 2012; Temple et 
al., 2004; Zhang et al., 2010), leading to inhibition. This rapid pathway for E2 to suppress 
GnRH neurons directly seems to play a role in optimising negative feedback. When 
CREB is knocked out of GnRH neurons specifically, rapid suppression of LH by E2 is 
lost (Kwakowsky et al., 2012). Global knockouts of ERb have not been especially useful 
to determine how important this isoform is to maintain fertility, as phenotypes range 
between completely fertile, subfertile, and infertile (Dupont et al., 2000; Krege et al., 
1998). What is clear, however, is that this isoform is not involved in positive feedback in 
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females, as ERb-KO mice still display an LH surge in response to high exogenous E2 
(Wintermantel et al., 2006). 
In contrast to ERb, global ERa-KO invariably leads to infertility, and the 
abolishment of both positive and negative feedback of LH (Dorling et al., 2003; Dupont 
et al., 2000; Wintermantel et al., 2006). ERa is thought to act in a ‘classical’ genomic 
manner, interacting with estrogen-response elements on target genes to exert actions on 
positive and negative feedback. Positive feedback is thought to be entirely mediated by 
this process, as LH surges occur only after 7-14 hours of E2 treatment, and persist after 
E2 has been removed (Evans et al., 1997; Legan et al., 1975). Additionally, mutation of 
the estrogen-response element binding site of ERa leads to complete abolishment of E2 
mediated positive feedback (Glidewell-Kenney et al., 2007). Interestingly, similar 
mutations show that these genomic actions of ERa are also responsible for between 50-
70% of E2-mediated feedback of LH secretion (Glidewell-Kenney et al., 2007; McDevitt 
et al., 2008). As GnRH neurons do not express ERa (Herbison and Pape, 2001), 
signalling by this isoform is thought to occur transsynaptically. The sites of action and 
neural phenotypes thought to be involved in these processes are outlined in section 1.3.4 
‘Neural mediation of GnRH neurons’. 
1.3.3.2 Progesterone 
Feedback by P4 is also a critical component of both negative and positive 
feedback, however its role in positive feedback appears to be specific to rodents. There 
is evidence that GnRH neurons express the membrane progesterone receptor PgRMC1, 
but the reported direct effects of P4 on GnRH neurons are variable, and possibly 
inconsequential in adult neurons (Bashour and Wray, 2012; Sim et al., 2001). The 
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predominant actions of P4 occur genomically via the classical progesterone receptor 
(PR). Genetic KO of this receptor leads to a lack of ovulation and abnormal sexual 
behaviour, as well as a considerable increase in basal LH levels, highlighting the 
importance of P4 signalling in facilitating negative feedback (Chappell et al., 1997; 
Lydon et al., 1996). Mice with PR KO are also unable to generate an LH surge in response 
to E2, indicating these receptors are also critical in generating the surge along with ERa 
(Chappell et al., 1999). Moreover, P4 amplifies and advances E2 driven positive 
feedback (Krey et al., 1973), lending further support to the synergistic interactions of 
these two signalling pathways. Similar to ERa, GnRH neurons do not express PR 
(Skinner et al., 2001), so like E2, the actions exerted by P4 are proposed to be 
transsynaptic. 
1.3.3.3 Androgens 
Direct androgen mediated effects on the female HPG axis can be difficult to 
ascertain pharmacologically, as androgens exert their actions either directly via ARs, or 
indirectly via estrogen receptors. This is because T and its metabolic precursors such as 
DHEA and A4 may be metabolised to both E1 and E2 via CYP19A1 aromatase enzymes 
(Ghayee and Auchus, 2007), and exert actions on both ERa and ERb. While non-
aromatisable DHT is often used to pharmacologically assess AR actions, it can be 
metabolised into 3b-androstanediol (Steckelbroeck et al., 2004), which also acts on ERa 
and ERb with weak and moderate affinity respectively (Kuiper et al., 1997). To 
circumvent this, one way in which androgenic actions in the HPG axis have been assessed 
is by utilising global and tissue-specific genetic KO of AR (ARKO), revealing a 
facilitatory role of androgens in female fertility. 
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Global ARKO female mice display a range of indicators of subfertility, including 
lengthened estrus cycles, decreased ovary weight, decreased follicle and corpora lutea 
number with an associated increase in unhealthy follicles, as well as delayed and 
undersized litters, with 50% of mice unable to generate a litter (Cheng et al., 2013; Hu et 
al., 2004; Shiina et al., 2006; Walters et al., 2007). Additionally, ARKO mice exhibit 
neuroendocrine disruption, including altered timing of the LH surge, reduced surge 
amplitude, and the rise in LH following ovariectomy is diminished, indicating 
disruptions to negative feedback (Cheng et al., 2013). Interestingly, exogenous 
gonadotrophin administration to simulate an LH surge is able to induce ovulation 
(Walters et al., 2007). This provided early evidence that subfertility in ARKO mice is 
extraovarian in nature. Moreover, ovary transplants from wild-type fertile females to 
ARKO mice are unable to restore fertility, and wild-type mice that are transplanted with 
ARKO ovaries remain fertile (Walters et al., 2009).  
The evidence that female ARKO mice exhibit subfertility and neuroendocrine 
defects in a manner that appears extraovarian has led researchers to investigate the action 
of androgens in the neural component of the female HPG axis. Supporting this, AR is 
expressed abundantly within the brain (Sar et al., 1990), including hypothalamic areas 
such as the POA, AVPV, and arcuate nucleus (ARN) in both females and males 
(Apostolinas et al., 1999; Brock et al., 2015; Lu et al., 1998). GnRH neurons, similar to 
their lack of ERa and PR described above, do not express AR (Huang and Harlan, 1993), 
indicating actions of androgens via AR occur transsynaptically. Expression of kisspeptin, 
a critical regulatory peptide for GnRH neurons (see section 1.3.4.2), is reduced in the 
AVPV of global ARKO mice (Cheng et al., 2013), supporting an indirect role of 
androgen actions on GnRH activity. 
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Recently, the neural component of AR mediated feedback was explored by 
Walters and colleagues using a neuron-specific ARKO transgenic mouse (Walters et al., 
2018). This resulted in a milder phenotype than global ARKO mice, with diminished LH 
surge amplitude and fewer, unhealthier follicles, but ultimately normal fertility. 
Strangely, an increase in LH secretion during diestrus was also observed (Walters et al., 
2018), which is not a feature that others have reported in global ARKOs. Ultimately, 
androgen-mediated feedback of the HPG axis is clearly important to optimise fertility, 
but its role is not yet as clear cut as estrogen or progesterone mediated events. The most 
compelling evidence so far in female fertility is that AR actions facilitate the generation 
of the preovulatory LH surge in tandem with E2-postive feedback, and that disruption of 
this leads to decreased ovulation and subfertility.  
1.3.4 Neural mediation of GnRH neurons 
As GnRH neurons do not express the nuclear receptors critical for steroid 
hormone mediated feedback, they rely on an afferent neural network to detect and relay 
this information. The following section will discuss what is known about regulation of 
neurotransmitters and neuropeptides that are expressed by key neural populations that 
are known to be critical for regulation of hormonal feedback. 
1.3.4.1 Glutamate  
As the primary excitatory neurotransmitter within the mammalian brain, it is 
unsurprising that glutamatergic afferent inputs compose a major class of excitatory input 
to GnRH neurons. Three distinct classes of ionotropic glutamate receptors are present in 
adult GnRH neurons, the α-Amino-3-hydroxyl-5-methyl-4-isoxazole-propionate 
(AMPA) (Bailey et al., 2006), N-methyl-D-aspartic acid (NMDA) (Abbud and Smith, 
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1995), and kainate receptors (Eyigor and Jennes, 2000). The distribution and proportion 
of GnRH neurons expressing each of these receptors as well as their subunit composition 
is highly heterogeneous, however the significance of this is not yet known (Iremonger et 
al., 2010). Depending on the study examined, between 50-100% of GnRH neurons 
respond to AMPA, whereas 10-20% respond to NMDA, implicating AMPA receptors as 
the primary driver of glutamatergic transmission (Constantin et al., 2010; Spergel et al., 
1999). While currents evoked by AMPA and NMDA receptor activation have a similar 
temporal onset, AMPA driven events have a much lower amplitude and faster decay than 
NMDA driven events (Liu et al., 2011), suggesting differential control of GnRH neurons 
by this one transmitter. Some evidence for slow glutamatergic transmission via 
metabotropic glutamate receptors (mGluRs), a class of g-protein coupled receptor 
(GPCR), has also been demonstrated in subsets of GnRH neurons (Chu and Moenter, 
2005; Dumalska et al., 2008). However, these events may be presynaptic, altering the 
activity of GABAergic terminals rather than the GnRH neuron directly (Chu and 
Moenter, 2005).  
Ionotropic glutamate receptors concentrate within spines of most neurons (Sorra 
and Harris, 2000), which GnRH neurons possess scattered throughout their cells bodies 
and vast dendritic processes (Campbell et al., 2005). It has been identified that some axon 
terminals that form synapses onto GnRH neuron spines do indeed express vesicular 
glutamate transporters (VGLUTs), presynaptic markers of glutamatergic input (Kiss et 
al., 2003), and the VGLUT apposition to GnRH neurons occurs at the proximal dendrite 
(Moore et al., 2018a). Increases in GnRH neuron spine density across puberty (Cottrell 
et al., 2006), as well as during the LH surge (Chan et al., 2011), may reflect an important 
role for glutamatergic inputs in these cases; however, it is worth noting that GABAergic 
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inputs may also associate with spines on GnRH neurons (Moore et al., 2015). Spines on 
GnRH neuron somata and proximal dendrites greatly increase over postnatal 
development before and after puberty (Cottrell et al., 2006), and their expression of 
NMDA receptors also increases across this time frame (Gore et al., 1996; Simonian and 
Herbison, 2001). Furthermore, exogenous NMDA, or NMDA antagonists, have been 
shown to advance or delay the onset of puberty respectively (Plant et al., 1989; Urbanski 
and Ojeda, 1990). This appears to be mediated by E2 signalling, as specific deletion of 
the gene for ERa (Esr1) from glutamate neurons leads to precocious puberty in mice 
(Cheong et al., 2015). Puberty is associated with a maturation of the GnRH neuron itself 
(Cottrell et al., 2006), and may be shaped in part by postnatal increases in synaptic input. 
This appears to be a co-ordinated event in which GABAergic input rises initially 
(elaborated further in section 1.3.4.3), followed by a rise in glutamatergic input just prior 
to puberty onset [hypothesis outlined in (Clarkson and Herbison, 2006a)].  
Glutamate neurons are implicated as important relays of E2 mediated feedback. 
During proestrus, administration of an NMDA agonist increases GnRH gene expression 
within the rPOA (Gore et al., 2000), and as stated above, spine density increases in the 
somata and proximal dendrites in a subset of GnRH neurons within the rPOA during the 
LH surge (Chan et al., 2011). Conversely, an NMDA antagonist administered during 
proestrus will block the LH surge and decrease GnRH gene expression (Suzuki et al., 
1995). In a model of negative feedback in mice, E2 suppresses glutamatergic 
transmission to GnRH neurons, indicating a role in this mode of feedback in addition to 
positive feedback (Christian et al., 2009). Moreover, genetic KO of Esr1 specifically 
within glutamatergic neurons leads to the abolition of the LH surge in mice, persistent 
estrus, infertility, and impairment of E2-negative feedback (Cheong et al., 2015). Taken 
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together, it is apparent that glutamatergic signalling to GnRH neurons is an important 
regulator of their activity and subsequently on fertility, in a manner that is, at least in 
part, independent of co-expression with other transmitters.  
1.3.4.2 Kisspeptin 
Kisspeptin as a key regulator of fertility was made apparent in 2003, when two 
high-impact clinical studies demonstrated the critical nature of this peptide (de Roux et 
al., 2003; Seminara et al., 2003). Since then, kisspeptin has been at the forefront of 
research questions centred on the neural regulation of GnRH neurons, leading to a field 
of research which is now largely regarded as kisspeptinocentric (Plant and Herbison, 
2018). These initial clinical reports identified families in which there were homozygous 
mutations to Gpr54, a gene encoding the kisspeptin receptor (Ohtaki et al., 2001), leading 
to idiopathic hypogonadotropic hypogonadism (de Roux et al., 2003; Seminara et al., 
2003). Hypogonadotropic hypogonadism is a failure to undergo puberty, and is 
associated with a reduction or absence in LH secretion (Seminara et al., 1998) but normal 
response to exogenous GnRH (Crowley and McArthur, 1980), indicating impairment of 
endogenous GnRH neural activity in these individuals. Furthermore, genetic KO of 
Gpr54 or Kiss1 in mice leads to hypogonadism, arrest of puberty, acyclicity in females, 
and low circulating steroid hormones and gonadotropins (d'Anglemont de Tassigny et 
al., 2007; Funes et al., 2003; Seminara et al., 2003). Interestingly, KO of Gpr54 leads to 
a more severe phenotype than Kiss1 (Lapatto et al., 2007). This could possibly indicate 
there may be homologous peptides that can behave as ligands for GPR54 in the absence 
of kisspeptin, however these remain to be identified. Alternatively, this may reflect 
constitutive internalisation of GPR54 that may activate second messenger pathways, 
which has been described in cell culture (Pampillo and Babwah, 2010). It has since been 
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identified more specifically that kisspeptin signalling via GPR54 on the GnRH neuron is 
sufficient to maintain fertility in mice (Kirilov et al., 2013).  
Neurons expressing kisspeptin are found predominantly within two hypothalamic 
regions, the AVPV and the ARN (Clarkson and Herbison, 2006b; Smith et al., 2005a; 
Smith et al., 2005b). The AVPV population is continuous with caudally located neurons 
in the periventricular nucleus (PeN), and are postulated to have a similar role in E2-
postive feedback, leading to this population sometimes being referred to collectively as 
the rostral periventricular area of the third ventricle (RP3V) (Herbison, 2008). This RP3V 
population is highly dimorphic between sexes, containing approximately 10-times more 
kisspeptin immunoreactive cells in females than in males (Clarkson and Herbison, 
2006b). These two populations of kisspeptin both extend projections to GnRH neurons, 
but appear to innervate distinct regions where RP3V kisspeptin neurons project to GnRH 
neuron somata and both proximal and distal dendrites, while ARN kisspeptin neurons 
project to the distal dendrite only (Yip et al., 2015), but may still be interacting with 
neurons in the immediate vicinity of the proximal regions of GnRH neurons.  
A notable feature of RP3V and ARN kisspeptin neurons is that they are 
differentially regulated by E2, leading to speculation of potential distinct roles in 
mediating both E2-postive and negative feedback. Gonadectomy leads to a loss of cells 
expressing Kiss1 mRNA in the RP3V (Smith et al., 2005a; Smith et al., 2005b), which is 
restored by exogenous administration of E2. The LH surge is dependent on E2 signalling 
via the ERa isoform (Wintermantel et al., 2006), which is expressed in abundance in the 
RP3V (Herbison, 2008), including in kisspeptin neurons (Clarkson et al., 2008; Smith et 
al., 2005a; Smith et al., 2006). RP3V Kiss1 mRNA is more highly expressed in proestrus 
where circulating E2 is high (Smith et al., 2006), and RP3V kisspeptin neurons express 
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cFos, a marker of neural activation, during an LH surge protocol in which E2 is applied 
(Clarkson et al., 2008; Smith et al., 2006). Genetic KO of Gpr54 or Kiss1 leads to a loss 
of cFos in rPOA GnRH neurons during the LH surge (Clarkson et al., 2008), which are 
normally active at this time point (Chan et al., 2011). Recently, it has been demonstrated 
that knocking Esr1 out of the RP3V in adults using viral delivery methods leads to a 
similar loss in GnRH neuron cFos, as well as a large blunting of the LH surge (Porteous 
and Herbison, 2019). Overall, there is a strong link between E2 signalling in the RP3V 
positively regulating kisspeptin neurons, and that kisspeptin-GPR54 signalling is critical 
for the LH surge. 
Unlike RP3V kisspeptin neurons, E2 seems to potently downregulate Kiss1 
mRNA expression in the ARN (Smith et al., 2005a; Smith et al., 2005b), with virtually 
all Kiss1 expressing neurons in this region also expressing ERa (Smith et al., 2005a). In 
male mice this mechanism also predominantly appears to be through estrogen signalling, 
however DHT administration in castrated mice also lowers Kiss1 mRNA, implicating a 
role for direct androgen signalling, albeit in a less potent manner than E2 (Smith et al., 
2005b). ARN kisspeptin neurons are frequently referred to with the more descriptive 
moniker of ‘KNDy’ neurons, reflecting their co-expression of neurokinin B (NKB) and 
dynorphin (Lehman et al., 2010). This was first described in the sheep (Goodman et al., 
2007), and subsequently in rats and mice (Burke et al., 2006; Navarro et al., 2009). 
Interestingly NKB and its receptor NK3 appear similarly crucial to fertility as kisspeptin 
as mutations in either gene have been identified in patients with hypogonadotropic 
hypogonadism (Guran et al., 2009; Topaloglu et al., 2009). The presence of these three 
peptides and their receptors on KNDy neurons has led to an interesting hypothesis that 
these neurons behave autosynaptically to coordinate bursts of activity that ultimately 
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generate GnRH pulses (Lehman et al., 2010; Navarro et al., 2009). Recent work using 
fibre photometry to detect calcium release in ARN KNDy neurons has identified that 
spontaneous bursts of activity do in fact occur in vivo preceding LH pulse secretion 
(Clarkson et al., 2017). Optogenetic activation of ARN KNDy neurons has also been 
used to elicit LH pulses (Clarkson et al., 2017; Han et al., 2015), which are larger in 
ovariectomised mice (Han et al., 2015) again implicating E2 as having an inhibitory role 
on the activity of this population. The bursting activity within these neurons varies across 
the estrous cycle, and paradoxically appears highest during proestrus when circulating 
E2 is increasing, and reduces dramatically in estrus, when E2 again falls (McQuillan et 
al., 2019). Presently, it seems that what is known about E2 negative regulation of ARN 
KNDy neurons, and observations of the spontaneous calcium release within these 
neurons are somewhat still at odds, and that further research is required to elucidate the 
nature of regulating pulse generation. 
1.3.4.3 GABA 
Arguably the largest component of GnRH neural regulation in terms of sheer 
input is transmission via g-aminobutyric acid (GABA). The great majority of GnRH 
neurons exhibit post-synaptic currents (PSCs) in response to GABA, and through various 
electrophysiological and gene expression studies, this is thought to be predominantly 
GABAA receptor mediated (Pape et al., 2001; Sim et al., 2000; Spergel et al., 1999) 
(Bhattarai et al., 2011; DeFazio et al., 2002; Liu et al., 2011). Electrophysiological 
experiments recording glutamatergic and GABAergic transmission onto GnRH neurons 
demonstrate that GABAergic transmission occurs at a rate up to 10 times greater than 
glutamate-mediated events (Herbison and Moenter, 2011; Sim et al., 2000). To date, 
there appears to be two modes of GABAergic transmission onto GnRH neurons that have 
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different electrophysiological effects. Fast, phasic transmission via synaptic GABAA 
receptors has been shown to produce PSCs (Liu et al., 2011; Spergel et al., 1999), while 
tonic GABAergic signalling creates synaptic ‘spillover’ that activates extra-synaptic 
GABAA receptors and alters the resting membrane potential (VM) and by extension, 
GnRH neuron excitability (Bhattarai et al., 2011; Sim et al., 2000). 
While GABA is the primary inhibitory neurotransmitter in the mammalian brain, 
there is a hypothesis backed by an ever growing body of work that suggests GABAA 
mediated transmission onto adult GnRH neurons can be excitatory [reviewed in depth in 
(Herbison and Moenter, 2011)]. Briefly, the depolarization or hyperpolarization that 
occurs is dependent upon the intracellular chloride concentration ([Cl-]i) of the neuron, 
and thus will determine the direction of Cl- flux through the pore of the GABAA receptor 
(depicted in Figure 1.6). The [Cl-]i of a cell is dependent on relative levels of membrane 
expression of the chloride-cation family of transporters. In neurons, this is principally 
NKCC1 which transports Cl- inward, and KCC2 that transports Cl- outward (Delpire, 
2000; Payne et al., 2003). Relatively higher NKCC1 expression will drive [Cl-]i upward, 
and will set an equilibrium potential for Cl- (ECl, and by extension EGABA) that is higher 
than the neuron’s resting VM, thus GABAA opening will depolarise the neuron towards 
EGABA. In contrast, higher KCC2 will decrease [Cl-]i and EGABA will be lower than the 
neuron’s resting VM, causing Cl- influx through GABAA and hyperpolarization of the 
neuron. Typically, over the course of postnatal development in neurons, expression of 
NKCC1 decreases (Plotkin et al., 1997), while KCC2 expression increases (Lu et al., 
1999). In neuroscience dogma, this is thought of as the developmental switch that causes 
GABAA transmission to become inhibitory in adult neurons, and that deviations to this 
occur only in states of disease or trauma (Delpire, 2000; Kahle et al., 2008; Payne et al., 
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2003). GnRH neurons on the other hand, appear to maintain a higher [Cl-]i in adulthood 
by maintaining expression of NKCC1, while KCC2 is either not present (DeFazio et al., 
2002; Taylor-Burds et al., 2015), or may only be expressed in a subset of neurons 
(Leupen et al., 2003). Interestingly, GnRH neurons may further accumulate [Cl-]i - by 
expression of Cl-/HCO3- anion exchangers in adulthood (Taylor-Burds et al., 2015).  
The question of whether GABAergic transmission ultimately excites or inhibits 
adult GnRH neurons has been conflicted over the years as one could point to numerous 
studies where either depolarization (Constantin et al., 2010; DeFazio et al., 2002), 
hyperpolarization (Han et al., 2002; Han et al., 2004), or both (Bhattarai et al., 2011; Liu 
et al., 2011) have been reported. However, slice preparations designed to maintain intact 
circuitry, as well as in vivo studies appear to indicate that GABA is predominantly 
excitatory. For example, Liu and colleagues demonstrated that in preparations in which 
AVPV-to-GnRH neural circuits are maintained, GABAergic transmission resulted in 
excitatory events in the majority (60%) of GnRH neurons (Liu et al., 2011). In live 
anaesthetised mice, in vivo electrophysiology in GnRH neurons revealed that application 
of the GABAA agonist muscimol could both excite or inhibit GnRH neurons, however 
the GABAA antagonist picrotoxin inhibited all GnRH neurons (Constantin et al., 2013), 
indicating a net excitatory influence of ARN GABAergic transmission onto GnRH 
neurons. Recent compelling evidence by Silva, Desroziers and colleagues has employed 
both optogenetics and chemogenetics to demonstrate the net effect of endogenous 
GABAergic transmission on the GnRH neural network in intact mice for the first time 
(Silva et al., 2019). In this study, either the blue-light activated cation channel, ChETA 
(a fast variant of channelrhodopsin 2 with higher and more specific spike fidelity), or a 
modified human muscarinic receptor (hM3Dq; a designer receptor exclusively activated 
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by designer drugs, DREADD) was delivered to GABAergic neurons residing in the 
ARN. Activation of ARN GABAergic terminals residing close to GnRH neurons in the 
rPOA was achieved by blue light stimulation (ChETA) or application of clozapine-N-
oxide (CNO, hM3Dq), while simultaneous blood sampling was collected for assessment 
of LH. Remarkably, activation of GABAergic terminals in both experiments led to a 
considerable and sustained increase in LH secretion, indicating overall excitation of 
GnRH neurons (Silva et al., 2019). While these experiments do not exclude trans-
synaptic or presynaptic events resulting in activation of GnRH neurons by GABA, they 
do provide strong evidence that the net role of ARN GABAergic transmission on the 
GnRH neural network is to elicit LH secretion.  
Alterations in GABAergic transmission to GnRH neurons in models of PCOS 
have become a large area of focus among groups that study the neural component of this 
disorder that potentially underpin many of the reproductive abnormalities that occur. 
These alterations will be outlined further in section 1.4.  
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Figure 1.6. Intracellular chloride concentration determines depolarization and hyperpolarization 
following GABAA receptor activation. The intracellular chloride concentration ([Cl-]i ) of a neuron is 
determined by relative membrane expression of chloride-cation exchangers: the inward NKCC1 and the 
outward KCC2. When expression of NKCC1 > KCC2 (left), [Cl-]i is higher than the extracellular 
environment; whereas if expression of NKCC1 < KCC2 (right), [Cl-]i will be lower than then extracellular 
environment. The direction of flux across the GABAA receptor, a ligand-activated Cl- channel, is 
determined by [Cl-]i. When [Cl-]i is high the equilibrium potential of GABAA activation (EGABA) is higher 
than the neuron’s resting membrane potential, leading to depolarization of the cell. Conversely, low [Cl-]i 
leads to an EGABA that is lower than resting membrane potential, leading to hyperpolarization. Figure 
reproduced from (Herbison and Moenter, 2011). 
1.3.4.4 Neuropeptide Y, a potential integrator of reproductive and metabolic cues 
Neuropeptide Y (NPY) is the most abundantly expressed peptide transmitter in 
the mammalian central nervous system (CNS) that we know of to date, and is present at 
almost every organisational level of the fore-, mid-, and hindbrain in both rodents and 
humans (Adrian et al., 1983; Morris, 1989). It is a 36 amino acid polypeptide rich in 
tyrosine residues (hence the name) that was first isolated from the pig brain, identified 
solely from its structural similarities to other known peptides, with no known function at 
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the time (Tatemoto et al., 1982). This stands in stark contrast to today where NPY has 
been implicated in a myriad of functions, ranging from behavioural roles in 
anxiety/depression (Heilig, 2004) and regulation of alcohol dependence (Thorsell and 
Mathé, 2017), through to learning and memory (Redrobe et al., 2004), neuroprotection 
(Silva et al., 2005), and even anti-aging (Botelho and Cavadas, 2015). The most well-
known and extensively researched function of NPY is in the neural regulation of feeding 
behaviour, where it acts as the most potent orexigenic signalling molecule in the brain 
that we know of to date (Kalra and Kalra, 2003). NPY achieves this range of functions 
in the CNS through several different members of a class of GPCRs: NPY Y1R, Y2R, Y4R 
and Y5R [extensively characterised in (Parker and Herzog, 1999)]. NPY also has a role 
in exerting effects on GnRH neuron function and LH secretion; however, the question of 
whether this effect is ultimately stimulatory or inhibitory remains difficult to definitively 
state, as it varies by receptor, species, and steroid hormone milieu.  
NPY neural fibres that project close appositions to GnRH neurons in their 
proximal regions have been commonly reported from immunolabelling in mice and rats 
(Campbell et al., 2001; Li et al., 1999; Tsuruo et al., 1990; Turi et al., 2003), as well as 
humans (Dudas et al., 2000). Retrograde tracers applied in the rPOA reveal that NPY 
fibres predominantly originate from two distinct sites in the brain, projecting from the 
ARN, as well as another population projecting from the ventrolateral medulla of the 
brainstem (Simonian et al., 1999). These two anatomically distinct populations of central 
NPY neurons are distinguishable by immunolabelling, and genetic targeting, by the 
transmitters that are co-expressed. In the brainstem, NPY neurons co-express both 
adrenalin and noradrenalin (Everitt et al., 1984; Sawchenko et al., 1985; Turi et al., 2003). 
In the ARN, virtually all NPY neurons express agouti-related peptide (AgRP) (Hahn et 
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al., 1998). Triple labelling experiments reveal that 50% of NPY fibres in close apposition 
to GnRH neurons in the rPOA are positive for AgRP, while only 25% were 
adrenergic/noradrenergic (Turi et al., 2003). The same study found a 64% reduction in 
NPY-immunoreactive fibres in close apposition to GnRH neurons if the ARN was 
chemically ablated (Turi et al., 2003), therefore it appears that NPY neurons residing in 
the ARN compose the largest population that innervate GnRH neurons. In rats and 
primates, electron microscopy (EM) reveals only very sparse synapses between NPY 
neuron terminals and GnRH neurons at the level of the soma (Thind et al., 1993; Tsuruo 
et al., 1990), however this work does not take into account the rest of the vast GnRH 
neuron input zone. In contrast, EM reveals frequent synapses to GnRH neurons by AgRP-
containing terminals in mice (Turi et al., 2003), indicating large amounts of synaptic 
input by ARN NPY neurons at the proximal region of the GnRH neuron. 
Morphologically, synapses formed by NPY/AgRP axon terminals have symmetrical 
thickenings of the synaptic membranes (Tsuruo et al., 1990; Turi et al., 2003), an 
indicator of a synapse being classically inhibitory (GABAergic) in nature (Colonnier, 
1968; Gray, 1959). This is in agreement with morphological evidence in the ARN that 
identifies that a large subset of NPY neurons are GABAergic (Horvath et al., 1997). 
Overall there is strong morphological evidence that NPY neurons innervate GnRH 
neurons, and that a large subset that innervate the GnRH neural soma are GABAergic in 
nature, residing in the ARN. 
GnRH neurons express just a small subset of NPY receptors, that appear to vary 
between species. This is most well characterised in the rat, in which there is 
morphological evidence that Y5R is expressed at the soma (Campbell et al., 2001), while 
Y1R positive fibres closely appose GnRH neuron somata, and appear to be expressed on 
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the GnRH neuron itself in distal dendrites, near the ME (Li et al., 1999). NPY action 
through Y5R has been demonstrated to exert an inhibitory influence upon LH secretion 
(Raposinho et al., 1999), and electrophysiological experiments demonstrate that Y5R 
activation suppresses GnRH neuron excitability, and this action occurs postsynaptically 
(Xu et al., 2009), possibly by modulating resting membrane potential (VM) through G-
protein coupled inwardly rectifying K+ (GIRK) channels (Sun and Miller, 1999). The 
influence of Y1R action on GnRH neurons in rats is more complex, but is proposed to 
facilitate GnRH release in the presence of ovarian steroids or at the time of the 
preovulatory surge (Besecke and Levine, 1994; Crowley et al., 1987; Crowley and Kalra, 
1987). 
In the mouse, the action of NPY receptors upon GnRH neurons is provided 
mostly by electrophysiological studies. Roa and Herbison report that NPY suppresses 
GnRH neuron firing with no alteration to VM, and through subtractive use of agonists 
and antagonists, this was found to be mediated by Y1R (Roa and Herbison, 2012). In 
nasal explants containing developing GnRH neurons, Klenke and colleagues explored 
the mechanism of Y1R inhibition using a combination of second messenger antagonising 
drugs and calcium imaging (Klenke et al., 2010). Using pertussis toxin to block inhibitory 
coupling of GPCRs and TPN-Q to block GIRK channels they demonstrated that blocking 
these pathways abolished the inhibitory effect of NPY (Klenke et al., 2010); however, it 
should be reiterated that this was performed using immature GnRH neurons, and the 
mechanism of inhibition in adult neurons may be different. Interestingly, agonists of Y4R 
caused depolarisation in the majority of GnRH neurons. The endogenous ligand of Y4R 
is pancreatic peptide (Bard et al., 1995), however this peptide is not produced in the brain 
(Sainsbury et al., 2010), and NPY acts only as a weak agonist towards this receptor 
	 	 CHAPTER ONE 
 49 
making its role less clear (Lundell et al., 1996; Yan et al., 1996). Recordings of GnRH 
neurons from mice in a fasted state where NPY expression is increased, in combination 
with blockade of postsynaptic activity, provide evidence that activation of Y1R 
presynaptically acts to reduce GABA release from NPY/GABAergic terminals (Sullivan 
and Moenter, 2004a), thus reducing excitatory GABAergic input to GnRH neurons 
during fasting. Overall, direct actions of NPY upon GnRH neurons are complex, and may 
depend largely upon the presence of steroid hormones or the energy status of the animal 
at the time, but these actions, both pre- and postsynaptic, appear to be predominantly 
inhibitory. 
In surprising contrast to the direct inhibitory effects of NPY on GnRH neurons, 
NPY administered in vivo in rodents often has stimulatory effects upon LH secretion 
(Bauer-Dantoin et al., 1991; Crowley et al., 1987; Crowley and Kalra, 1987; Guy et al., 
1988). In the rat this may result from direct stimulatory effects of Y1R activation on 
GnRH nerve terminals (Crowley et al., 1987; Crowley and Kalra, 1987), however direct 
Y1R activation in the mouse is inhibitory, at least at the level of the GnRH neuron soma 
(Roa and Herbison, 2012). There is evidence, however, that NPY acts at multiple levels 
of the axis. In addition to the aforementioned direct effects on GnRH neurons, it may 
also directly potentiate the downstream gonadotrophs themselves via Y1R (Hill et al., 
2004; Leupen et al., 1997; Woller et al., 1993). Upstream, has also been shown to 
increase Kiss1 mRNA expression in hypothalamic nuclei that contain GnRH neuron 
afferents (Luque et al., 2007). In fact, antagonism of Y1R greatly diminishes GnRH 
induced LH release, suggesting NPY activity on the gonadotroph may be obligatory 
(Leupen et al., 1997). The expression of Y1R is upregulated by ovarian steroids and varies 
over the estrous cycle (Hill et al., 2004), and is highest during mid-morning to mid-
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afternoon of proestrus (Xu et al., 2000b). NPY administered in ovariectomised rats will 
inhibit LH secretion, but will stimulate secretion of LH when E2 replacement is given 
(Sahu et al., 1987). Moreover, NPY KO mice are relatively reproductively normal, except 
for the amplitude of both physiological or induced LH surges, which are halved in 
comparison to wild-type mice (Xu et al., 2000a). Overall, in rodents NPY plays a role in 
the generation of the preovulatory LH surge by acting at several levels of the GnRH 
neural network and the gonadotroph itself, while acting to suppress basal GnRH neuron 
activity outside of the surge. Interestingly this complexity of NPY actions is not present 
in the female non-human primate, in which NPY exclusively elicits LH secretion (Woller 
and Terasawa, 1991, 1992), and is even secreted in pulses that are concurrent with LH 
(Terasawa et al., 1988).  
Recent work conducted within the Campbell laboratory has clarified much of this 
complexity of NPY actions on LH secretion by specific activation of NPY neurons 
residing in the ARN in vivo (Coutinho et al., 2019). Similar to previous approaches in 
GABA neurons (Silva et al., 2019), ARN NPY neurons were activated using both 
optogenetic and chemogenetic stimulation, paired with measurement of LH in serial 
blood samples. In both sets of experiments, ARN NPY neuron activation potently 
suppressed LH secretion, and chemogenetic activation slowed LH pulse frequency. 
These results have provided strong evidence that NPY signalling to GnRH neurons acts 
to restrain LH secretion and may be an important physiological ‘break’ for LH pulse 
generation.  
Given that NPY neurons have a role in both energy balance and reproduction, 
they pose a potential point of integration between these two physiological systems. 
Reproduction is a profoundly energy intensive process, particularly in mammals where 
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a period of lactation follows parturition. It therefore stands to reason that, from an 
evolutionary perspective, there are likely to be systems in place to sense states of lowered 
energy status and subsequently suppress fertility during this time. The key hormone that 
is thought to relay long term energy status to feeding circuits in the hypothalamus is 
leptin, as this is secreted from adipocytes in a manner that is proportional to adiposity 
(Lönnqvist et al., 1997). Leptin is also a permissive regulator of fertility. A lack of 
functional leptin in humans suppresses gonadotrophin secretion, which can be rectified 
by exogenous leptin treatment (Farooqi et al., 1999). Infertility is present in in the obese, 
leptin-deficient ob/ob mouse, which cannot be corrected by diet-restriction, and instead 
is restored only when leptin is replaced in these animals (Chehab et al., 1996). Quennell 
and colleagues demonstrated that this permissive signalling by leptin occurs centrally, as 
KO of the leptin receptor (LepR) within forebrain neurons led to infertility (Quennell et 
al., 2009). This likely occurs indirectly as GnRH neurons do not express Lepr mRNA.  
NPY neurons in the ARN are highly sensitive to leptin signalling, where leptin 
potently downregulates their expression of NPY (Schwartz et al., 1996; Stephens et al., 
1995) to suppress feeding behaviour. As NPY neurons are also an upstream regulator of 
GnRH neurons, this makes ARN NPY neurons an attractive candidate for relaying the 
permissive signal of leptin. In this case, low energy status may suppress GnRH neural 
drive via NPY, which is lifted by leptin signalling in states of energy availability. This is 
supported by a set of experiments conducted by Wu and colleagues in which certain 
leptin-sensitive neural populations were ablated in ob/ob mice (Wu et al., 2012). 
Remarkably, ablation of only ARN NPY neurons specifically leads to restoration of 
fertility. Additionally, when LepR is restored genetically within ARN NPY neurons of 
LepR-null mice, a similar restoration to fertility is observed, as well as restoration of 
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estrus cyclicity and E2-negative feedback (Egan et al., 2017). Surprisingly, genetic KO 
of LepR within ARN NPY neurons leads to mice with delayed puberty, but normal 
fertility in adulthood (Egan et al., 2017). Perhaps this highlights redundancy in this 
circuit, in which KO of leptin signalling in ARN NPY neurons leads to compensatory 
changes in other GnRH neural afferents to maintain fertility. Acute LepR KO within 
ARN NPY neurons in adulthood would need to be conducted to address this. Relay of 
leptin signalling is unlikely to solely result from direct ARN NPY neuron action onto 
GnRH neurons, and may also involve ARN NPY neural communication to other GnRH 
neural afferents. For example, ARN NPY neurons form direct inhibitory synaptic 
contacts with kisspeptin neurons in both the ARN and AVPV (Padilla et al., 2017). Taken 
together, this evidence provides support to the hypothesis that signalling from ARN NPY 
neurons in the absence of leptin leads to infertility, and that ARN NPY neurons act as a 
relay of energy reserves within the GnRH neural network.   
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1.4 The PNA mouse elucidates circuit alterations that may underpin 
neuroendocrine derangement in PCOS 
As noted earlier, the vast majority of women with PCOS have alterations to 
gonadotrophin secretion, commonly manifesting as an altered LH/FSH ratio (Taylor et 
al., 1997), or overt increases in LH secretion (Balen et al., 1995; Franks, 1989). 
Additionally, elevated LH is linked to a decrease in responsiveness to ovarian steroid 
hormones feedback, which appears to be worsened by high circulating androgens 
(Daniels and Berga, 1997; Eagleson et al., 2000; Pastor et al., 1998), creating a 
breakdown of negative-feedback and persistently elevated LH. This creates a vicious 
cycle in which elevated LH drives androgen production at the level of the ovary, which 
disrupts negative feedback, leading to persistent over-activation of the GnRH neural 
network, and subsequent GnRH/LH pulsatile secretion. GnRH neurons themselves do 
not express AR (Huang and Harlan, 1993), thus the neuroendocrine disruptions caused 
by elevated androgens are likely transsynaptic, acting instead on the afferent portion of 
the GnRH neural network.  
Work over the past 15 years in the PNA mouse has revealed alterations to specific 
hypothalamic circuitry that regulates GnRH neural function, and may underpin the 
disruptions to neuroendocrine function observed in women with PCOS. Early work in 
brain slices from the PNA mouse revealed an increase in GABAA-mediated PSCs onto 
GnRH neurons (Sullivan and Moenter, 2004b). Furthermore, this is reversible by in vivo 
AR blockade using flutamide, suggesting this is androgen mediated. This increase in 
GABAergic PSCs in the PNA mouse was not reduced by action potential blockade using 
tetrodotoxin, which indicates it is not activity-dependent, and may be a result of increased 
synaptic input (Wong et al., 2000). Further brain slice work demonstrated that P4 
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treatment decreases GABAergic PSC frequency in GnRH neurons, but that this effect is 
blocked by the presence of DHT (Sullivan and Moenter, 2005). Finally, GnRH neurons 
themselves have an increased basal firing rate in the PNA mouse (Roland and Moenter, 
2011). This work provided evidence that GABAergic input to GnRH neurons plays a role 
in P4 negative feedback, and that androgens could potentially disrupt this feedback. 
Additionally, it provided early insight that GABAergic synaptic input to GnRH neurons 
is elevated in PNA mice, and is associated with higher GnRH neural activity. 
Morphological and in vivo work within our lab has further elucidated the nature 
and role of GABAergic input to GnRH neurons in this PNA model. Close appositions 
between the proximal regions of GnRH neurons and terminals containing the vesicular 
GABA transporter (VGAT) are markedly increased in the PNA-treated mouse (Moore et 
al., 2015). This finding is consistent with the predicted mechanism for increased activity-
dependent GABAergic PSCs found via previous electrophysiological work (Sullivan and 
Moenter, 2004b). Moreover, anterograde tract tracing revealed GABA neurons within 
the ARN specifically double their close appositions with the GnRH neuron proximal 
dendrite in PNA-treated mice (Moore et al., 2015). This specific circuit alteration 
originating from the ARN is associated with a large decrease in the proportion of GABA 
neurons that express the P4 receptor (Moore et al., 2015). Remarkably, when PNA-
treated mice are given a regime of daily flutamide to block androgen activity from late 
puberty to early adulthood, estrus cyclicity and ovarian function are restored. Moreover, 
this is associated with a decrease in VGAT appositions with GnRH neurons in adulthood 
(Silva et al., 2018). Finally, when ARN GABA neurons are chronically activated for 2-3 
weeks chemogenetically, mice exhibit PCOS-like features (Silva et al., 2019). 
Specifically, estrus cyclicity is disrupted, corpora lutea present in the ovaries is reduced, 
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plasma T is increased, and LH levels are elevated in some mice. Interestingly there may 
be a clinical equivalent of this, as women prescribed anti-epileptic GABA agonists 
frequently exhibit PCOS-like symptoms (Isojarvi et al., 1993; Prabhakar et al., 2007; 
Stephen et al., 2001). Together these data establish ARN GABA-to-GnRH neurons as an 
important regulator of GnRH neuron activity, and mediator of feedback by ovarian 
steroids. The increased innervation of GnRH neurons and decreased P4 receptor 
expression in ARN GABA neurons within PNA mice, as well as their apparent sensitivity 
to disruption by the presence of androgens, make this neural population a candidate for 
driving the neuroendocrine abnormalities that occur in PCOS. ARN GABA neurons are 
a large population with a diverse range of functions and a varied molecular profile, 
therefore further work is needed to narrow down potential specific populations of ARN 
GABA neurons that may be disrupted in PCOS.  
NPY neurons in the ARN are a population that are highly co-expressed with 
GABA in rodents (Horvath et al., 1997), particularly in mice (Marshall et al., 2017). 
Recent evidence has implicated that ARN NPY neurons restrain LH secretion (Coutinho 
et al., 2019), which likely occurs via inhibition of GnRH neurons or their afferents 
(Padilla et al., 2017; Roa and Herbison, 2012). Interestingly plasma NPY is reduced in 
women with PCOS (Romualdi et al., 2008), which may indicate reduction of this 
important physiological break on GnRH neurons, and could contribute to LH 
hypersecretion. As the ARN, and ARN GABA neurons are remodelled following 
androgen excess (Moore et al., 2015), ARN NPY neurons presented an attractive 
candidate for a specific subset of GABA neurons that are remodelled in PNA-treated 
mice.  
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1.5 Summary, aims and hypotheses 
PCOS is a common disorder that causes infertility, is associated with co-
morbidities that lead to poor health outcomes, and is highly distressing for those affected. 
Despite its prevalence, the aetiology and pathophysiology of PCOS remains poorly 
understood. However, evidence in humans and a variety of animal models indicates that 
androgen excess in utero may be associated with neuroendocrine derangement in later 
life. Prenatal androgen exposure in mice can faithfully recapitulate the reproductive 
abnormalities that occur in PCOS, and has allowed further insight into whether PCOS is 
associated with alterations in brain circuitry that control the HPG axis. Previously, PNA 
mice have revealed that elevated LH secretion is associated with strengthening of a 
circuit between ARN GABA neurons and GnRH neurons, as well as reduced expression 
of PR that could contribute to a reduction in negative feedback. The ARN is a central 
point of control for many diverse systems, and GABA neurons within this nucleus 
compose a heterogeneous population that express a range of other transmitters that 
ultimately define their function. One such population are the ARN NPY neurons that 
may be an important population for restraint of GnRH/LH secretion. As ARN NPY 
neurons are a candidate population that may be altered in PNA-treated mice, the broad 
aims of this PhD thesis were: to determine whether NPY expressing neurons are 
altered in PNA-treated mice and to identify what proportion of the ARN GABA 
population express NPY.  
I hypothesised that ARN NPY neurons would have altered GABA-to-GnRH 
neural circuitry, as well as altered steroid hormone sensitivity in PNA-treated mice that 
may contribute to elevated LH secretion. My first objective was to characterise the 
molecular identity of ARN GABA neurons and the proportion that express each of the 
	 	 CHAPTER ONE 
 57 
transmitters examined, as well as determine if this proportion was altered in PNA mice 
(Chapter 3). Following identification that a large subset of ARN GABA neurons express 
NPY, my second objective was comprised of two components: firstly, to determine if 
these neurons alter their close appositions with GnRH neurons in PNA-treated mice; and 
secondly, to assess if ARN NPY neuron sensitivity to steroid hormones, and the 
metabolic cue leptin, is altered in PNA-treated mice (Chapters 5 & 6). Finally, my third 
objective assessed the relative expression of mRNA to examine whether expression of 
transmitters and receptors involved in ARN NPY-to-GnRH neuron circuitry, as well as 
the genes involved in the broader control of fertility, were altered in PNA-treated mice 
(Chapter 7).  
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2  GENERAL METHODS 
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2.1 Animals 
The procedures involved in the research conducted for this thesis were carried 
out with permission from the University of Otago Animal Ethics Committee (Dunedin, 
New Zealand), under the approval number 07/15. Mice (Mus musculus) with a C57BL/6 
genetic background were generated and housed in the University of Otago Hercus-Taieri 
Resource Unit. Mice were group housed and given ad libitum access to food and water 
unless specified otherwise in individual methods sections. Rooms were kept at a constant 
21°C with light-dark cycles of 12:12 hours (h, lights on at 0700 h). The specific 
transgenic strains utilised in these experiments were vesicular GABA transporter 
(VGAT)-IRES-Cre mice (Vong et al., 2011) crossed with Ai9 Cre-dependent tdTomato 
reporter mice (Madisen et al., 2010); agouti-related peptide (AgRP)-IRES-Cre mice 
(Tong et al., 2008) crossed with ROSA26-CAGS-tGFP floxed-stop reporter mice (Wen 
et al., 2011b).  
2.2  Prenatal androgen exposure 
Prenatal androgen treatment (PNA) was performed as described previously 
(Moore et al., 2013; Sullivan and Moenter, 2004b). Pregnant dams were treated with 250 
µg of dihydrotestosterone (DHT) by subcutaneous (s.c.) injection in late pregnancy (days 
16, 17, and 18). DHT stock solution was prepared by dissolving into absolute ethanol (25 
mg/mL), then on the day of injection, diluting in sesame oil (1:10). Mice were injected 
with 0.1 mL of either DHT or sesame oil vehicle (VEH control), once per day. Offspring 
were weaned at postnatal day 21 and female offspring were studied in adulthood.  
	 	 CHAPTER TWO 
 60 
2.3 Estrous cycle monitoring 
In order to verify acyclicity of PNA mice, and to ensure all female mice were in 
diestrus when samples or tissue was collected, daily vaginal cytology samples were 
collected for a period of 8-14 days at 0900 – 1100 h. Swabs were collected by gentle 
insertion of a wire loop into the vagina of each mouse and transfer of cells to a glass 
slide. Once dried, the samples were stained using 0.5% toluidine blue and examined 
using light microscopy with a 10x objective. The cells present in the sample were used 
to determine estrous cycle stage using previously described guidelines (Byers et al., 
2012). Briefly, diestrus was determined by the presence of leukocytes with very few 
epithelial cells. Proestrus was determined by the presence of predominantly nucleated 
epithelia with a small number of cornified epithelia. Estrus presents as predominantly 
cornified epithelia, often in large sheets. Metestrus was determined where mostly 
cornified epithelia are present, with some nucleated epithelia and leukocytes also being 
present. Metestrus was often confirmed post hoc by being succeeded by a diestrus phase. 
In the rare occasion where pseudopregnancy occurred (persistent presence of only 
cornified epithelia), estrous cycle monitoring was halted for seven days and then 
resumed. 
2.4 Blood sampling 
Two blood samples were collected from a cohort of mice, first in a fed state, then 
following a 12-h fast for leptin ELISA outlined in Chapter 6. In diestrus, fine surgical 
scissors were used to cut approximately 1mm from the tail tip, and 30-40 µm of blood 
was collected from each mouse in heparin-coated capillary tubes. Blood samples were 
separated by centrifuge using a Thermoscientific Heraeus Pico 17 (Thermo Fisher 
Scientific, Waltham, MA, USA) at 12,000 RPM for 8-10 minutes (min). Packed red 
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blood cells were disposed of and the plasma phase of each sample was transferred using 
a pipette to a collection tube and stored at -20°C until use. 
2.5 Stereotaxic surgery 
Prior to surgery, equipment, gauze and cotton swabs were sterilised by autoclave, 
and an anti-bacterial hibitane solution was used throughout surgery to maintain aseptic 
conditions. Mice were placed inside an anaesthetic delivery chamber (VetEquip) where 
they were initially anaesthetised with 4% isofluorane in combination with delivery of 
oxygen at 1000 mL/min. The mouse was then placed onto an incisor bar affixed to a 
stereotaxic frame (Stoelting Co., IL, USA) and tubing delivered 1.5% isofluorane in 
combination with 600 mL/min oxygen for the duration of the procedure. Before 
commencing surgery, post-surgical pain management was achieved by s.c. injection of 
Norocarp (0.1 mg/kg), a non-steroidal anti-inflammatory analgesic. Tricin eye and ear 
ointment was also applied to the eyes in order to prevent drying during the procedure. 
Stereotaxic bars were placed into the ear canals of the mouse and secured onto the 
stereotaxic frame, which in combination with the incisor bar prevented movement of the 
head in all axes. 
Anaesthesia was confirmed by checking for a toe-pinch reflex in the hind limb. 
When anaesthesia was achieved, the surface of the head was shaved, exposing the skin, 
and an incision was made along the midline of the head to expose the dorsal surface of 
the skull. The points bregma, lambda and the intersection of the sagittal and nasal sutures 
were used to align the skull horizontally. Using bregma as point zero, a Hamilton needle 
was then moved to established anteroposterior (AP), mediolateral (ML), and dorsoventral 
(DV) coordinates for injection into the site of interest (specific co-ordinates are given in 
their respective methods sections). A small hole was made in the skull at the appropriate 
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coordinates using a surgical drill, and the dura mater was removed in order to expose the 
underlying brain tissue. The syringe was then loaded with a specific volume of treatment 
to be delivered (outlined in Chapter 3 and 4), then slowly lowered, while simultaneously 
displacing the sagittal sinus to one side when midline injections were performed, to the 
desired dorsoventral (DV) coordinate for each injection site using the dorsal surface of 
the brain as point zero. Once inserted, the syringe was left for 5 min before injection. The 
treatment was injected at a rate of 50 nL/min, and the syringe was then left for a further 
5 minutes before being retracted. After retracting the syringe, bleeding was quenched 
with sterile cotton swabs when necessary, then the incision site was closed with surgeon’s 
knots using a 6-0 size suture. The surgical site was cleaned and disinfected with a 
sterilised cotton swab and hibitane antiseptic solution. All mice were then returned to 
heated housing to recover, and were monitored for 5 days following surgery with animal 
welfare post-surgical score sheets.  
2.6 Tissue collection and preparation 
2.6.1 Unfixed frozen brain tissue 
Mice were sacrificed by rapid, manual dislocation of the cervical spine and 
decapitated. Fresh brains were dissected from the skull on a bed of ice to keep cool, and 
then immediately frozen in isopentane on dry ice, they were then stored at -80°C for later 
processing. In batches, brains were cut into thick coronal 250 µm slices on a cryostat 
(Leica CM1950, Leica Biosystems GmbH, Nussloch, Germany) where the chamber and 
tissue mounting stage temperature were both set to -20°C; during cutting, brains were 
embedded in Tissue-Tek OCT compound to affix them to the stage (Sakura Finetek Ltd., 
Netherlands). Coronal tissue slices from approximately Bregma +0.86 mm to -2.70 mm 
were arranged in order onto glass microscope slices. Tissue throughout the rostral 
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preoptic area (rPOA), the rostral periventricular area of the 3rd ventricle (RP3V), and 
arcuate nucleus (ARN) were micro-dissected for RNA purification (details of micro-
dissection given in Chapter 7). 
2.6.2 Fixed brain tissue 
Mice were sacrificed by a lethal dosage of sodium pentobarbital (3 mg/100µL) 
delivered intraperitoneally. The thoracic cavity was accessed and a transcardial perfusion 
of 4% paraformaldehyde (PFA) solution in phosphate buffer (25 mM monobasic sodium 
phosphate, 87 mM dibasic sodium phosphate; pH 7.6) was delivered via the left ventricle 
of the still beating heart, delivering 20 mL at a rate of approximately 10 mL/min. PFA 
prevents decomposition of tissue while maintaining cell structure and integrity of the 
entire brain, including its deep structures. Following perfusion, the brain was removed 
and post-fixed in 4% PFA for one h at room temperature (RT). Brains were then 
cryoprotected in a 30% sucrose in tris-buffered saline (TBS) solution (0.05 M tris- HCl, 
0.05 M tris-base, 0.15 M sodium chloride; pH 7.6) for a further 12-24 h at 4°C. At this 
point the tissue was cut into 30 µm sections on a freezing microtome. In experiments 
where the hindbrain was examined, a razor blade was first used to remove the olfactory 
bulb and the brain was placed upon a frozen platform of 30% sucrose solution with the 
brainstem facing upwards. In all other experiments, the hindbrain was removed and the 
forebrain was placed directly upon the freezing stage. The brain was then frozen between 
-23°C and -21°C, and 30 µm coronal sections were collected. The brain sections were 
then stored in TBS at 4°C, or for long-term storage, in cryoprotectant (0.05 M phosphate 
buffer, 0.15 M sodium chloride, 0.87 M D-sucrose, 1mM polyvinylpyrrolidone-10, 30% 
ethylene glycol; pH 7.6) at -20°C.  
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2.7 Immunohistochemistry 
2.7.1 Generic single and double-label fluorescent immunohistochemistry 
Tissue was washed in TBS (three 10 min washes) to remove cryoprotectant that 
the tissue was stored in. Where antigen retrieval was required, brain sections were 
incubated in 1mM ethylenediamine tetraacetic acid (EDTA) in a water bath at 90°C for 
15 min. Otherwise, brain sections were first incubated in 5-10% NGS in incubation 
solution (TBS with 0.3% Triton X-100, 0.25% bovine serum albumin (BSA); pH 7.6) for 
30 min at RT. Following this, brain tissue was washed in TBS and then incubated in 
either a single or a cocktail of primary antibodies against the antigen of interest in 
incubation solution with 2% NGS for 48 h at 4°C (primary antibody concentration ranged 
from 1:200 to 1:50,000; individual antibodies and their concentrations are outlined in 
their respective chapters as well as Appendix I). Brain sections were then washed in 
TBS, and incubated in a secondary IgG raised against the species of the primary 
antibodies used conjugated with either AlexaFluor 488 or 568 for 2 h at RT (1:200-
1:1000 in incubation solution). Sections either went through a final wash in TBS and 
were immediately mounted onto glass microscope slides, or where Hoechst stain was 
used, incubated in Hoechst solution for 5 min (1:100) before being washed and mounted. 
2.7.2 Single-label chromogenic GFP immunohistochemistry  
Tissue was washed in TBS to remove cryoprotectant that the tissue was stored in. 
Endogenous peroxidase activity was quenched by incubating in a 1% hydrogen peroxide 
solution (11 mL TBS, 8 mL methanol, 600 µL 30% H2O2) for 10 min at RT. Sections 
were then washed TBS and incubated with rabbit anti-GFP (1:10,000, Molecular Probes, 
Invitrogen, Eugene, OR, USA) and 2% NGS in incubation solution for 48 h at 4°C. 
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Sections were then washed and then incubated with a biotinylated goat anti-rabbit 
secondary antibody (1:200, Vector Laboratories Inc., Burlingame, CA, USA) in 
incubation solution for 60 min at RT. Sections were washed in TBS and incubated with 
the A/B Vectastain Elite kit (Vector Laboratories Inc., Burlingame, CA, USA) for 60 min 
at RT, to amplify staining of the tissue. Another wash was carried out before performing 
a nickel-enhanced 3,3’-diaminobenzidine (DAB) reaction (nickel-DAB solution; 0.1 M 
acetate buffer, 1% DAB, 0.16 M nickel sulphate, 0.2 M D-glucose, 15 mM ammonium 
chloride, 1.88 x 10
-7 
M glucose oxidase) with glucose oxidase added immediately before 
incubation of sections. Tissue was incubated until sufficient labelling of GFP-positive 
cells and neural projections was observed, approximately 10-15 min, then washed in TBS 
to stop the nickel-DAB reaction. 
2.7.3 Antibody controls 
Primary antibody validation has been demonstrated in the scientific literature, 
citations to these data are provided in Appendix I. Secondary antibody specificity was 
verified in each individual immunohistochemistry run by primary antibody omission in 
a subset of tissue.  
2.8 RNA purification 
Purification of RNA from tissue collected from the rPOA, RP3V and ARN of 
fresh brain tissue was performed using an RNeasy Mini Kit (QIAGEN Group, Hilden, 
Germany) following manufacturer instructions. Micro-dissected tissue was immediately 
suspended in 350 µL of lysis buffer with 1% b-mercaptoethanol (10 µL of b-
mercaptoethanol per mL of supplied buffer RLT), and homogenised using a sterilised 
pestle. Following homogenization, 350 µL of 70% ethanol was added to the lysate and 
	 	 CHAPTER TWO 
 66 
each 700µL sample was transferred to a supplied RNeasy Mini spin column with 
collection tube, then centrifuged at 8000 relative centrifugal force [RCF; 9300 
revolutions per min using an Eppendorf Centrifuge 5415D (Hamburg, Germany)] for 15 
seconds (s). Discarding the flow through between steps, a series of centrifuge spins were 
performed on each sample; firstly 700 µL of supplied Buffer RW1 was added to each 
spin column, centrifuging again at 8000 RCF for 15 s. Then, 500 µL of Buffer RPE was 
added and centrifuged at 8000 RCF for 15 s, then repeated at 8000 RCF for 2 min. 
Finally, each spin column was placed into a new collection tube, and 30 µL of RNase-
free water was added to the columns and centrifuged at 8000 RCF for 1 min to elute the 
RNA. Purified RNA samples were stored at -80°C until use. Before storage, 1 µL of elute 
was collected from each sample and a Qubit assay was performed with a high-sensitivity 
RNA kit (Molecular Probes, Invitrogen, Eugene, OR, USA) using manufacturer 
instructions to quantify the yield. A Qubit working solution was prepared by diluting 
supplied Qubit Reagent into Qubit Buffer (1:200). Two standards were prepared by 
diluting 10 µL of standards A or B into 190 µL of Qubit working solution, while samples 
were prepared by diluting 1 µL of eluted RNA to 199 µL Qubit working solution. All 
standards and samples were vortexed and incubated at RT for 2 min, and then read using 
a Qubit 2.0 Fluorometer. Samples where the yield was < 20 ng per µL were concentrated 
using a Speedvac (ThermoSavant DNA120 Speedvac, Thermo Bioscience Technologies, 
Milford, MA, USA) for 20 min and re-assayed.  
2.9 Microscopy and image analysis 
Light microscopy to analyse chromogen stained tissue and assist with image 
acquisition in various experiments was performed using an Olympus BX51 
light/epifluorescent microscope (Olympus Optical, Hamburg, Germany) and SPOT 
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camera software (Diagnostic Instruments Inc., Sterling Heights, MI, USA) using 4x, 10x 
and 20x objectives. Confocal microscopy was performed either using a Zeiss LSM710 
upright microscope (Carl Zeiss AG, Oberkochen, Germany) with an argon laser exciting 
at 488 nm and a helium laser exciting at 543 nm, or a Nikon A1R upright multi-photon 
confocal microscope (Nikon Instruments Inc., Melville, NY, USA) using diode lasers 
exciting at 488, 543 and 647 nm. Images were collected using a 20x air objective and 
40x oil objectives; details on Z-thickness, pinhole size and laser power are provided in 
Chapters 3, 4, 5 and 6. Image analysis was performed with ImageJ software (National 
Institutes of Health, Bethesda, MD, USA) and NIS-Elements software v4.00.00 (Nikon 
Instruments Inc.). Figure and diagram composition was performed using Adobe 
Photoshop CS5 (Adobe Systems Inc., San Jose, CA, USA) and Inkscape v0.92.2 
software. 
2.9.1 Anatomical division of the arcuate nucleus 
Throughout this thesis (Chapters 3, 4, 5 and 6) images taken through the ARN 
of the hypothalamus were utilized for analysis. As this represents a large, heterogeneous 
population of cells, the ARN was subdivided through its rostro-caudal axis in order to 
more finely assess changes within this nucleus. This was achieved by dividing the ARN 
by approximate thirds into rostral (rARN; Bregma -1.46 mm to -1.82 mm), middle 
(mARN; Bregma -1.94 mm to 2.30 mm) and caudal (cARN; Bregma -2.46 mm to 2.80 
mm) subregions.  
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Figure 2.1. Anatomical divisions of the rostral, middle, and caudal ARN. Coronal brain diagrams 
throughout the rostro-caudal extent of the ARN are shown with their position relative to Bregma defined. 
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2.10 Statistical analysis 
Statistical analyses were performed using PRISM software v7.0 & v8.0 
(GraphPad Software, La Jolla, CA, USA) and nSolver Analysis Software v4.0.70 
(NanoString Technologies Inc., Seattle, WA, USA). Specific statistical tests are provided 
in the methods section of each chapter. All results are presented as mean ± standard error 
of the mean (SEM). P-values < 0.05 were considered to be statistically significant. In 
figures, standard asterisk or letter notation is used to differentiate statistically significant 
data. 
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3 DEFINING THE MOLECULAR IDENTITY 
OF ARCUATE NUCLEUS GABA 
NEURONS 
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3.1 Introduction 
The hypothalamic arcuate nucleus (ARN) is a critical integration point for the 
translation of peripheral hormone cues into neuronal signalling pathways in the 
mammalian brain. Multiple neuronal phenotypes, typically defined by classical or 
neuropeptidergic signalling molecules, are located in the ARN and project widely 
throughout the brain to regulate a variety of critical functions including, but not limited 
to, energy homeostasis, growth, reproduction, and lactation. In particular, the ARN is 
considered a central node in gonadal steroid hormone feedback, particularly the restraint 
of the GnRH axis, and direct, hormone-sensitive afferent inputs project from the ARN to 
GnRH neurons (Wintermantel et al., 2006). The medial basal hypothalamus is a critical 
site of estrogen feedback signalling (Akema et al., 1983; Smith and Davidson, 1974), 
where selective adult knockdown of estrogen receptor-α (ESR1) expression disrupts 
chronic estrogen negative feedback (Yeo and Herbison, 2014). The specific molecular 
identity of the ARN neurons mediating steroid hormone feedback information to GnRH 
neurons has not been clearly defined; however, recent work has implicated GABA 
signalling neurons in the ARN (Moore et al., 2015).  
A role for ARN GABA neurons in mediating feedback signals to GnRH neurons 
has emerged from investigating polycystic ovary syndrome (PCOS), which is 
characterised by impairments in steroid hormone mediated feedback (Burt Solorzano et 
al., 2012; Taylor et al., 1997; Yoo et al., 2006a). In a prenatally androgenised (PNA) 
mouse model of PCOS negative feedback is also impaired (Moore et al., 2013; Moore et 
al., 2015), and this is associated with both increased innervation to GnRH neurons by 
GABA neurons (Moore et al., 2015), as well as increased activation of GnRH neurons 
by GABA neurons (Sullivan and Moenter, 2004b). Notably, increased innervation to 
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GnRH neurons was observed when investigating ARN GABA neurons specifically, and 
these neurons also display reduced steroid hormone sensitivity (Moore et al., 2015). 
These findings have raised the possibility that an ARN GABA-to-GnRH neuron circuit 
plays a key role in the development and ongoing perturbations of fertility in PCOS. 
Virtually all GABA neurons in the brain express and release neuropeptides or 
other neurotransmitters in addition to GABA that may be involved in downstream 
signalling. For example, increased ARN GABA innervation to GnRH neurons in the 
PCOS model may be reflective of increased GABA signalling, or increased signalling 
from neurotransmitters co-released from GABA neurons. Previous work in the rodent 
suggests that a large subset of ARN GABA neurons express neuropeptide Y (NPY) 
(Horvath et al., 1997), which is a known regulator of GnRH neurons (Roa and Herbison, 
2012), however the co-expression of GABA and NPY in the mouse has not been well 
defined. To definitively assess the functional importance of ARN GABA neurons in the 
regulation of fertility and other critical homeostatic mechanisms, it is important to have 
a better understanding of potentially co-released neurotransmitters.  
The aim of these experiments was to therefore define the molecular identity of 
ARN GABA neurons via genetic targeting of the vesicular GABA transporter (VGAT), 
coupled with a transgenic reporter (Vong et al., 2011) to visualise neurons that use 
synaptic transmission of GABA. This was paired with immunohistochemistry in male 
and female mice, labelling neuropeptides and markers that identify neural phenotypes 
with known important roles in the central regulation of fertility, as well as presence 
within the ARN: kisspeptin, b-endorphin, tyrosine hydroxylase (TH), neuronal nitric 
oxide synthase (nNOS) and NPY. Neurotransmitters with significant co-localization with 
ARN GABA neurons were furthermore investigated in PNA mice, in order to determine 
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whether differences in the proportion of ARN GABA neurons expressing these 
transmitters was altered in this model of PCOS. 
The results described and discussed here are adapted from a manuscript published from 
experimental work conducted for the completion of this PhD (Marshall et al., 2017) (full 
manuscript provided in Appendix II). All results are provided for completeness, however credit 
for collection and analysis of data related to nNOS goes to Dr Elodie Desroziers, who also 
provided images shown in Figure 3.1, E. Additionally, immunohistochemistry for b-endorphin 
and TH were partially conducted by Timothy McLennan, however completion of data sets as well 
as all analyses were conducted by myself.  




To identify ARN vesicular GABA transporter (VGAT) expressing neurons, 
VGAT-IRES-Cre knock-in mice (Vong et al., 2011) were crossed with Ai9 Cre-
dependent tdTomato reporter mice (Madisen et al., 2010), generating mice in which 
VGAT neurons express a fluorescent tdTomato reporter (VGAT-tdTomato mice). 
Previous validation demonstrates that VGAT-IRES-Cre mice express Cre selectively in 
GABAergic neurons (Vong et al., 2011), and that the vast majority of GABA neurons 
express VGAT (Wojcik et al., 2006). Adult male and adult female mice (60-90 days) 
were housed in the Hercus Resource Unit (University of Otago, Dunedin, NZ) under 12 
h light cycles, with food and water provided ad libitum.  
3.2.1.1 Prenatal androgen treatment 
Prenatal androgen treatment to model PCOS in the female mice was carried out 
as previously described in section 2.3 (Moore et al., 2013; Sullivan and Moenter, 2004b). 
Briefly, on days 16-18 of pregnancy, dams were given daily s.c. injections of sesame oil 
(200 µL) either alone (vehicle control, VEH), or containing 250 µg of 
dihydrotestosterone (PNA treated group). VEH and PNA female offspring were then 
studied in adulthood. 
3.2.2 Intracerebroventricular colchicine injections and tissue collection 
To investigate NPY, nNOS and kisspeptin immunoreactivity, mice were treated 
with colchicine prior to tissue collections to halt axonal transport in order to improve 
neuropeptide immunoreactivity in the cell bodies. Mice were anaesthetised with 
isoflourane, delivered at 4 L/min within an induction chamber initially, and then 
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maintained at 0.6 L/min for the duration of surgery via a nose-cone. Mice were then 
secured onto a stereotaxic frame (Stoelting) and a small hole was drilled in the skull 0.1 
mm anterior to Bregma and 0.7 mm lateral to the sagittal suture. A Hamilton needle 
containing 1 µL of colchicine solution (30 µg/µL in saline) was lowered to a depth of 2.4 
mm ventral to the dorsal surface of the brain. Colchicine was then immediately injected 
i.c.v. over 1 min, and the cannula was removed 5 min following injection. Animals were 
killed for tissue collection within 24 h.  
Mice treated with or without colchicine were overdosed with 0.1 mL of 
pentobarbital (30 mg/mL) and transcardially perfused with 4% paraformaldehyde. Fixed 
brains were dissected, postfixed for 1 h at room temperature and transferred to 30% 
sucrose in Tris-buffered saline (TBS) overnight for cryoprotection. Brains were then cut 
using a freezing microtome (Leica 2400, Leica Biosystems) into three sets of 30 µm thick 
coronal slices.  
3.2.3 Single-label immunohistochemistry 
Free-floating single label immunohistochemistry (IHC) was performed on one in 
every three coronal slices containing the ARN (Bregma -1.22 to 2.80 mm) (Paxinos and 
Franklin, 2001) using the protocol outlined in section 2.7.1. The following primary 
antibodies (detailed in Appendix I) were used to detected immunoreactivity (ir) for the 
following neuropeptides or gaseous signalling molecules: rabbit anti-kisspeptin (a kind 
gift from A. Caraty, 1:5000) (Clarkson and Herbison, 2006b), rabbit anti-b-endorphin 
(ImmunoStar, 1:500) to identify pro-opiomelanocortin (POMC) neurons (Clifton et al., 
1998), rabbit anti-NPY (Sigma-Aldrich, 1:5000) (Real et al., 2009), rabbit anti-TH to 
identify dopaminergic neurons (Millipore, 1:5000) (Lee et al., 1989), and sheep anti-
nNOS to identify nitric oxide signalling neurons (a kind gift of P. C. Emson, 1:5000) 
	 	 CHAPTER THREE 
 76 
(Simonian and Herbison, 1996). Where IHC was performed against NPY or kisspeptin, 
brain slices were incubated with a polyclonal goat anti-rabbit AlexaFluor 488 antibody 
(1:200, Molecular Probes, Invitrogen). Where IHC was performed against TH or b-
endorphin, brain slices were first incubated with a biotinylated goat anti-rabbit antibody 
(1:400, Vector Laboratories Inc.), followed immediately by incubation with streptavidin 
conjugated with AlexaFluor 488 (1:400, Molecular Probes, Invitrogen). Where IHC was 
performed against nNOS, brain slices were first incubated with biotinylated donkey anti-
sheep antibody (1:500, Vector Laboratories Inc.), followed by incubation with 
streptavidin conjugated with AlexaFluor488 (1:1000, Molecular Probes, Invitrogen). 
This was immediately followed up with incubation with Hoeschst nuclear label 
(Hoeschst 33258, Sigma-Aldrich, 1:100). 
3.2.4 Confocal microscopy 
To detect labelled ir and endogenous tdTomato fluorescence, confocal z-stacks 
were obtained using a Zeiss710 confocal microscope (for kisspeptin, b-endorphin, NPY 
and TH; Carl Zeiss AG, Oberkochen, Germany) or a Nikon A1R confocal microscope 
(for nNOS; Nikon Instruments Inc., Melville, NY, USA); details on excitation lasers are 
provided in section 2.9. Using the Zeiss710, image stacks were collected at 20x 
magnification with 2.12 µm z-intervals from two representative slices in one hemisphere 
of the rostral, middle and caudal ARN (rARN, mARN, cARN) of each animal. For each 
label, one representative high power image stack from the rARN, mARN and cARN was 
taken at 40x magnification with 2x digital zoom for representative purposes. Tissue 
labelled for nNOS was imaged using a NikonA1R confocal microscope, at 40x 
magnification with 2 µm z-intervals. 
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3.2.5 Analysis 
3.2.5.1 Image analysis 
Images collected using the Zeiss710 microscope were analysed using ImageJ 
software (v1.48, National Institutes of Health, USA), while images collected using the 
NikonA1R microscope were analysed using Nikon NIS Elements software (v4.0, Nikon 
Instruments Inc.). The number of cell bodies expressing tdTomato (GABA neurons) and 
single or double labelled cells expressing the various cell phenotype markers 
(kisspeptin/b-endorphin/NPY/TH/nNOS) were quantified within the field of view (a 
unilateral hemisphere of the ARN) in each confocal stack. During quantification, the sex 
and treatment group of each animal was blinded. Percentages of labelled cells co-
expressing tdTomato (GABA), and tdTomato expressing (GABA) cells co-labelled with 
each phenotypic marker were determined.  
3.2.5.2 Statistical analysis 
Statistical analysis was performed using PRISM software (PRISM 7, Graphpad). 
Differences in mean co-expressing of tdTomato and each respective phenotype label 
between male, VEH treated female and PNA treated female mice were compared in each 
region of the ARN using a two-way ANOVA, with multiple comparisons carried out by 
a Tukey’s multiple comparisons test. P-values < 0.05 were considered statistically 
significant.  
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3.3 Results 
3.3.1 Identifying ARN GABA neurons and co-expressed neurotransmitters 
Endogenous tdTomato reporter expression of VGAT was detected in neuronal 
cell bodies throughout the ARN (Figure 3.1). VGAT/tdTomato reporter expression was 
found abundantly throughout the rostral to caudal extent of the ARN, and found densely 
packed in the ventromedial aspect of the ARN. Immunofluorescence for each signalling 
molecule marker investigated (kisspeptin, β-endorphin, NPY, TH, and nNOS) was 
detectable in distinct cell bodies and fibre processes (Figure 3.1, A-E). 
Average counts of total ARN neurons positive for VGAT/tdTomato reporter 
expression and each immunoreactive marker is shown in Figure 3.2. Total kisspeptin 
(Figure 3.2, A) and β-endorphin-ir cells (Figure 3.2, B) were not different between 
groups or throughout the ARN, nor were VGAT/tdTomato reporter-positive cells 
counted across tissue sets from all experiments (Figure 3.2, F). Conversely, two-way 
ANOVA indicated an overall effect of sex and treatment on the total number of NPY-ir 
cells (Figure 3.2, C; F(2, 66) = 11.68, p < 0.0001), and TH-ir cells (Figure 3.2, D; F(2, 
35) = 11.43, p = 0.0002). Specifically, the number of NPY-ir cells was higher in males 
compared with VEH females (p = 0.0242) in the rARN, and higher in males compared 
with both VEH- (p = 0.0006) and PNA-treated (p = 0.0192) females in the mARN. The 
average number of TH-ir cells was lower in males compared with PNA-treated females 
(p = 0.0098) in the rARN, and higher in PNA-treated females compared with both males 
(p = 0.002) and VEH-treated females (p = 0.0233) in the mARN. The total number of 
nNOS-ir cells detected in males was significantly lower than PNA-treated females, but 
not different to VEH females in the cARN (Figure 3.2, E).   
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Figure 3.1. Co-labelling of phenotypic markers with VGAT-tdTomato expression throughout the 
ARN (Previous page). Representative confocal z-stacks (6.36 µm thickness) of kisspeptin (A), β-
endorphin (B), NPY (C), TH (D), and nNOS (E) (green) immunoreactivity with tdTomato expression (red) 
throughout the rostral, middle, and caudal regions of the ARN. Scale bars = 50 µm. Insets. High-power z-
stacks (5.12 µm thickness) corresponding to the areas highlighted in (A–E), with open arrowheads 
indicating single-labelled immunoreactive neurons, and filled arrowheads indicating double-labelled cells. 
Scale bars, 10 µm (A–D) and 5 µm (E). 3V, third ventricle; ARN, arcuate nucleus; nNOS, neuronal nitric 
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Figure 3.2. Average number of neurotransmitter- or enzyme-immunoreactive cells across the ARN. 
The mean total number of cells counted within each coronal section expressing: (A) kisspeptin (males n=4, 
females n=4), (B) β-endorphin (males n=4, females n=5), (C) NPY (males n=5, females n=6, PNA n=4), 
(D) TH (males n=5, females n=6, PNA n=5), (E) nNOS (males n=5, females n=6, PNA n=6), or (F) 
tdTomato (indicating VGAT-expressing GABA neurons; males n=5, females n=5, PNA n=4), 
immunoreactivity throughout the ARN in males (grey bars), females (black bars) and PNA-treated females 
(red bars). Results are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 determined by 
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3.3.2 Kisspeptin and β-endorphin are not highly co-expressed in ARN GABA 
neurons  
Kisspeptin-ir neurons were detected in a scattered distribution throughout the 
ARN (Figure 3.1, A, 3.2, A). β-endorphin-ir cells were more numerous than kisspeptin 
(Figure 3.2, B), but similarly found in a scattered distribution (Figure 3.1, B). Amongst 
both populations of cells, co-localization with VGAT/tdTomato-expressing neurons was 
rarely detected (Figure 3.1, A-B, Figure 3.3, A-D). In males (n=4), less than 1% of 
VGAT neurons were co-localised with kisspeptin-ir throughout the ARN (Figure 3.3, 
A). Similarly, low co-expression was detected in females (n=4) in the rostral and middle 
regions of the ARN. However, two-way ANOVA indicated an overall effect of sex 
throughout the ARN (F(1, 18) = 13.14, p = 0.0019) with co-localization statistically 
higher in females than in males in the cARN (Tukey’s multiple comparisons, p = 0.0053). 
Approximately 10–15% of ARN kisspeptin neurons were identified as GABAergic 
(Figure 3.3, B). An overall effect of sex was indicated by two-way ANOVA (F(1, 18) = 
5.437, p = 0.0315); however, post hoc analysis detected no specific differences between 
males and females in any region of the ARN.  
Throughout the ARN, the percentage of VGAT/tdTomato neurons co-localised 
with β-endorphin-ir (Figure 3.3, C) was also very small (less than 1%) and not different 
between males (n=4) and females (n=5) in the rostral, middle or caudal regions (F(1, 21) 
= 0.0043, p = 0.9485). Likewise, the percentage of β-endorphin neurons expressing 
VGAT/tdTomato was low (Figure 3.3, D) and not different between males and females 
in any subregion of the ARN (F(1, 21) = 0.0018, p = 0.9669).  
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Figure 3.3. Percentage of co-localization of kisspeptin and β-endorphin with VGAT in male and 
female mice. The mean percentage of VGAT neurons co-localised with kisspeptin (A) as well as the 
percentage of kisspeptin neurons co-localised with VGAT (B) was calculated in males (n=4, black bars) 
and females (n=4, white bars). The mean percentage of VGAT neurons co-localised with β-endorphin (C) 
as well as the percentage of β-endorphin neurons co- localised with VGAT (D) was calculated in males 
(n=4) and females (n=5). Results are presented as mean ± SEM. ** p < 0.01 determined by Tukey’s 
multiple comparisons test.  
3.3.3 GABA and NPY are highly co-expressed in the ARN 
NPY-ir neurons were predominantly confined to ventromedial regions 
throughout the ARN (Figure 3.1, C), and a high degree of co-localization with 
VGAT/tdTomato (33%) was identified at higher magnification (Figure 3.1, C, inset). 
No differences in the percentage of VGAT/tdTomato neurons expressing NPY (Figure 
3.4, A) were found between males (n=5), and VEH (n=6) or PNA-treated (n=4) females 
in any area of the ARN (F(2, 36) = 0.3079, p = 0.7369). The vast majority of NPY-ir 
neurons were co-labelled with the VGAT/tdTomato reporter in all of the groups 
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3.3.4 Co-localization of both TH-ir and nNOS-ir in ARN GABA neurons is 
sexually dimorphic 
Labelling for the monoamine rate-limiting enzyme TH was used to detect ARN 
GABA neurons that are putative dopamine neurons. TH-ir cells were located most 
abundantly in the rostral and middle regions of the ARN, primarily in the dorsomedial 
and ventrolateral areas of each coronal section (Figure 3.1, D). At high magnification, 
both single- and double-labelled TH-ir neurons were visible in both dorsal and ventral 
regions (Figure 3.1, D, inset). Approximately 10–15% of ARN GABA neurons co-
localised with TH-ir, and this was not different between males (n=5), VEH-treated 
females (n=6), and PNA-treated females (n=5) (Figure 4, C) in any region of the ARN 
(F(2, 36) = 1.566, p = 0.2227). The percentage of TH-ir neurons expressing VGAT/ 
tdTomato (Figure 3.4, D) was consistently higher in males than either female group (F(2, 
35) = 41.51, p < 0.0001). In the rARN, the percentage of TH-ir cells expressing 
VGAT/tdTomato was significantly higher in males compared to both VEH-treated (p = 
0.0001) and PNA-treated (p = 0.0246) females. This was also the case for the mARN, 
with the proportion of TH-ir GABA neurons higher in males compared to VEH-treated 
(p = 0.0002) and PNA-treated females (p = 0.0227), and the cARN, with male levels 
elevated compared with VEH-treated (p < 0.0001) and PNA-treated females (p < 
0.0001). 
Cells immunoreactive for nNOS were found scattered throughout the rostral to 
caudal extent of the ARN (Figure 1, E), with both single- and double-labelled cells 
detected (Figure 1, E, inset). Approximately 10% of ARN GABA neurons co-localised 
with nNOS-ir in both female groups, and this was significantly lower in males (Figure 
4, E). Two-way ANOVA indicated an overall effect of sex and treatment (F(2, 42) = 
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12.87, p < 0.0001) in the percentage of VGAT/tdTomato neurons co-localised with 
nNOS-ir throughout the ARN in males (n=5) and both VEH- (n=6) and PNA-treated 
females (n=6). In the rARN, the percentage was lower in males compared with VEH-
treated females (6.66 ± 2.6% vs. 12.3 ± 1.1%) (male vs. VEH female: p = 0.0316) but 
not PNA-treated females (9.91 ± 1.3%). Similarly, in the mARN, the percentage was 
lower in males compared to VEH-treated females (6.43 ± 1.8% vs. 12.5 ± 1.4%) (male 
vs. VEH female: p = 0.0204) but was not different to PNA-treated females (10.6 ± 1.8%). 
In the cARN, the percentage in males was lower compared with both VEH- and PNA-
treated females (2.70 ± 0.7% vs. 9.34 ± 1.1 vs. 9.32 ± 1.2) (male vs. VEH female: p = 
0.0101; male vs. PNA female: p = 0.0104). 
The percentage of nNOS-ir cells co-localised with VGAT/tdTomato in the ARN 
was approximately 20% in males, 50% in VEH-treated females and 43% in PNA-treated 
females (Figure 4, F). Two-way ANOVA showed an overall effect of sex and treatment 
(F(2, 42) = 32.12, p < 0.0001), with post hoc analysis revealing a significantly lower 
percentage of nNOS-ir cells positive for VGAT/tdTomato in males compared to VEH- 
and PNA-treated females in the rARN (male vs. VEH female: p < 0.0001; male vs. PNA 
female: p = 0.0135), mARN (male vs. VEH female: p = 0.0014; male vs. PNA 
female: p = 0.0049), and cARN (male vs. VEH female: p < 0.0001; male vs. PNA 
female: p = 0.0009). 
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Figure 3.4. Percentage of co-localization of NPY and TH with VGAT in males as well as VEH-treated 
and PNA-treated females. The proportions of co-localization relative to the total population of cells 
immunoreactive for each neuropeptide/neurotransmitter/ enzyme were assessed in males (grey bars, n=5), 
VEH-treated females (black bars, n=5-6), and PNA-treated females (red bars, n=4-6) throughout the 
regions of the ARN. The percentage of VGAT neurons co-localised with NPY (A), TH (C) and nNOS (E), 
is shown, as well as the percentage of neurons immunoreactive for NPY (B), TH (D) and nNOS (F) that 
co-localise with VGAT. Results are presented as mean ± SEM. * p < 0.05, *** p < 0.001, **** p < 0.0001 
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3.4 Discussion 
These experiments describe and quantify the co-localization of specific 
neuropeptides and neurotransmitters in VGAT/tdTomato-positive GABA neurons 
residing in the ARN of male, control female, and PNA female mice, in order to define 
the molecular identity of this population of neurons across sexes and determine if this is 
perturbed by early androgen exposure (summarised in Figure 3.5); principally in ARN 
NPY neurons which compose the population of GABAergic neurons of interest in the 
present thesis.  
The markers in these experiments were selected due to their known roles in 
regulating GnRH neuron activity, as well as having known populations in the ARN of 
the mouse, thus enhancing our understanding of the role of the ARN GABA-to-GnRH 
neuron circuitry. A VGAT-ires-Cre/tdTomato transgenic mouse was employed to clearly 
identify neurons in the ARN that use synaptic GABA neurotransmission (Vong et al., 
2011), overcoming the difficulty of assessing GABA neurons in the hypothalamus with 
immunolabelling of GAD enzymes or in situ hybridization, enabling the identification of 
GABA neurons with immunohistochemical identification of markers of interest: 
kisspeptin, β-endorphin, NPY, TH and nNOS. Colchicine treatment was applied prior to 
collection of brain tissue in order to sequester neuropeptides within neuronal cell bodies, 
facilitating detection of these markers by immunolabelling. The distribution of 
immunoreactive cell bodies within the ARN reflect previous findings reported for NPY 
(Ciofi et al., 1993; Fetissov et al., 2004; Kloukina et al., 2012), TH (Ciofi et al., 1993; 
Fetissov et al., 2004), β-endorphin (Fetissov et al., 2004), kisspeptin (Overgaard et al., 
2013), and nNOS (Sica et al., 2009) demonstrating accurate labelling in the present 
experiments.   
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Figure 3.5. Summary of neuropeptides and enzymes co-localised with GABA in the ARN. Schematic 
diagrams representing the male (left) and female (right) ARN. Each bubble represents the total population 
of the cell type labelled, with filled regions indicating the mean proportion of co-localization in the middle 
ARN for each cell type. The right hemisphere on each diagram represents the total GABAergic population 
in the middle ARN and the relative proportion of that population that co-localises with kisspeptin, β-
endorphin, NPY, TH, and nNOS. The left hemisphere represents the total kisspeptin-, β-endorphin-, NPY-
, TH-, and nNOS- immunoreactive population, and the proportion of each population that co-localises with 
GABA. The size of each bubble represents the population size of each marker/signalling molecule. ARN, 
arcuate nucleus; β-endo, β-endorphin; GABA, γ-aminobutyric acid; kiss, kisspeptin; nNOS, neuronal nitric 
oxide synthase; NPY, neuropeptide Y; PNA, prenatal androgen; TH, tyrosine hydroxylase; VEH, vehicle. 
Figure adapted from (Marshall et al., 2017). 
3.4.1 Kisspeptin and β-endorphin are predominantly not GABAergic 
The co-localization of both kisspeptin and β-endorphin with VGAT/tdTomato 
shown in these experiments was very limited, composing less than 1% of the ARN 
GABA neural population combined (Figure 3.5). Similarly, only 5-15% of kisspeptin 
neurons and 2-4% of β-endorphin-ir neurons were found to be GABAergic. Kisspeptin 
was of interest as it is an incredibly potent stimulator of GnRH neuron excitability (Han 
et al., 2005), and subsequently, LH secretion (Messager et al., 2005). In particular, ARN 
kisspeptin neurons are hypothesised to be the key generator of pulsatile GnRH/LH 
release in both males (Clarkson et al., 2017; Han et al., 2019) and females (Clarkson et 
al., 2017; McQuillan et al., 2019). The co-localization of these peptides with VGAT was 
predominantly not affected by sex, with the exception of a very small yet significant 
increase in the percentage of VGAT neurons co-localised with kisspeptin in the cARN 
of females vs. males (Figure 3.3, A). Previous work using genetic targeting of broad 
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excitatory and inhibitory transmission supports these findings, where immunolabelled 
ARN kisspeptin neurons were found to be predominantly glutamatergic, with a much 
smaller GABAergic population (Cheong et al., 2015). In contrast, the present findings 
report much lower co-localization than previous work suggesting that around 50% of 
kisspeptin neurons visualised by a genetic reporter expressed mRNA for glutamic acid 
decarboxylase (GAD) 67, the rate-limiting enzyme involved in GABA synthesis (Cravo 
et al., 2011). This could be due to underreporting of kisspeptin neuron cell bodies, as 
these are especially difficult to immunolabel in the ARN of the mouse, even with 
colchicine treatment. However, more recent functional studies utilising optogenetics 
reveal that the activity of ARN kisspeptin neurons upon target neurons is glutamatergic 
and not GABAergic (Nestor et al., 2016). In addition, limited co-localization of 
kisspeptin and GABA is consistent with the literature when the nature of the circuitry of 
ARN GABA and ARN kisspeptin neurons upon GnRH neurons is considered. It has been 
demonstrated that ARN GABA neurons extend many projections to GnRH neurons, 
which contact heavily along the soma and proximal dendrites of these cells (Moore et al., 
2015). In contrast, direct appositions from ARN kisspeptin neurons to GnRH neuron 
somata and proximal dendrites do not appear to be present at all in rodents (True et al., 
2011; Yip et al., 2015). Considering these data, it would have been surprising to find that 
ARN kisspeptin neurons are a subset of the ARN GABA population. 
β-endorphin immunoreactivity was used to identify POMC expressing neurons in 
the ARN, known primarily for their role in food intake and metabolism (Williams and 
Schwartz, 2005). The POMC precursor polypeptide is cleaved further into neuropeptides 
with known roles in regulating GnRH neuron activity. β-endorphin itself is the most well 
characterised, hyperpolarising GnRH neurons directly through interaction with the µ-
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opioid receptor (Lagrange et al., 1995), and decreasing LH secretion in vivo (Leadem 
and Kalra, 1985). On the other hand, α-melanocyte-stimulating hormone (α-MSH), 
increases excitability of most GnRH neurons in vitro through interaction with 
melanocortin receptors 3 and 4 (Roa and Herbison, 2012), so the net effect of POMC 
neuron interaction with GnRH neurons is somewhat unclear, perhaps depending on 
physiological states that determine the levels of these various cleavage products. The 
present results suggest that, despite evidence of β-endorphin expressing neural 
projections apposing and forming synapses with GnRH neurons (Leranth et al., 1988), 
they are not a part of the GABAergic input originating from the ARN. However, 
approximately half of ARN POMC neurons express GAD65 and GAD67, and low co-
expression of VGAT mRNA has been reported within ARN POMC neurons (Jarvie and 
Hentges, 2012). This raises the possibility that up to half of ARN POMC neurons are 
GABAergic, but use a transmission mechanism that is not VGAT dependent. 
3.4.2 Sexually dimorphic co-localisation of TH and GABA 
This work has identified that a large proportion of TH-expressing neurons are 
GABAergic, and that this was dependent upon sex, where VGAT/tdTomato was detected 
in 80% of TH neurons in males vs 60% in females (Figure 3.4, C-D; Figure 3.5), and 
that 10-15% of GABA neurons in the ARN express TH. These results stand in agreement 
with both anatomical (Yee et al., 2009) as well as recent functional work (Zhang and van 
den Pol, 2015) demonstrating that TH expressing neurons in the ARN are GABAergic, 
however this sex difference has not been reported previously. TH is a broad marker for 
catecholaminergic neurons, which in the ARN identifies both tuberoinfundibular 
dopamine (TIDA) neurons in the dorsal region (Zhang and van den Pol, 2015; Zoli et al., 
1993), as well as non-dopaminergic growth hormone-releasing hormone neurons in the 
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ventrolateral region (Meister et al., 1986). Dopamine, appears to have potent inhibitory 
effects on GnRH neuron activity in slice preparations, acting through both D1 and D2-
like receptors to directly decrease GnRH neuron excitability (Liu and Herbison, 2013b). 
On the other hand, dopamine has been found to have a stimulatory effect on GnRH 
release in excised hypothalamic fragments (Rotsztejn et al., 1977), and LH release in vivo 
(James et al., 1987), indicating the effect may be different in more intact preparations 
than slice preparations. While there is anatomical evidence for direct synaptic input to 
GnRH neurons from dopamine neurons (Horvath et al., 1993; Watanabe et al., 2014), it 
remains to be determined whether these originate from the ARN. 
3.4.3 Identification of GABAergic nNOS neurons in the hypothalamus 
While previous research has identified GABAergic nNOS populations in the 
hippocampus and olfactory bulb (Crespo et al., 2003; Szabadits et al., 2007), results 
presented in this chapter represent the first published report identifying co-localization 
of GABA and nNOS in the hypothalamus (Marshall et al., 2017), and was shortly 
thereafter supported by work carried out in other groups (Chachlaki et al., 2017). In 
contrast with ARN GABA/TH neurons, the population of ARN GABA/nNOS neurons 
was significantly lower in males compared with both VEH- and PNA-treated females. 
This was largely in the absence of differences in the mean number of nNOS-ir cells 
between groups, suggesting that only the cell population co-expressing GABA and nNOS 
in the ARN is sexually dimorphic. While preoptic area nNOS neurons are known to play 
a role in the control of reproductive function (reviewed in (Bellefontaine et al., 2011), 
the role of this ARN population remains unclear. This population in the ARN 
anatomically associates with the distal GnRH neuron dendrite just proximal to the 
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median eminence (Chachlaki et al., 2017), so may play a role in release of peptide or 
association with vasculature in this distal region. 
3.4.4 Abundant co-expression of NPY and GABA in the ARN 
NPY was by far the most abundantly co-localised neurotransmitter in ARN 
GABA neurons, and this proportion did not vary between groups. The present study 
found that NPY-ir neurons make up one-third of the ARN GABA population, and that 
NPY-ir neurons (>93%) are almost entirely GABAergic (Figure 3.4, A-B; Figure 3.5). 
These findings are similar to those in the rat using GAD-ir to identify GABA neurons, 
identifying that at least one-quarter of GABA neurons express NPY (Horvath et al., 
1997). These findings in the rat also indicate that only one-third of ARN NPY neurons 
are GABAergic, as opposed to virtually all NPY neurons in the present study, which may 
reflect a difference in these populations of cells between rats and mice. There is extensive 
evidence suggesting that GABAergic transmission upon postsynaptic targets of ARN 
NPY neurons is involved in food intake (Cowley et al., 2001), and may be essential for 
normal feeding behaviour (Krashes et al., 2013; Wu et al., 2009; Wu et al., 2008), 
establishing evidence for a system in which co-release of NPY and GABA is important 
for maintenance of physiological function.  
Previous work has established that NPY immunoreactive fibres project 
throughout the preoptic area (Broberger et al., 1998b; Turi et al., 2003), and synapse 
directly upon GnRH neurons (Tsuruo et al., 1990; Turi et al., 2003). Studies of the 
ultrastructure of these synapses have found NPY axon terminals to display symmetric-
type morphology in both the rat (Tsuruo et al., 1990) and mouse (Turi et al., 2003), 
indicating that they utilise GABAergic transmission. The effect of NPY on GnRH neuron 
excitability is complex, and appears to be dependent upon the specific NPY receptor 
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subtype interactions (Roa and Herbison, 2012), however the net effect of LH secretion 
appears to be inhibitory. ARN NPY neurons communicate with kisspeptin neuron 
populations that are excitatory afferents to GnRH neurons, and inhibit them through 
GABA driven transmission (Padilla et al., 2017). Additionally, recent work within our 
lab has demonstrated that specific activation of ARN NPY neurons reduces LH secretion 
in conscious mice in vivo (Coutinho et al., 2019). These data suggest that the role of ARN 
NPY neurons in the reproductive axis is to restrain LH secretion. In PNA mice that model 
PCOS, LH secretion is elevated through unidentified mechanisms (Moore et al., 2015), 
however it is possible that a reduction in ARN NPY restraint of GnRH neuron activity 
may play a role in this. 
Given that the NPYergic synapses to GnRH neurons are largely GABAergic, and 
that these findings demonstrate that the largest subset of ARN GABA neurons are also 
NPYergic in identity, it appears likely that a sizable fraction of the ARN GABA-to-
GnRH neuron circuit previously identified (Moore et al., 2015) is comprised of ARN 
NPY/GABA neurons. The findings presented within this chapter support further 
dissection of ARN NPY neural circuitry, examining whether it is perturbed in a PNA 
model of PCOS in a manner that reflects changes that occur in ARN GABA circuitry as 
whole. 
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4 VALIDATION OF THE AGRP-CRE 
MOUSE FOR GENETIC TARGETING OF 
ARN NPY NEURONS 
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4.1 Introduction 
In the previous chapter of this thesis (Chapter 3), I demonstrated that a large 
subset of ARN GABA neurons produce NPY, a peptide transmitter with established roles 
in regulating GnRH neurons and facilitating aspects of fertility. GABAergic neurons in 
the ARN have been demonstrated as undergoing remodelling in prenatally androgenised 
(PNA) mice that model PCOS (Moore et al., 2015). Given that NPY compose a large 
subset of these neurons, and NPY signalling exerts direct inhibitory effects upon GnRH 
neurons (Klenke et al., 2010; Roa and Herbison, 2012) and LH secretion (Coutinho et 
al., 2019), this raised the possibility that remodelling of circuitry between ARN NPY 
neurons and GnRH neurons may be present in PNA mice. To dissect this circuit and 
address whether remodelling occurs in the experiments presented in the following 
chapters, a mouse to genetically target NPY neurons in the ARN specifically was 
required. Given that AgRP and NPY are highly co-expressed within the ARN (Broberger 
et al., 1998a; Broberger et al., 1998b; Hahn et al., 1998), and AgRP is expressed within 
the ARN exclusively (Broberger et al., 1998b; Shutter et al., 1997), using genetic 
targeting of AgRP presented as an attractive option for specific targeting ARN NPY 
neurons. Therefore, mice were generated in which a tGFP reporter was targeted to AgRP 
expressing neurons using Cre-loxP technology (Tong et al., 2008; Wen et al., 2011b). 
Within this chapter I aimed to validate the use of this mouse for work described in future 
chapters by addressing the following questions: 
1.  How specific and how effective is AgRP-Cre driven reporter expression of 
tGFP in targeting ARN NPY neurons? 
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2. How effective is labelling of the tGFP reporter for assessing downstream 
projection targets of ARN NPY neurons? 
3. What proportion of ARN NPY neurons project to regions containing GnRH 
neurons? Is this subset anatomically defined in the way that could be utilised 
for more refined targeting? 
The data presented here assessing the specificity and efficacy of tGFP reporter 
expression for identifying ARN NPY neurons (section 4.3.1) are published within (Coutinho et 
al., 2019) to validate Cre-driven viral targeting of ARN NPY neurons. 
4.2 Methods 
4.2.1 Animals 
Adult male (used in section 4.3.1 only) and female mice were housed under 
conditions outlined in section 2.2. Mice in which ARN NPY neurons were identified by 
green fluorescent protein (GFP) were generated by crossing agouti-related peptide 
(AgRP)-IRES-Cre mice (Tong et al., 2008) with ROSA26-CAGS-tGFP floxed-stop 
reporter mice (Wen et al., 2011b) (refered to here as AgRP-tGFP mice). 
4.2.2 Experiment 1: Assessing the specificity of tGFP reporter 
4.2.2.1 Intracerebroventricular injection of colchicine 
In order to improve NPY-immunoreactivity (ir) in neuron cell bodies, colchicine 
treatment was carried out. Stereotaxic surgery was carried out as outlined in section 2.5 
on male (n=3) and female (n=3) AgRP-tGFP mice. A Hamilton needle containing 1 µL 
of colchicine diluted in saline (30 µg/µL) was placed in the lateral ventricle using the co-
ordinates +0.1 mm AP, +0.7 mm ML and -2.4 mm DV. Following needle placement, 
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colchicine was immediately delivered over the course of 1 min, and the needle was 
retracted 5 min following injection to allow colchicine to diffuse. Colchicine treated mice 
were monitored over 24 h following treatment, then brain tissue was collected for later 
use.  
4.2.2.2 Double-label fluorescent immunohistochemistry 
Fixed brain tissue was sliced into 30 µm thick coronal sections as outlined in 
section 2.6.2 in order to perform free-floating immunohistochemistry (IHC), and 
sections throughout the whole brain were utilised. Published evidence of primary 
antibody validation is provided in Appendix I. tGFP reporter expression was assessed 
using a chicken anti-GFP primary antibody (1:5000; Aves Labs), and NPY-ir was used 
to identify NPY neurons (rabbit anti-NPY, 1:5000; Sigma-Aldrich). Primary antibodies 
were directly labelled using goat anti-chicken AlexaFluor488 and goat anti-rabbit 
AlexaFluor568 fluorescent secondary antibodies. 
4.2.2.3 Image acquisition and analysis 
Confocal microscopy was performed using a Zeiss LSM710 upright microscope 
(Carl Zeiss AG, Oberkochen, Germany) using lasers and objectives described in section 
2.9. Confocal z-stacks of two representative sections of the rARN, mARN and cARN 
were collected from each animal at 20x magnification to capture one hemisphere in the 
visual field, using a 2.12 µm z-interval with a pinhole size of 1AU. High power images 
were collected at 40x magnification with 2x digital zoom to resolve individual soma, 
using a 2.56 µm z-interval with a pinhole size of 1AU. GFP- and NPY-ir outside the 
ARN was assessed using an Olympus BX51 light microscope (Olympus Optical, 
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Hamburg, Germany) and images were captured using SPOT imaging software 
(Diagnostic Instruments Inc., Sterling Heights, MI, USA). 
Images were analysed using ImageJ software (National Institutes of Health, 
Bethesda, MD, USA). The number of cell bodies where GFP- and NPY-ir was present in 
each stack of images was counted, along with the number of double-labelled cells. The 
percentage of GFP-positive neurons containing NPY-ir was calculated to assess the 
specificity of the reporter in the rostral, middle and caudal ARN (rARN, mARN, cARN). 
Similarly, the percentage of NPY-ir cells expressing GFP was calculated to assess the 
efficacy of reporter expression in the ARN. 
Specificity and efficacy were defined using the following equations: 
!"#$%&%$%'( = 	 +,-	"./%'%0#	$#11/2-3	"./%'%0#	$#11/ ∗ 100 
7&&%$8$( = 	 2-3	"./%'%0#	$#11/+,-	"./%'%0#	$#11/ ∗ 100 
4.2.3 Experiment 2: Mapping of ARN NPY axon projections throughout the brain 
using tGFP 
4.2.3.1 Single label chromogenic immunohistochemistry 
Free-floating IHC was performed on fixed 30 µm thick coronal brain slices 
throughout the majority of the forebrain and hindbrain from one female mouse 
(approximately Bregma +1.98 to -7.08 mm). To visualise GFP-expressing fibres 
throughout the brain, chromogenic IHC was performed as described in section 2.7.2; 
tGFP was targeted using a rabbit anti-GFP (1:10,000; Molecular Probes) followed by a 
biotinylated goat anti-rabbit secondary antibody (1:200, Vector Laboratories Inc.). 
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Visualisation of GFP was achieved using a nickel-enhanced DAB reaction, creating a 
black precipitate in all GFP immunoreactive somata and neural projections.  
4.2.3.2 Mapping of ARN NPY fibre projections 
Neural projections originating from ARN NPY neurons were assessed by 
visualisation of chromogen labelled GFP-positive fibres. Using an Olympus BX51 light 
microscope (Olympus Optical, Hamburg, Germany), sections throughout the rostral-to-
caudal extent of the brain were scanned manually using 10x and 20x objectives, plotting 
individual fibres by hand observed in brain slices onto corresponding coronal brain slice 
schemata from the Mouse Brain in Stereotaxic Coordinates (Paxinos and Franklin, 2001) 
that most closely matched the section in question. Care was taken to accurately represent 
the relative size, orientation and density of fibre projections in schematic recreations.  
4.2.4 Experiment 3: Assessing the distribution and proportion of ARN NPY 
neurons projecting to the preoptic area 
4.2.4.1 Injection of fluorescent RetroBeads into the preoptic area 
Intracerebral injections of red RetroBead tracer was performed in adult female 
mice (n=3). A Hamilton needle was loaded with 100 nL of red fluorescent RetroBeads 
(Lumafluor Inc., Maples, FL, USA) and placed at stereotaxic co-ordinates targeting the 
rPOA that have been previously established (Zuure et al., 2016). Prior to placement, a 
further 50 nL of air was drawn into the needle and the tip was thoroughly cleaned with 
ddH2O followed by absolute ethanol to limit off-target RetroBead tracer delivery as the 
needle was being lowered. Adjusted for body weight, the needle was placed +0.9 mm (£ 
19 g), +1.0 mm (20-22 g) or +1.1mm (³ 23 g) AP relative to bregma, then at the midline, 
lowered to a depth of -4.2 mm, -4.3 mm or -4.4 DV respectively to place the tip of the 
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needle into the rPOA. After 5 mins following placement of the needle, RetroBeads were 
injected over a course of 2 mins, then the needle was left in place for 10 mins before 
being retracted. Following injection, estrous cycle monitoring confirmed that two cycles 
had passed before brain tissue was collected in diestrus. In the case of acyclic PNA mice, 
brain tissue was collected after 8 days. Needle placement was later assessed by 
observation of concentrated Retrobeads in the rPOA (placements shown in Figure 4.1).  
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Figure 4.1. Evaluation of RetroBead injection needle placement. Photomicrographs in the preoptic area 
are shown where red RetroBeads were injected in each mouse, as indicated by the presence of high-
intensity fluorescence (i-iii). These injection sites have been mapped onto a mouse brain atlas schematic 
at +0.67 mm relative to bregma. Scale bars = 100 µm. 
4.2.4.2 Single label fluorescent immunohistochemistry 
Free-floating IHC was performed of 30 µm thick coronal sections throughout the 
rARN, mARN, and cARN (Bregma -1.22 to 2.80 mm). GFP expressing NPY neurons 
were labelled using a chicken anti-GFP primary antibody (1:5000; Aves Labs), with a 
goat anti-chicken AlexaFluor488 antibody amplify GFP and contrast the endogenous 
fluorescence from red RetroBeads. 
4.2.4.3 Image acquisition and analysis 
Confocal microscopy was performed using a Nikon A1R multi-photon 
microscope (Nikon Instruments Inc., Melville, NY, USA) using lasers and objectives 
described in section 2.9. Two representative images were collected of the rARN, mARN 
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and cARN in each animal using a 40x air objective using 2 µm z-intervals. Pinhole size 
was maintained at 1 AU using a laser power of 1.2 units between animals, while digital 
gain and offset of red and green channels was kept consistent (< 5% variation) to prevent 
imaging artefacts from confounding or biasing later analysis. 
Images were analysed using NIS Elements software (Nikon Instruments Inc.). 
The number of cell bodies where GFP-ir was present in each stack of images was 
counted, along with the number of GFP-ir cells with red RetroBeads present in the cell 
bodies. The percentage of GFP-positive neurons containing Retrobeads was calculated 
in the rARN, mARN and cARN. In one mouse, the distribution of GFP-ir cells containing 
RetroBeads and unlabelled cells containing RetroBeads was plotted by hand onto 
corresponding coronal brain slice schemata from the Mouse Brain in Stereotaxic 
Coordinates (Paxinos and Franklin, 2001). 
4.2.5 Descriptive statistics 
Group means and SEM for descriptive purposes in the above experiments were 
calculated using PRISM software v7.0 & v8.0 (GraphPad Software, La Jolla, CA, USA). 
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4.3 Results 
4.3.1 Validation of AgRP-τGFP specificity 
To assess the specificity and efficacy of genetic targeting of reporter to ARN 
NPY neurons in the AgRP-τGFP mouse, IHC was performed in the ARN of colchicine 
treated mice (n=6). Within the ARN, the specificity of GFP expression in NPY-ir cells 
was examined. At low magnification, GFP-positive cells identified in the ventro-medial 
region of the ARN where NPY neuron cell bodies are typically found (Figure 4.2, A), 
while red NPY-immunoreactive fibres were observed projecting throughout the ARN 
(Figure 4.2, B). The presence of yellow label at low magnification indicates co-
localization of GFP- and NPY-ir cell bodies in this ventro-medial region (Figure 4.2, C). 
At higher magnification, it is apparent that the majority of GFP-positive cells are also 
NPY-ir, while the occasional NPY-ir cell is observed that does not express GFP (Figure 
4.2, C). The percentage of GFP-positive cells co-localised with NPY and NPY-ir cells 
expressing GFP, as well as averaged cell counts are reported in Table 4.1. 
Table 4.1. Co-expression of GFP and NPY and total cell counts in the ARN of AgRP-τGFP mice. 
 rARN mARN cARN 
% of GFP-positive 
cells co-localised with 
NPY (specificity) 
96.7 ± 1.3% 96.3 ± 0.6% 96.9 ± 0.6% 
% of NPY-positive 
cells co-localised with 
GFP (efficacy) 
94.6 ± 0.6% 93.8 ± 1.0% 93.2 ± 1.5% 
Number of GFP cells 
per section 
99.5 ± 2.2 109.9 ± 1.7 102.3 ± 2.8 
Number of NPY cells 
per section 
101.6 ± 1.8 112.9 ± 2.0 106 ± 3.1 
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Figure 4.2. NPY and GFP are highly co-localised in the ARN of AgRP-tGFP mice. A single confocal 
z-plane image taken in the mARN where immunoreactivity for GFP (A) (green) and NPY (B) (red) is 
shown. Merged images (C) display a high degree of co-expression of NPY within GFP-positive neurons. 
High power images (right) were taken within the area highlighted by the white box, demonstrating double-
labeled cells (filled arrows) and an NPY-immunoreactive single labelled cell (open arrow). Scale bars = 
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While the overwhelming majority of GFP-positive cells were confined to the 
ARN, a small amount of GFP expressing cells were observed in other regions (Figure 
4.3). The area where GFP-positive cells were most abundant outside of the ARN was the 
ventral cochlear nucleus of the brainstem, though this was typically confined to small 
groups of approximately five cells per 30 µm coronal section. Sporadic GFP-positive 
cells were also observed in various cortical areas, typically between 1-3 cells per coronal 
section. Very infrequently, GFP-positive cells were also observed in the lateral 
hypothalamic area and various nuclei of the thalamus, however these were only ever 
observed as single cells in any given section. The areas where GFP-positive cells were 
located appear stereotyped between the six animals assessed. In each of these areas 
outside of the ARN, no GFP-positive cells observed also co-expressed NPY. 
	
Figure 4.3. Negligible expression of GFP outside of the ARN does not co-localise with NPY. 
Representative photomicrographs show NPY immunoreactivity (red, empty arrows) and GFP-expressing 
cells (green, filled arrows) in a number of areas outside of the ARN. GFP-positive cell bodies were 
observed in the cortex, central medial nucleus (CM) of the thalamus, the lateral hypothalamic area (LHA), 
and the posterior ventral cochlear nucleus (VCP) of the brainstem. Scale bars = 100 µm.  
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4.3.2 ARN NPY projections throughout the brain 
In order to assess the effectiveness of the τGFP reporter’s ability to label axon 
projections in their entirety, as well as to assess the breadth of brain regions that ARN 
NPY neurons extend projections to, including those that contain known afferents to 
GnRH neurons, single-label chromogenic IHC for GFP was performed in one 
representative female AgRP-τGFP mouse. Fibres were observed in a strikingly wide 
distribution extending through the rostral forebrain to the hindbrain in every section that 
was mapped. The distribution of fibres that was observed in each section was mapped 
onto the corresponding schematic coronal brain section (Figure 4.4), taking care to 
accurately represent the relative size and orientation of each fibre. Using post-hoc 
qualitative analysis, the areas and nuclei containing ARN NPY fibres were defined, and 
a semi-qualitative score was assigned to each region based upon the number of fibres 
within the region in a given brain section; these are defined and outlined in Table 4.2.  
Fibres were found widely, from Bregma +1.42 to -6.36 mm anterodorsally 
(Figure 4.4). This consisted of processes with 144 distinct areas, nuclei and white matter 
tracts throughout the cerebral cortex, septum, pallidum, striatum, hypothalamus, 
thalamus, amygdala, hippocampus, midbrain and hindbrain. ARN NPY neuron processes 
were overwhelmingly found most densely within the hypothalamus, particularly within 
medial regions such as the medial preoptic area (MPA), ventromedial preoptic nucleus 
(VMPO), anteromedial periventricular nucleus (AVPV), periventricular nucleus (PeN), 
paraventricular nucleus (PVN), subparaventricular zone (SPa), retrochiasmatic zone 
(RCh), and ventral tuberomammillary nucleus (VTM). Dense projections were observed 
in lateral hypothalamic regions such as the lateral hypothalamic area (LHA) and 
particularly dense projections were observed in the supraoptic nucleus (SON). Outside 
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of the hypothalamus, NPY neural projections were observed predominantly in a sparse 
distribution, with a few notable exceptions: within the pallidum, the bed nucleus of the 
stria terminalis (BNST) contained particularly dense innervation, as did the mediodorsal 
(MD) and paraventricular (PV) nuclei of the thalamus. In the midbrain, fibres were 
observed mainly in a sparse distribution, with a prominent concentration of processes 
throughout the entire extent of the periaqueductal grey (PAG). Similarly, in the hindbrain 
fibres were exceptionally sparse, aside from concentrations of processes within the 
parabrachial nucleus (PBN) and nucleus tractus soliarius (NTS). Example 
photomicrographs from projection targets in the hypothalamus, amygdala and hindbrain 
are shown in Figure 4.5. 
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Figure 4.4. Distribution of tGFP reporter expression in ARN NPY neural projections throughout 
the brain. Neural projections (red) mapped in one representative VEH treated AgRP-tGFP animal are 
indicated or schematic diagrams of coronal brain sections. The anteroventral coordinate in relation to 
Bregma is indicated to the top-right of each schematic. All abbreviations are defined in Table 4.2. 
(Continued on next page). 
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Figure 4.4. Distribution of tGFP reporter expression in ARN NPY neural projections throughout 
the brain. (Continued on next page). 
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Figure 4.4. Distribution of tGFP reporter expression in ARN NPY neural projections throughout 
the brain.  
	 	




Figure 4.5. The expression of tGFP reporter in select nuclei. Example photo micrographs are shown 
where tGFP expressing fibres are visualised by black chromagenic precipitate. The position of each image 
taken is shown relative to Bregma. Nuclei containing fibres are outlined and labeled. Sclae bars = 200 µm. 
3V, 3rd ventricle; ac, anterior commissure; ARN, arcuate nucleus; AVPV, anteroventral periventricular 
nucleus; BNST, bed nucleus of the stria terminalis; LA, lateroanterior hypothalamic area; MnPO, median 
preoptic area; MPA, medial preoptic area; MPO, medial preoptic nucleus; MS, medial septum; ox, optic 
chiasm; PeN, periventricular nucleus; PVN, paraventricular nucleus; SCh, suprachiasmatic nucleus; SON, 
supraoptic nucleus; VMH, ventromedial hypothalamic nucleus. (Continued on next page).  
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Figure 4.5. The expression of tGFP reporter in select nuclei. Aq, cerebral aqueduct; DMH, dorsomedial 
hypothalamic nucleus; LHA, lateral hypothalamic area; LM, lateral mammillary nucleus; MeA, medial 
amygdala; MM, medial mammillary nucleus; ot, optic tract; PAG, periaqueductal grey; PBN, parabrachial 
nucleus; RPO, rostral periovulatory region; SuM, supramammillary nucleus; VMH, ventromedial 
hypothalamic nucleus; VTM, ventral tuberomammillary nucleus.  
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Table 4.2. List of brain regions containing projections from ARN NPY neurons. 
Brain region Abbreviation Score 
Cerebral cortex 
Cingulate cortex, area 1 Cg1 + 
Cingulate cortex, area 2 Cg2 + 
Cortex-amygdala transition zone CxA + 
Dorsal peduncular cortex DP + 
Infralimbic cortex IL + 
Lateral olfactory tract nucleus LOT + 
2nd motor cortex M2 + 
Piriform cortex Pir + 
Posterolateral cortical amygdaloid nucleus PLCo + 
Posteromedial cortical amygdaloid nucleus PMCo + 
Primary somatosensory cortex S1 + 
Ventral endopiriform nucleus VEn + 
Septum 
Horizontal limb of the diagonal band of Broca HDB + 
Lambdoid septal zone Ld + 
Lateral septal nucleus, dorsal LSD + 
Lateral septal nucleus, intermediate LSI + 
Lateral septal nucleus, ventral LSV + 
Medial septum MS + 
Septofimbrial nucleus SFi + 
Septohypothalamic nucleus SHy + 
Vertical limb of the diagonal band of Broca VDB ++ 
Zona limitans ZL + 
Pallidum 
Anterior commissural nucleus AC + 
Basal nucleus B ++ 
Bed nucleus of the anterior commissure BAC + 
Bed nucleus of the stria terminalis BNST +++ 
Interstitial nucleus of the posterior limb of the anterior commissure IPAC + 
Substantia innominata SI ++ 
Ventral pallidum VP + 
Striatum 
Anterior amygdaloid area AA ++ 
Nucleus accumbens Acb ++ 
Nucleus accumbens, shell AcbSh ++ 
Bed nucleus of the accessory olfactory tract BAOT + 
Olfactory tubercle Tu ++ 
Hypothalamus 
Anterodorsal preoptic nucleus ADP ++ 
Anterior hypothalamic area AHA ++ 
Arcuate nucleus ARN +++ 
Anteroventral periventricular nucleus AVPV ++ 
Dorsomedial hypothalamic nucleus DMH ++ 
Dorsal tuberomammillary nucleus DTM + 
Lateroanterior hypothalamic area LA + 
Lateral hypothalamic area LHA +++ 
Lateral mammillary nucleus LM + 
Lateral preoptic area LPO ++ 
Magnocellular nucleus of the lateral hypothalamus MCLH + 
Magnocellular preoptic nucleus MCPO + 
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Brain region Abbreviation Score 
Medial mammillary nucleus, lateral part ML + 
Medial mammillary nucleus, medial part MM + 
Median preoptic area MnPO ++ 
Medial preoptic area MPA +++ 
Medial preoptic nucleus MPO ++ 
Organum vasculosum of the lamina terminalis OVLT ++ 
Periventricular nucleus PeN +++ 
Premammillary nucleus, dorsal PMD + 
Premammillary nucleus, ventral PMV ++ 
Paraventricular nucleus PVN +++ 
Retrochiasmatic zone RCh +++ 
Suprachiasmatic nucleus SCh + 
Subparaventricular zone of the hypothalamus SPa +++ 
Supraoptic nucleus SON +++ 
Subthalamic nucleus STh ++ 
Subincertal zone SubI ++ 
Supramammillary nucleus SuM ++ 
Supramammillary nucleus, medial part SuMM ++ 
Ventromedial hypothalamic nucleus VMH ++ 
Ventromedial preoptic nucleus VMPO +++ 
Ventral tuberomammillary nucleus VTM +++ 
Zona incerta ZI ++ 
Thalamus 
Anteromedial thalamic nucleus AM + 
Central medial thalamic nucleus CM + 
Dorsal lateral geniculate nucleus DLG + 
Interanteromedial thalamic nucleus IAM + 
Intermediodorsal thalamic nucleus IMD + 
Lateral habenular nucleus LHb ++ 
Mediodorsal thalamic nucleus MD +++ 
Mediodorsal thalamic nucleus, central MDC + 
Mediodorsal thalamic nucleus, medial MDM + 
Medial habenular nucleus MHb + 
Posterior thalamic nuclear group Po ++ 
Paratenial thalamic nucleus PT + 
Paraventricular thalamic nucleus PV +++ 
Reuniens thalamic nucleus Re + 
Rhomboid thalamic nucleus Rh + 
Reticular thalamic nucleus Rt + 
Submedius thalamic nucleus Sub + 
Ventral lateral geniculate nucleus, magnocellular part VLGMC + 
Ventral posterolateral thalamic nucleus VPL + 
Ventral posteromedial thalamic nucleus VPM + 
Ventral reuniens nucleus VRe + 
Amygdala 
Anterior cortical nucleus of the amygdala ACo + 
Amygdalohippocampal area, anterolateral part AHiAL + 
Basolateral nucleus of the amygdala anterior BLA + 
Basomedial nucleus of the amygdala, anterior BMA + 
Basomedial nucleus of the amygdala, posterior BMP + 
Central amygdaloid nucleus, capsular part  CeC + 
Central amygdaloid nucleus, anterodorsal CeMAD + 
Central amygdaloid nucleus, anteroventral CeMAV + 
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Brain region Abbreviation Score 
Intercalated amygdaloid nucleus IM + 
Medial amygdaloid nucleus, anteroventral MeAD ++ 
Medial amygdaloid nucleus, posterodorsal MePD ++ 
Medial amygdaloid nucleus, posteroventral MePV ++ 
Hippocampus 
Granular layer of the dentate gyrus GrDG + 
Midbrain 
Deep grey layer of the superior colliculus DpG + 
Deep mesencephalic nucleus  DpMe + 
Dorsal raphe nucleus DR ++ 
External cortex of the inferior colliculus ECIC + 
Edinger-Westphal nucleus EW + 
Intergeniculate leaf IGL + 
Interfascicular nucleus IF + 
Interpeduncular nucleus IP + 
Intermediate grey layer of the superior colliculus InG + 
Median raphe nucleus MnR + 
Periaqueductal grey PAG +++ 
Precommissural nucleus PrC + 
Rostral linear raphe nucleus RLi ++ 
Red nucleus, magnocellular part RMC + 
Retrorubral nucleus RR + 
Optic nerve layer of the superior colliculus Op + 
Substantia nigra, compact  SNC + 
Substantia nigra, lateral  SNL ++ 
Substantia nigra, reticular  SNR + 
Ventral tegmental area VTA + 
Hindbrain 
Central periovulatory nucleus CPO + 
Intermediate nucleus of the lateral lemniscus ILL ++ 
Kölliker-Fuse nucleus KF + 
Lateral superior olive LSO + 
Microcellular tegmental nucleus MiTg + 
Motor trigeminal nucleus Mo5 + 
Nucleus tractus solitarius NTS ++ 
Parabrachial nucleus PBN +++ 
Pontine nucleus Pn ++ 
Pontine nucleus, oral part PnO + 
Pontine nucleus, ventral part PnV + 
Principal sensory trigeminal nucleus Pr5 ++ 
Raphe magnus nucleus RMg + 
Rostral periovulatory region RPO +++ 
Reticulotegmental nucleus RtTg ++ 
Superior paraovulatory nucleus SPO + 
Nucleus of the trapezoid body Tz + 
Ventral nucleus of the lateral lemniscus VLL ++ 
Ventral periolivary nucleus VPO + 
White matter 
Corpus callosum cc + 
Basal cerebral peduncle cp ++ 
Supraoptic decussation sox ++ 
+, <10 fibres within area/section; ++, 10-20 fibres within area/section; +++, >20 fibres within area/section.   
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4.3.3 Distribution of ARN NPY neurons projecting to the rPOA 
In order to determine whether a particular anatomical subset of ARN NPY 
neurons project to the rPOA and therefore putatively innervate GnRH neurons, as well 
as the proportion of ARN NPY neurons that project to this region, fluorescent 
RetroBeads were injected into the rPOA and the neural uptake in the ARN was 
subsequently calculated across the mice injected (n=3) and mapped in one representative 
mouse (Figures 4.6 and 4.7). Cells with uptake of RetroBeads are found scattered 
throughout the rostro-caudal axis of the ARN, including within GFP-ir NPY neurons 
(Figure 4.6, A). When the proportion of ARN NPY neurons with RetroBead uptake was 
calculated, it was found that a subset of 10-12% of neurons across all regions of the ARN 
contained the tracer following injection into the rPOA (Figure 4.6, C). When the 
anatomical distribution was mapped (Figure 4.7), RetroBead positive cell bodies 
(represented as red single labelled or yellow double labelled points) were observed in 
abundance throughout the rostro-caudal span of the ARN. When observed in the coronal 
plane they did not appear concentrated in any particular region, instead appearing evenly 
scattered within the ARN. Retrobeads were also seen in GFP expressing NPY neural cell 
bodies in the same regions. In the rostral, early mid, and late caudal ARN, these double 
labelled NPY neurons were predominantly concentrated in the ventromedial ARN, which 
is where the majority of ARN NPY neurons reside. Surprisingly, in the late mid and early 
caudal ARN, double labelling NPY neurons appeared to be more evenly scattered into 
the dorsomedial and ventrolateral subregions of the ARN. Overall, no distinct 
organisation or concentration of double labelled NPY neurons was observed.   
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Figure 4.6. A subset of ARN NPY neurons project to the preoptic area. (A) Representative single z-
planes in the rARN, mARN and cARN of one mouse showing localization of GFP (green) and RetroBeads 
(red). Across the mice injected (n=3) the number of GFP-ir NPY neurons in each region of the ARN was 
counted (B), and the number of NPY neurons containing RetroBeads in their cell bodies was calculated 
(C), indicating the proportion that are projecting to the rPOA across the ARN. Results are presented as 
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Figure 4.7. Distribution of ARN neurons projecting to the rPOA. The distribution of neural cell bodies 
in the ARN containing RetroBeads that were taken up following injection into the rPOA in one mouse is 
represented on coronal brain diagrams. RetroBead positive soma were scattered throughout the ARN, both 
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4.4 Discussion 
In order for dissection of ARN NPY neurons throughout this thesis to be 
effectively performed, genetic targeting of GFP reporter to NPY neurons specifically 
within the ARN is necessary. This was achieved by crossing the AgRP-Cre mouse to a 
constitutively expressed Cre dependant reporter line (Tong et al., 2008; Wen et al., 
2011b). As AgRP and NPY are highly co-expressed within the ARN (Broberger et al., 
1998a; Broberger et al., 1998b; Hahn et al., 1998), and AgRP is exclusively expressed 
within the ARN (Broberger et al., 1998b; Shutter et al., 1997), this presented a viable 
way to achieve the desired specificity. To confirm the specificity of Cre expression 
within ARN NPY neurons, and the efficacy of the reporter expression to visualise them, 
dual IHC was performed in the ARN of colchicine treated mice. It was found that this 
reporter was remarkably specific and effective at identifying ARN NPY neurons, where 
approximately 95% of GFP-positive neurons are also positive for NPY, and vice versa 
(Figure 4.2, Table 4.1).  
It should be noted that others report a small population of ARN NPY neurons that 
do not express AgRP, larger than the approximately 5% observed in the present study. 
When AgRP neurons are ablated by diphtheria toxin, approximately 15% of NPY 
neurons remain un-ablated (Luquet et al., 2005), however this could be due to less-than-
total efficacy of the technique. Additionally, Herzog and colleagues have discussed 
unpublished data that also indicates there is a small population of AgRP-negative ARN 
NPY neurons [discussed in (Zhang et al., 2019)]. Perhaps this discrepancy is due to Cre-
expression reflecting the ‘developmental history’ of AgRP expression in the ARN, due 
to its constitutive expression in cells that have expressed AgRP at any developmental 
time point. It is possible that a small proportion of ARN NPY neurons that express AgRP 
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during development no longer express this peptide in adulthood, however Cre-driven 
GFP expression would still be present in these cells. Nonetheless, the fact that GFP 
expression was present in approximately 95% of NPY-ir cells in the ARN indicates the 
mouse line used in the present study is effective at identifying the vast majority of the 
ARN NPY neuron population. 
Additionally, when the expression of GFP outside of the ARN was assessed, 
neurons positive for GFP were only found infrequently, and in limited numbers (Figure 
4.3). These exogenous GFP-positive neurons were confined to the cortex, thalamus, 
lateral hypothalamic area, and a small collection (< 5 cells per 30 µm coronal section) in 
the VCP of the brainstem. Given that the ARN NPY neuron population is composed of 
approximately 10,000 cells across the ARN (Betley et al., 2013), this small handful of 
exogenous GFP-ir cells are negligible by comparison. The experiments presented in the 
remainder of this thesis are therefore highly likely to reflect a true NPY expressing 
population within the ARN using this reporter, and are likely to represent the vast 
majority of ARN NPY neurons. 
4.4.1 Axon-localised τGFP demonstrates ARN NPY neurons project widely 
throughout the brain, including to GnRH neuron afferent regions 
In order to assess the effectiveness of τGFP for visualising axonal projection 
targets of ARN NPY neurons, including regions containing GnRH neurons or their 
afferents, projections throughout the brain were mapped and semi-quantitatively 
characterised with respect to the density of fibres projecting to each region. ARN NPY 
neurons were found to project widely to every organisational level of the brain, to 144 
individual nuclei or anatomical areas. This is unsurprising, given the wide ranges of roles 
that NPY as a neuropeptide is implicated in within the brain (Botelho and Cavadas, 2015; 
	 	 CHAPTER FOUR 
 120 
Heilig, 2004; Redrobe et al., 2004; Silva et al., 2005; Thorsell and Mathé, 2017), and the 
wide, almost ubiquitous distribution of its various receptors (Parker and Herzog, 1999). 
The density of fibres found in any particular region was semi-qualitatively assessed, by 
ranking each region into low, middle and high density (defined in 4.3.4). Notably, the 
hypothalamus was the region in which there were the greatest number of nuclei with high 
density fibres, namely the ARN itself, the AVPV and PeN (together composing the 
RP3V), as well as the LHA, MPA, PVN, RCh, SPa, SON, VMPO and VTM. Several 
extrahypothalamic regions also received the highest density score: the BNST, the MD 
and PV of the thalamus, PAG of the midbrain, and the RPO and PAG of the hindbrain. 
It should be noted that this technique does not discriminate between fibres of passage 
and terminal fibres, it merely sought to assess areas in which the greatest degree of 
innervation is likely to occur. To assess and quantify the level of innervation to an area, 
one possible follow up could be achieved through the use of a viral vector carrying a Cre-
dependant reporter tagged synaptophysin (Groh et al., 2008) delivered into the ARN of 
AgRP-Cre mice.  
While the breadth of ARN NPY projection targets has not been reported in the 
literature as extensively as the results presented here, several of these high density 
regions have previously been defined with functional tract tracing. Dense fibre 
projections to the BNST, PVN, LHA, PV, MD, PAG and PBN have been defined and 
optogenetic stimulation elicits feeding behaviour (Betley et al., 2013); this implicates 
ARN NPY projections in these regions as primarily activating second order neurons 
within feeding circuits. Perhaps most notably in respect to GnRH neural afferents, a 
dense intra-ARN projection was observed, as well as projections to the AVPV and PeN, 
regions where kisspeptin neurons primarily reside (Clarkson and Herbison, 2006b; Smith 
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et al., 2005a; Smith et al., 2005b). In fact, circuits between ARN NPY neurons and both 
ARN and AVPV kisspeptin neurons have been functionally described, where ARN NPY 
neurons suppress kisspeptin neurons and chronic activation of this circuit attenuates 
fertility (Padilla et al., 2017). As ARN kisspeptin neurons are becoming viewed as the 
hub for GnRH neuron pulse generation (Clarkson et al., 2017), they are an attractive 
candidate as an upstream target of ARN NPY neurons to alter GnRH pulse generation in 
a PNA-treated state. 
4.4.2 ARN NPY neurons projecting to the rostral preoptic area are scattered 
throughout the ARN 
To assess the possibility of anatomical targeting of ARN NPY neurons that 
project to the rPOA specifically, I wished to determine whether these neurons were 
concentrated in one anatomical region of the ARN, and what proportion of ARN NPY 
neurons project to this region. As ARN NPY neurons have a one-to-one relationship with 
their projection targets, and do not extend collateral projections (Betley et al., 2013), this 
would have allowed manipulation of an anatomically distinct subset of rPOA targeting 
neurons. To assess this, fluorescent RetroBeads were injected intracerebrally into the 
rPOA and the ARN NPY neurons where beads were observed and mapped. Contrary to 
residing in an anatomically defined region, RetroBead positive ARN NPY neurons were 
observed throughout the rostro-caudal continuum of the ARN, and in the coronal plane 
appeared scattered in a non-organised distribution, although more resided in the dense 
ventromedial cluster of ARN NPY neurons. This is seemingly in contrast to previous 
descriptions using retrograde tracing from projection targets related to energy balance 
function (Betley et al., 2013). These studies describe a degree of organisation where ARN 
NPY neurons projecting to anterior targets such as the BNST or PVN are located 
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predominantly in the rARN. Conversely, ARN NPY neurons that project to hindbrain 
structures are located in the cARN. The scattered distribution of rPOA targeting ARN 
NPY neurons may reflect that they are poised to receive intra-ARN projections from the 
range of ARN NPY neurons that extend parallel circuits to multiple targets governing 
energy balance. Ultimately, in order to perform manipulations upon ARN NPY neurons 
projecting to the rPOA and GnRH neurons, either the entire population would have to be 
targeted at the level of the ARN, or if the manipulation permitted, the level of the nerve 
terminals and fibres within the rPOA itself.  
4.4.3 Summary 
The data presented here demonstrate that AgRP-τGFP reporter mice are an 
effective model for targeting ARN NPY neurons with a very high degree of specificity, 
and are appropriate for use in assessing differences in this circuit that may occur as a 
result of prenatal androgen treatment in experiments presented in the following chapters. 
Additionally, τGFP is effective in revealing axon projections throughout the brain, and 
these projection targets include regions where GnRH neurons reside, as well as their 
afferents. Combining τGFP reporter with retrograde tracing from the rPOA revealed that 
a small, scattered subset of ARN NPY neurons project to this region and may therefore 
innervate GnRH neurons.  
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5 EXAMINING ALTERATIONS TO THE 
ARN NPY-TO-GNRH NEURAL CIRCUIT 
IN PNA MICE 
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5.1 Introduction 
As the underlying pathophysiology of PCOS is being elucidated, there is a 
growing body of evidence that this is a neuroendocrine disorder. Over 90% of women 
exhibit abnormal ratios of luteinising hormone (LH) to follicle-stimulating hormone 
secretion from the anterior pituitary (Taylor et al., 1997). This is expressed in the form 
of overt LH hypersecretion in 50% of women with PCOS, and is associated with more 
severe iterations of the disorder (Balen et al., 1995; Franks, 1989). As LH secretion can 
be used as a readout of GnRH secretion (Clarke and Cummins, 1982; Levine et al., 1982; 
Moenter et al., 1992), by proxy this informs us that in PCOS, GnRH neuron activity is 
likely to be elevated.  
In mammals, the rate of pulsatile LH release is dependent upon steroid hormones 
that exert negative feedback upon GnRH neural activity, principally mediated by 
estradiol (E2) and progesterone (P4) in females. Additionally, evidence from studies in 
female mice implicate androgens as having a direct modulatory role in LH secretion 
(Walters et al., 2018). GnRH neurons themselves do not express estrogen receptor a 
(ERa), progesterone receptor (PR), or androgen receptor (AR) (Herbison and Pape, 
2001; Huang and Harlan, 1993; Skinner et al., 2001), the respective nuclear receptors for 
these hormones that are necessary for maintaining fertility (Chappell et al., 1997; Cheng 
et al., 2013; Hu et al., 2004; Walters et al., 2007; Wintermantel et al., 2006). Feedback is 
therefore achieved primarily by a broad network of steroid hormone sensitive afferent 
neurons that relay hormone status to GnRH neurons.  
Concordant with LH hypersecretion, women with PCOS have a diminished 
response to steroid hormone mediated negative feedback. Exogenous P4 in the presence 
of E2 will lower LH secretion in reproductively healthy women, whereas women with 
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PCOS are resistant to this effect (Daniels and Berga, 1997; Pastor et al., 1998). Negative 
feedback resistance may result from elevated androgens, as long-term pharmacological 
blockade of AR restores sensitivity to P4 in women with PCOS (Eagleson et al., 2000). 
This observation has led to a recent effort using animal models of androgen excess that 
mimic PCOS features to determine the loci of disrupted hormone sensitivity and 
associated circuit alterations in the GnRH neural network.  
A pre-clinical, prenatal androgen (PNA) exposure model in mice, recapitulates 
key features of PCOS including diminished negative feedback (Moore et al., 2013; 
Moore et al., 2015), and LH hypersecretion (Moore et al., 2015). Early work from other 
researchers within this model identified that GnRH neurons display a greater frequency 
of GABAergic post-synaptic currents compared with fertile controls (Sullivan and 
Moenter, 2004b). We have since identified that this elevation in transmission occurs in 
part because of enhancement of a circuit between GABA neurons residing in the arcuate 
nucleus (ARN), and GnRH neurons (Moore et al., 2015). Additionally, fewer ARN 
GABA neurons express PR in PNA-treated mice, indicating reduced P4 sensitivity 
(Moore et al., 2015). Moreover, specific activation of this circuit elicits LH secretion 
(Silva et al., 2019), supporting prior speculation that GABAergic transmission to GnRH 
neurons is excitatory (Herbison and Moenter, 2011). This evidence points to ARN 
GABA-to-GnRH signalling potentially being the source of elevated LH secretion in 
PNA-treated mice.  
Similar to restoration of P4 sensitivity in women with PCOS given anti-
androgens (Eagleson et al., 2000), blockade of androgen signalling improves 
reproductive function in mice that model PCOS. Fertility is restored in PCOS-model 
mice chronically treated with androgens when AR is knocked out of neurons specifically 
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(Caldwell et al., 2017), implicating excess androgen signalling within the brain. In PNA-
treated mice, pharmacological blockade of AR also leads to a restoration in reproductive 
function (Silva et al., 2018), and this is associated with a decrease in GABAergic 
innervation to GnRH neurons, down to similar levels as fertile controls (Silva et al., 
2018). As ARN GABA neurons are implicated in this increased wiring, it appears the 
ARN is a site that is highly remodelled by androgen excess. 
Earlier in this thesis (Chapter 3), I demonstrated that a large subset of ARN 
GABA neurons produce NPY, a peptide transmitter with established roles in regulating 
GnRH neurons and facilitating aspects of fertility. NPY exerts direct inhibitory effects 
upon GnRH neurons (Klenke et al., 2010; Roa and Herbison, 2012), and recent evidence 
demonstrates than ARN NPY neurons reduce and slow pulsatile LH secretion (Coutinho 
et al., 2019). Anatomical evidence demonstrates that ARN NPY neurons innervate GnRH 
neurons at their proximal regions (Turi et al., 2003), the site where plasticity of 
innervation by ARN GABA neurons occurs in PNA treated mice (Moore et al., 2015). 
Ultrastructural work demonstrates that synapses formed by ARN NPY neurons in these 
proximal regions are GABAergic in nature (Tsuruo et al., 1990; Turi et al., 2003). 
Notably, in women with PCOS, plasma NPY is reduced compared to fertile women 
irrespective of body weight (Baranowska et al., 1999b; Romualdi et al., 2008). If this 
reduction in NPY secretion reflects a reduction in NPY transmission to GnRH neurons, 
this may hint at a mechanism for how GnRH neural activity is elevated in PCOS. Given 
that the ARN, and specifically GABA neurons within the ARN, appear susceptible to 
plasticity in PNA treated mice, the ARN NPY neural subpopulation presented as an 
attractive candidate population that may be remodelled in PCOS and contribute to the 
subsequent pathophysiology of the disorder such as elevated LH secretion (Figure 5.1). 
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Figure 5.1. Alterations in ARN NPY neurons may lead to LH hypersecretion. ARN NPY neurons 
predominantly inhibit GnRH neuron excitability and restrain LH secretion. I hypothesised that a reduction 
in ARN NPY-to-GnRH neuron innervation, or altered modulation of ARN NPY neurons by circulation 
steroid hormones, may contribute to LH hypersecretion present in PNA-treated mice.  
5.1.1 Aims and hypotheses 
I hypothesised that: 
1. ARN NPY neurons display alterations to their steroid hormone sensitivity 
in PNA-treated mice. 
2. ARN NPY neuron innervation of GnRH neurons is reduced in PNA-treated 
mice. 
To address these hypotheses, I aimed to: 
• Quantify the expression of PR, ERa and AR in ARN NPY neurons in 
PNA treated mice compared with fertile control mice. 
• Quantify the degree of putative synaptic input to GnRH neurons by 














Adult female mice were housed under conditions outlined in section 2.2. Mice in 
which ARN NPY neurons were identified by green fluorescent protein (GFP) were 
generated by crossing agouti-related peptide (AgRP)-IRES-Cre mice (Tong et al., 2008) 
with ROSA26-CAGS-tGFP floxed-stop reporter mice (Wen et al., 2011b) (AgRP-tGFP 
mice). PNA mice were generated using the protocol outlined in section 2.3, by injection 
of dams on days 16, 17 and 18 of pregnancy with 200 µL of sesame oil alone (vehicle 
controls, VEH) or containing 250 µg of dihydrotestosterone (DHT). Female offspring 
were later studied in adulthood (60-90 days). 
5.2.2 Experiment 1: Assessing steroid hormone receptor expression in ARN NPY 
neurons 
5.2.2.1 Double label fluorescent immunohistochemistry 
Fixed brain tissue was sliced into 30 µm thick coronal sections as outlined in 
section 2.6.2 in order to perform free-floating immunohistochemistry (IHC), and 
sections throughout the rostral, middle and caudal ARN (rARN, mARN, cARN) were 
utilised (Bregma -1.22 to 2.80 mm). NPY neuron cell bodies were labelled via GFP 
reporter expression using a chicken anti-GFP primary antibody (1:5000; Aves Labs), as 
well as labelled for the following steroid hormone receptors: progesterone receptor 
(rabbit anti-PR, 1:100; DAKO; VEH n=8, PNA n=10), estrogen receptor a (rabbit anti-
ERa, 1:5000; Millipore; VEH n=5, PNA n=5), or androgen receptor (rabbit anti-AR PG-
21, 1:200; Millipore; VEH n=4, PNA n=4). Published evidence of primary antibody 
validation is provided in Appendix I. To amplify green GFP signal, goat anti-chicken 
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AlexaFluor488 antibody was used, while steroid hormone receptors were labelled in red 
using goat anti-rabbit AlexaFluor568 antibody. 
5.2.2.2 Image acquisition and analysis 
Confocal microscopy was performed using a Zeiss LSM710 upright microscope 
(Carl Zeiss AG, Oberkochen, Germany) using lasers and objectives described in section 
2.9. Confocal z-stacks of two representative sections of the rARN, mARN and cARN 
were collected from each animal in each experiment at 20x magnification to capture one 
hemisphere in the visual field, using a 2.12 µm z-interval with a pinhole size of 1AU. 
High power images were collected at 40x magnification with 2x digital zoom to resolve 
individual soma, using a 0.5 µm z-interval with a pinhole size of 1 AU. 
Images were analysed using ImageJ software (National Institutes of Health, 
Bethesda, MD, USA). The number of cell bodies expressing GFP in each respective stack 
of images was counted, along with the number of cell bodies or nuclei immunoreactive 
for either PR, ERa or AR, and finally the number of double-labelled cells in the visual 
field (a unilateral hemisphere of the ARN). Using this, the percentage of GFP-positive 
ARN NPY neurons co-labelled with each receptor could be calculated, and vice versa. 
5.2.3 Experiment 2: Assessing putative innervation of GnRH neurons by ARN NPY 
neurons 
5.2.3.1 Double-label fluorescent immunohistochemistry 
Fixed brain tissue was sliced into 30 µm thick coronal sections as outlined in 
section 2.6.2 in order to perform free-floating IHC. To assess ARN NPY-to-GnRH 
neuron circuitry, sections containing the medial septum (MS), rostral preoptic area 
(rPOA) and anterior hypothalamic area (AHA) populations of GnRH neurons 
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(approximately Bregma +1.34 to -0.46 mm) were utilised from VEH- (n=5) and PNA-
treated (n=8) mice. GnRH neurons were labelled using a guinea pig anti-GnRH primary 
antibody (1:5000; GA2, kindly gifted by Dr Greg Anderson) and NPY neural fibres 
originating from the ARN were labelled via tGFP reporter using a chicken anti-GFP 
primary antibody (1:5000; Aves Labs). GFP-positive fibres were amplified using a goat 
anti-chicken AlexaFluor488 antibody, while GnRH neurons were visualised using a goat 
anti-guinea pig AlexaFluor568 antibody was used to provide contrasting red 
fluorescence. 
5.2.3.2 Image acquisition 
Confocal microscopy was performed using a Nikon A1R multi-photon 
microscope (Nikon Instruments Inc., Melville, NY, USA) using lasers and objectives 
described in section 2.9. Images of individual GnRH neurons in the MS, rPOA and AHA 
were collected using the Nikon A1R. In each animal, z-stacks from five GnRH neurons 
in both the MS and AHA, and ten GnRH neurons in the rPOA were collected. Using a 
40x oil objective and 3x digital zoom using the rectangular selection tool, scans 
throughout the soma and first 75 µm of primary dendrite of each GnRH neuron were 
performed using 0.5 µm z-intervals. Pinhole size was maintained at 1 AU using a laser 
power of 1.2 units between animals, while digital gain and offset of red and green 
channels was kept consistent (< 5% variation) to prevent imaging artefacts from 
confounding or biasing later analysis. 
5.2.3.3 Image analysis 
Images collected of individual GnRH neurons and surrounding GFP-expressing 
ARN NPY neural fibres were analysed using NIS Elements software (Nikon Instruments 
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Inc.). The soma circumference in each neuron was measured using pre-established pixel-
to-µm conversion preprogramed into the software; each soma was measured using the 
image in the stack where the soma was at its largest, and this measurement was recorded. 
Each primary dendrite was divided into 15 µm segments up to 75 µm, using the 
measurement tool and manual demarcation of each segment. The number of GFP-
expressing fibres contacting each GnRH neuron was recorded, as well as how many times 
each fibre contacted, and the location of contact (soma or individual dendrite segments). 
A contact was defined as the point where no black pixels were present between the red 
GnRH label and the green GFP label, and required that this was present in the XY plain 
of view that the images were taken in, as well as orthogonal YZ view in a single focal 
plane. When a fibre passed across the soma or a segment of dendrite, or ‘bundled’ with 
the neuron before projecting away, this was recorded as one point of contact. These data 
were used to calculate the total number of contacts at the level of the soma, primary 
dendrite as a whole, and each 15µm segment individually. To calculate the density of 
contact, the total number of contacts at the soma were divided by the soma 
circumference, and the number of contacts upon each segment of dendrite were divided 
by 15, giving a density in contacts/µm. This provided a putative measurement of the 
density of innervation upon each neuron.  
5.2.4 Statistical analysis 
Statistical analysis was performed using PRISM software (Graphpad Software 
Inc., LA Jolla, CA, USA). Where values from the entire ARN were grouped, VEH and 
PNA group means were compared using two-tailed unpaired Student’s t-tests to compare 
absolute values, or Mann-Whitney U tests to compare percentage means. Where VEH 
and PNA group means were compared in the rARN, mARN and cARN separately, a two-
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way ANOVA was used, with post-hoc analysis performed using Bonferroni’s multiple 
comparisons tests. Mean number and density of contacts onto GnRH neurons was 
compared between VEH and PNA groups using a one-way ANOVA, and post-hoc 
analysis was performed using Tukey’s multiple comparisons tests. P-values < 0.05 were 
considered statistically significant.  
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5.3 Results 
5.3.1 Assessing steroid hormone receptor expression in ARN NPY neurons in PNA 
mice 
5.3.1.1 Progesterone receptor 
To assess the sensitivity of ARN NPY neurons to progesterone in VEH (n=8) and 
PNA (n=10) mice, IHC against PR and GFP reporter was performed throughout the 
rostro-caudal extent of the ARN. Initial qualitative assessment of images collected 
revealed that the distribution of PR-ir was predominantly scattered nuclei contained in 
the dorsomedial and ventrolateral subregions of the ARN, with very few in the 
ventromedial regions where NPY neuron somata are present (Figure 5.2). Additionally, 
PR-ir appeared less abundant and less intense in PNA-treated mice (Figure 5.2, bottom) 
compared with images collected from VEH-treated mice (Figure 5.2, top). When all 
regions of the ARN were grouped and the mean number of cells counted in each section 
were compared, it was revealed that PNA-treated mice had fewer PR-ir cells per section 
(108.4 ± 6.2 cells) compared with VEH-treated mice (137.2 ± 5.8; p = 0.0043; Figure 
5.3, A). When the rARN, mARN and cARN were compared separately, two-way 
ANOVA indicated an effect of treatment on the number of PR-ir cells (F(1, 48) = 13.07, 
p = 0.0007; Figure 5.3, B), and post-hoc analysis revealed fewer PR immunoreactive 
cells in the rARN of PNA mice (VEH 123.9 ± 4.9 cells vs. PNA 87.0 ± 8.2 cells; p = 
0.031), but not in the mARN (VEH 153.7 ± 9.0 cells vs. PNA 121.3 ± 7.6 cells) or cARN 
(VEH 134.0 ± 12.5 cells vs. PNA 116.9 ± 12.8 cells). The number of GFP-expressing 
NPY neurons was not different between VEH-treated and PNA-treated mice (Figure 5.3, 
C), and the co-expression of PR within ARN NPY neurons was revealed to be almost 
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entirely absent, with just 0.38 ± 0.2% in VEH-treated mice, and 0.25 ± 0.1% of NPY 
neurons in PNA-treated mice co-expressing PR (Figure 5.3, D). 
	
Figure 5.2. PR-immunoreactivity and GFP expressing NPY neurons within the ARN of VEH- and 
PNA-treated mice. Representative single z-planes throughout the ARN showing PR immunoreactivity 
(red) and amplified tGFP reporter expression within NPY neurons (green). Images collected from a VEH- 
(top) and PNA-treated (bottom, n=10) mouse are both shown. Scale bars = 50 µm. ARN, arcuate nucleus; 
GFP, green fluorescent protein; NPY, neuropeptide Y; PNA, prenatal androgen treated; PR, progesterone 
receptor; VEH, vehicle treated. 
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Figure 5.3. Fewer cells express PR within the ARN of PNA mice, while PR expression is absent from 
NPY neurons. (A) The mean number of PR immunoreactive cells counted in VEH- (black bars, n=8) and 
PNA-treated mice (red bars, n=10), where each region of the ARN has been averaged. (B) The mean 
number of PR immunoreactive cells counted in VEH- and PNA-treated mice in the rostral, middle and 
caudal regions of the ARN. (C) The mean number of GFP-expressing NPY neurons in VEH- and PNA-
treated mice across the entire ARN. (D) The percentage of NPY neurons co-expressing PR in VEH- and 
PNA-treated mice across the entire ARN. Results are presented as mean ± SEM. * p < 0.05, **, p < 0.01 
as determined by two-tailed unpaired Student’s t-test (A) or Bonferroni’s multiple comparisons (B). 
5.3.1.2 Estrogen receptor alpha 
To assess the sensitivity of ARN NPY neurons to estrogens in VEH (n=5) and 
PNA (n=5) mice, IHC against ERa and GFP reporter was performed throughout the 
rostro-caudal extent of the ARN. Images collected throughout the ARN displayed typical 
ventromedial localisation of NPY neurons, whereas ERa-ir was scattered around the 
entire ARN (Figure 5.4, top); high power images (Figure 5.4, bottom) revealed that 
while ERa-ir nuclei lay in close proximity to ARN NPY neuron cell bodies, they did not 
co-localise with ARN NPY neurons. When all regions of the ARN were grouped and the 
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expression of ERa (VEH 171.2 ± 7.6 cells vs. PNA 189.9 ± 11.2 cells; Figure 5.5, A), 
nor GFP-expressing NPY neurons (VEH 95.6 ± 7.1 cells vs. PNA 105.6 ± 8.9 cells; 
Figure 5.5, B) was detected between VEH- and PNA-treated mice. The co-expression of 
ERa within ARN NPY neurons was entirely absent in VEH-treated mice, and extremely 
limited in PNA-treated mice (0.15 ± 0.08%; Figure 5.5, C). 
	
Figure 5.4. Distribution of ERa and NPY expression in the ARN. (Top) Representative images 
composed from z-projections (6.36 µm thickness) collected throughout the ARN of a VEH-treated mouse 
where ERa immunoreactivity (red) and GFP expression within NPY neurons (green) is shown. (Bottom) 
single plane high magnification images taken within the highlighted area indicated in the top row. 
Individual single-labelled NPY neuron cell bodies are indicated by the empty arrowheads, while ERa 
immunoreactive nuclei are shown in close proximity. Scale bars = 100 µm (top), 10 µm (bottom). 3V, third 
ventricle; ARN, arcuate nucleus; ERa, estrogen receptor alpha; GFP, green fluorescent protein; NPY, 
neuropeptide Y.  
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Figure 5.5. ERa co-expression within NPY neurons is virtually absent in both VEH- and PNA-
treated mice. (A) The mean number of ERa immunoreactive cells counted in VEH- (black bars, n=5) and 
PNA-treated mice (red bars, n=5), where each region of the ARN has been averaged. (B) The mean number 
of GFP-expressing NPY neurons in VEH- and PNA-treated mice across the entire ARN. (C) The 
percentage of NPY neurons co-expressing ERa in VEH- and PNA-treated mice across the entire ARN. 
Results are presented as mean ± SEM. No significant differences were detected by two-tailed unpaired 
Student’s t-test. 
5.3.1.3 Androgen receptor 
To assess the sensitivity of ARN NPY neurons to androgens in VEH- (n=4) and 
PNA-treated (n=4) mice, IHC against AR and GFP reporter was performed throughout 
the rostro-caudal extent of the ARN. Assessment of images collected revealed abundant 
cytoplasmic AR-ir that was scattered throughout the ARN of both VEH- and PNA-
treated mice, including within the ventromedial subregions where NPY neurons reside 
(Figure 5.6). High magnification images revealed AR-ir co-localised within NPY 
neurons, where it was observed as low-level labelling within the entire cell body, with 
bright puncta aggregated within the cytoplasm (Figure 5.6, rows 2 & 4). As observed in 
sections 5.3.1.1 and 5.3.1.2, the number of GFP-expressing NPY neurons was not 
different between VEH- and PNA-treated mice (VEH 76.4 ± 2.7 cells vs. PNA 82.1 ± 
10.0 cells; Figure 5.7, A). Likewise, when all regions of the ARN were grouped and the 
mean number of AR-ir cells counted in each section were compared there was no 
difference between VEH- and PNA-treated mice (VEH 194.0 ± 18.2 cells vs. PNA 241.5 
± 16.6 cells; Figure 5.7, B). However, when the rARN, mARN and cARN were 
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number of AR-ir cells (F(1, 18) = 9.46, p = 0.0065), but post-hoc analysis did not reveal 
significant differences in any of these regions. When the co-expression of AR within 
NPY neurons was compared where the whole ARN was grouped, it was revealed that a 
greater proportion of ARN NPY neurons in PNA-treated mice express AR (33.2 ± 5.3%) 
compared with VEH treated mice (18.9 ± 1.8%, p = 0.045; Figure 5.7, C). When the 
rARN, mARN and cARN were compared separately, two-way ANOVA indicated a 
significant effect of treatment on the percentage of NPY neurons expressing AR (F(1, 
18) = 13.35, p = 0.0018), however post-hoc analysis did not reveal significant differences 
between VEH- and PNA-treated mice in any individual region (Figure 5.7, D). 
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Figure 5.6. Distribution of AR and NPY expression within the ARN of VEH- and PNA-treated mice. 
(Rows 1, 3) Representative images composed from z-projections (6.36 µm thickness) collected throughout 
the ARN where AR immunoreactivity (red) and GFP expression within NPY neurons (green) is shown. 
(Rows 2, 4) single plane high magnification images taken within the highlighted area indicated in the top 
row where cytoplasmic GFP and AR labelling is observed. AR, androgen receptor; ARN, arcuate nucleus; 
GFP, green fluorescent protein; NPY, neuropeptide Y. Scale bars = 50 µm (top), 10 µm (bottom).  
	 	 CHAPTER FIVE 
 140 
	
Figure 5.7. Expression of AR within NPY neurons is elevated in PNA-treated mice. (A) The mean 
number of GFP expressing NPY neurons counted in VEH- (black bars, n=4) and PNA-treated mice (red 
bars, n=4), where each region of the ARN has been averaged. (B) The mean number of AR immunoreactive 
cells across the entire ARN in VEH- and PNA-treated mice. (C) The percentage of NPY neurons co-
expressing AR in VEH- and PNA-treated mice across the entire ARN. (D) The mean number of NPY 
neurons co-expressing AR in the rostral, middle and caudal regions of the ARN within VEH- and PNA-
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5.3.2 Examining putative ARN NPY innervation to GnRH neurons in PNA mice 
To determine whether ARN NPY neuron projections to GnRH neurons undergo 
remodelling in PNA-treated mice, IHC was performed to label GnRH neurons and GFP 
expressing ARN NPY neuron fibre projections. Imaging was performed in the MS, rPOA 
and AHA of individual GnRH neurons and their proximal primary dendrites to assess the 
degree of close appositions made by ARN NPY fibres in these three regions (Figure 5.8). 
In the rPOA and AHA regions (Figure 5.8, ii-iii), dense collections of ARN NPY neural 
fibres were observed in close proximity to GnRH neurons, while these fibres were not as 
abundant in the MS (Figure 5.8, i). Of the GnRH neurons imaged, 98% of neurons in the 
rPOA and 93% of neurons in the AHA received at least one close apposition from an 
ARN NPY fibre; in contrast, just 5% of neurons in the MS received any close appositions.  
In the rPOA and AHA regions, images collected from both VEH- (Figure 5.9, A, 
i-ii; n=5) and PNA-treated mice (Figure 5.9, A, iii-iv; n=8) displayed abundant close 
appositions between ARN NPY neural fibres and GnRH neurons, with no remarkable 
qualitative differences between each treatment group. When the mean number of contacts 
per GnRH neuron in each region was compared by two-way ANOVA, no effect of VEH- 
vs. PNA-treatment was found (F(1, 66) = 0.32, p = 0.57; Figure 5.9, B). Likewise, when 
the mean density of contacts upon GnRH neuron somata and primary dendrites in the 
rPOA was compared between VEH and PNA mice using one-way ANOVA, no 
difference as an effect of treatment was found (F(1, 66) = 0.027, p = 0.87; Figure 5.9, 
C).  
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Figure 5.8. ARN NPY fibres appose GnRH neurons in the rostral preoptic area and anterior 
hypothalamic area, but not in the medial septum. Representative images composed from z-projections 
(thickness 12-14 µm) of GnRH neurons (red) residing in the MS (i), rPOA (ii) and AHA (iii); GFP-
expressing ARN NPY fibres (green) form close appositions with GnRH neurons in the rPOA and AHA, 
but not the MS. AHA, anterior hypothalamic area; GFP, green fluorescent protein; GnRH, gonadotropin-
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Figure 5.9. Close appositions made by ARN NPY neurons onto GnRH neurons is not different 
between VEH- and PNA-treated mice. (A) Representative images composed from z-projections 
(thickness 12-14 µm) of GnRH neurons (red) residing in the rPOA of VEH- (A, i-ii) and PNA-treated (A, 
iii-iv) mice. This region in both groups receives dense fibre projections from ARN NPY neural projections 
(green), that closely appose GnRH neurons. (B) The mean number of contacts made by ARN NPY neural 
fibres onto GnRH neurons in the MS, rPOA, and AHA, at the level of the soma and the primary dendrite 
in VEH- (black bars, n=5) and PNA-treated mice (red bars, n=8). (C) The mean density of contacts made 
onto GnRH neurons in the rPOA by ARN NPY fibre projections, at the level of the soma and 15 µm 
subsections of the primary dendrite. Scale bars = 5 µm. Results are presented as mean ± SEM. No 
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5.4 Discussion 
In this chapter, I presented two hypotheses based upon previous observations that 
ARN GABA neurons undergo remodelling in PNA treated mice that are consistent with 
the elevated LH pulse frequency seen in this model and PCOS in humans (Balen et al., 
1995; Franks, 1989; Moore et al., 2015). Specifically, I aimed to address whether ARN 
NPY neurons undergo alterations in their steroid hormone sensitivity, and a remodelled 
innervation to GnRH neurons occurs in PNA treated mice.  
5.4.1 ARN NPY neurons do not express nuclear estrogen or progesterone receptors 
As progesterone receptor expression is markedly reduced in ARN GABA neurons 
(Moore et al., 2015), of which NPY neurons compose a large subset (Marshall et al., 
2017), I hypothesised that steroid hormone sensitivity may be altered within ARN NPY 
neurons specifically. When IHC against PR was performed within the ARN a decrease 
in the number of cells positive for this receptor was observed as has been reported 
previously (Moore et al., 2015). Consistent again with this same study, the number of 
ERa expressing cells was unchanged. Surprisingly, however, dual IHC for GFP with PR 
or ERa in the ARN, revealed that there was either no co-expression in the vast majority 
of animals, or very little, consisting of only one or two cells. This is surprising in light of 
previous reports that NPY expression in the ARN varies over the estrous cycle of both 
the rat and mouse (Bennett et al., 1999; Olofsson et al., 2009), in which variations to 
NPY mRNA that occur are typically attributed to the changing ovarian steroid hormones 
throughout this cycle (for overview refer to section 1.3.3).  
In the mouse, NPY mRNA levels are decreased in the transition from estrus to 
proestrus (Olofsson et al., 2009), at which time both E2 and P4 levels are likely to be at 
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or near their peak levels for the cycle, suggesting negative regulation of the NPY gene in 
this phase. Moreover, elegant work by Yang and colleagues defining the E2-mediated 
transcriptome in the ARN indicates the presence of ERa in this population (Yang et al., 
2017). They describe that in wild-type mice, E2 benzoate reduces AgRP gene expression, 
but this is not the case in mice with global knockouts of ERa or with mutant ERa lacking 
DNA binding ability (Yang et al., 2017). Interestingly, ARN NPY neurons are also 
regulated by a membrane ER specific ligand (Smith et al., 2013), however the effects 
described are rapid and unlikely to explain effects on the transcript level. Past work 
examining ERa in ARN NPY neurons via immunodetection is sparsely reported and 
inconsistent. In an in vitro cell model, immunoblotting reveals the presence of ERa as 
well as a regulatory site on the NPY gene (Titolo et al., 2006); whereas Kim et al. 
demonstrate a similarly low co-expression via IHC in mice while also demonstrating E2 
reduces NPY mRNA levels (Kim et al., 2016). It is also possible that estrogen regulates 
ARN NPY neurons via peripheral actions. In female mice with ERa KO in the liver, 
estrous cycle-dependant variation of NPY and AgRP mRNA in the ARN is abolished, 
which may be due to altered hepatic lipid metabolism in KO mice (Benedusi et al., 2017). 
Evidence of PR mediated effects on NPY neurons are also surprisingly sparse 
given its apparent regulation by steroid hormones. However, one study in the ewe 
indicates that NPY mRNA is not affected by P4 administration, nor do ARN NPY 
neurons possess PR (Estrada et al., 2003), despite NPY mRNA being upregulated in the 
luteal phase of these animals when P4 is persistently elevated. This body of evidence 
makes it clear that the mechanism by which hormonal variation effects ARN NPY 
expression is still undetermined; however, the results presented in this chapter make a 
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strong case that the ARN GABA neurons which lose PR expression in PNA mice cannot 
consist of the NPY expressing subpopulation.  
5.4.2 A greater proportion of ARN NPY neurons express androgen receptors in 
PNA mice 
In light of the body of work utilising early androgen exposure models, it has 
recently been postulated that androgen signalling in the brain is the source of synaptic 
plasticity and disruptions to steroid hormone sensitivity that could underpin infertility in 
PCOS (Moore and Campbell, 2017; Ruddenklau and Campbell, 2019). Given that the 
ARN appears as a hub for where androgens may act to cause this remodelling to occur, I 
hypothesised that alterations to AR expression within ARN NPY neurons may be present 
in PNA-treated mice. Consistent with previous findings (Moore et al., 2015), the number 
of cells expressing AR did not change in the ARN of PNA-treated mice; nor was there a 
change in the number of GFP expressing cells. This is consistent with the number of NPY 
immunoreactive cells being unchanged in PNA-treated mice as demonstrated earlier in 
this thesis [Chapter 3, (Marshall et al., 2017)]. However, within ARN NPY neurons, 
approximately 20% were positive for AR throughout the ARN in VEH-treated mice, and 
interestingly, a greater proportion (~35%) co-expressed AR in PNA-treated mice. As 
circulating T levels are elevated in PNA-treated mice (Moore et al., 2013), and AR 
expression in the brain appears to be positively auto-regulated by androgens (Brock et 
al., 2015; Lu et al., 1998), it is possible that hyperandrogenism in this mouse model is 
the source of increased AR expression in ARN NPY neurons. It is interesting, however, 
that this represents an alteration to androgen sensitivity within a subpopulation of the 
ARN, while AR expression is unchanged within the ARN as a whole. It remains to be 
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determined how this elevation in AR may impact steroid hormone feedback or LH 
pulsatility in the PNA-treated mouse.  
Recent work by Caldwell and colleagues provides useful insight into the actions 
of AR in the context of a mouse PCOS model in which DHT is administered postnatally 
(Caldwell et al., 2017). In this paradigm, DHT induces a range of metabolic effects 
including increased body mass and greater adiposity, which may result from increased 
food intake. The primary neural regulation of body weight and food intake is well known 
to occur within the ARN, composed of the orexigenic NPY/AgRP neurons and the 
anorexigenic POMC neurons (Parker and Bloom, 2012). While androgen-mediated 
differences in body weight could result from reduced POMC expression following DHT 
treatment, anatomical evidence in the male rat suggests very little expression of AR 
within this population of cells (Fodor and Delemarre-van de Waal, 2001). This is in 
contrast to ARN NPY neurons which, as demonstrated in the present chapter, are 
androgen sensitive. Interestingly, when postnatal DHT treatment is given to mice with a 
neuron-specific knockout of AR, the metabolic effects resulting from this treatment do 
not occur, and measures of fertility improve (Caldwell et al., 2017). Thus, this increase 
in body weight following DHT treatment, and the protection from that body weight 
increase in AR knockout mice, may indicate that androgens are able to positively regulate 
ARN NPY neurons to increase orexigenic drive.  
The possibility that androgens acting via AR may increase ARN NPY activity is 
interesting, as it would indicate that this population is more active in PNA-treated mice; 
however, this is in contrast to the known characteristics of the PNA-treated mouse. 
Principally that PNA-treatment leads to only relatively mild metabolic disturbances, and 
body mass is not elevated (Roland et al., 2010). Furthermore, as ARN NPY neurons 
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appear to restrain LH secretion via inhibition of GnRH neurons (Coutinho et al., 2019; 
Roa and Herbison, 2012), elevated ARN NPY activity would be at odds with the 
increased pulse frequency present in PNA-treated mice (Moore et al., 2013). It is 
therefore clear that further work is needed to dissect the actions of androgens in ARN 
NPY neurons and how these actions play a role in altered GnRH neuron regulation in 
PNA-treated mice; possible experiments to achieve this are outlined in Chapter 8.  
5.4.3 The ARN NPY to GnRH neuron circuit does not appear to be remodelled by 
PNA treatment 
One way in which GnRH neural activity may be elevated in PNA-treated mice is 
by alterations to excitatory or inhibitory synaptic input. The ARN GABAergic circuit to 
GnRH neurons is thought to provide a predominantly excitatory input, which is supported 
by recent work demonstrating that specific activation of ARN GABA neurons elicits LH 
secretion in mice (Silva et al., 2019). This excitatory circuit is remodelled in PNA-treated 
mice, where GnRH neurons receive greater synaptic input by ARN GABA neurons 
(Moore et al., 2015). In contrast, NPY released from ARN GABAergic terminals on the 
proximal GnRH neuron may act via the Y1 or Y4 receptors to inhibit or excite GnRH 
neural firing rate (Roa and Herbison, 2012), however NPY binds to Y1R at a far greater 
affinity than Y4R (Lundell et al., 1996; Yan et al., 1996), so the net effect is likely to be 
inhibitory. Very recently, work within our lab has used optogenetic and chemogenetic 
activation of ARN NPY neurons to strongly support an inhibitory role of NPY on LH 
secretion (Coutinho et al., 2019). Thus, in PNA conditions where GnRH firing rate is 
higher (Roland and Moenter, 2011), I hypothesised there may be a reduction in the 
synaptic input of ARN NPY neurons to GnRH neurons, using close appositions between 
ARN NPY fibres and GnRH neurons to assess putative innervation.  
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When assessing the proportion of GnRH neurons imaged that received synaptic 
input from ARN NPY neurons, the vast majority within the rPOA and AHA 
subpopulations received close contacts with fibres, at approximately 98% and 93% 
respectively. In contrast, just 5% of neurons in the MS subpopulation received close fibre 
contacts, and when present, in all cases was a single fibre in close apposition. This was 
very surprising, given that anterograde tract tracing of ARN GABA neurons to MS 
GnRH neurons revealed contact with approximately half these neurons (Moore et al., 
2015), possibly suggesting that different ARN GABA subpopulations have different 
projection patterns with respect to the specific GnRH neurons they innervate. This 
finding that ARN NPY neurons appear to strongly innervate rPOA and AHA, but not MS 
GnRH neurons does not appear to have been previously reported, and may lend evidence 
to an ongoing yet unproven hypothesis that GnRH neurons at different regions along 
their anatomical axis represent functional subpopulations. 
When putative innervation of GnRH neurons by ARN NPY neurons was 
compared between VEH and PNA treated mice, no difference was detected, and in fact 
was strikingly similar across all groups regardless of GnRH neural subpopulation or 
whether the soma or dendrite was examined. This analysis was refined further, where the 
density of contacts was assessed to normalise for variations in soma circumference 
between GnRH neurons, and by looking at 15 µm sections of the primary dendrite. In 
this instance, again, there were no differences between VEH and PNA groups. This 
finding is somewhat surprising, first of all given that ARN NPY neurons compose such 
a sizable proportion of the total ARN GABA population that is known to undergo 
plasticity with respect to innervation of GnRH neurons (Marshall et al., 2017; Moore et 
al., 2015). Furthermore, this is surprising in light of the finding also presented in this 
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chapter, that a greater proportion of ARN NPY neurons are sensitive to androgens, as we 
have postulated that androgen signalling may be responsible for the increased 
GABAergic input to GnRH neurons in PNA-treated mice and thus driving circuit 
remodelling (outlined in (Moore and Campbell, 2017). In fact, androgens appear to play 
a role in modulating the development of the ARN NPY neural population, as male mice 
have a larger population ARN NPY neurons compared to females [Chapter 3, (Marshall 
et al., 2017)], which is also seen in male vs. female rats (Urban et al., 1993). Moreover, 
in female ewes treated with both T and DHT, there is an increase in the number of AgRP 
(thus presumably NPY) neurons in the mARN (Sheppard et al., 2011); however, this is 
not the case in DHT-treated female mice (Marshall et al., 2017). Interestingly, prenatal 
androgen treatment in female ewes also produces greater AgRP fibre density in the POA 
and other hypothalamic areas (Sheppard et al., 2011). These observations in the ewe are 
interesting, and suggest that perhaps further work in the PNA-treated mouse to assess 
density of innervation to projection targets afferent to GnRH neurons may be of interest 
to assess whether alterations to projection density occur elsewhere.  
5.4.4 Summary 
These data suggest that, while composing a large subpopulation of ARN GABA 
neurons, the ARN NPY neurons do not undergo the same degree of remodelling that 
occurs in PNA-treated mice. There is, however, a moderate increase in the proportion of 
ARN NPY neurons that are sensitive to androgens, which are elevated in PCOS and the 
PNA-treated mouse, and are known to interfere with steroid hormone mediated feedback. 
More work is required to determine the functional significance of this increase, as it 
stands there is very little information in the mouse to suggest how androgens may 
regulate ARN NPY neurons. ARN NPY neurons extend dense projections that form close 
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appositions with GnRH neurons, however this putative metric of innervation is not 
remodelled in PNA mice. As ARN NPY neurons are androgen-sensitive, additional work 
to determine whether androgens modify ARN NPY innervation to GnRH neural afferents 
may be of interest for future research. 
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6 ASSESSING ARN NPY NEURON LEPTIN 
SENSITIVITY IN THE PNA MOUSE  
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6.1 Introduction 
As central regulators of feeding behaviour, ARN NPY neurons are highly 
receptive to leptin, a crucial hormonal signal of energy balance that is secreted from 
adipocytes proportional to adiposity (Lönnqvist et al., 1997). In addition to its classic 
role in metabolism, leptin is thought to be a permissive cue for maintaining fertility, as 
both humans and rodents lacking leptin signalling are infertile (Chehab et al., 1996; 
Farooqi et al., 1999). This particular role of leptin appears to occur at the hypothalamic 
level via the GnRH neuronal network as it accelerates GnRH/LH pulse frequency in 
rodents in a dose-dependent manner (Lebrethon et al., 2000). Additionally, humans 
exhibit plasma leptin rhythmicity that is concurrent with elevated LH and estradiol levels 
(Licinio et al., 1998). Interestingly, hyperleptinaemia is frequently reported in women 
with PCOS compared with fertile women (Brzechffa et al., 1996; Laughlin et al., 1997; 
Mantzoros et al., 1997; Rouru et al., 1997). Generally, this is attributed to obesity, 
however, significant elevations in plasma leptin have been reported in PCOS women 
irrespective of BMI (Chakrabarti, 2013), including in lean women with PCOS (Yildizhan 
et al., 2011). Hyperleptinaemia and leptin resistance in PCOS has been speculated to 
influence LH hypersecretion (Spritzer et al., 2001), as well as contribute to 
hyperandrogenism by reducing plasma sex hormone binding globulin (Rouru et al., 
1997). 
As GnRH neurons themselves do not express leptin receptors (Quennell et al., 
2009), GnRH/LH regulation most likely occurs via leptin-responsive afferents. Leptin is 
a potent down regulator of expression of NPY expression in the ARN (Schwartz et al., 
1996; Stephens et al., 1995), therefore hyperleptinaemia in women with PCOS may lead 
to chronically suppressed NPY signalling. There is evidence for this in both lean and 
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obese women with PCOS, where they possess reduced plasma NPY levels compared 
with weight-matched fertile women (Romualdi et al., 2008). As NPY signalling to GnRH 
neurons is predominantly inhibitory (Coutinho et al., 2019; Roa and Herbison, 2012), it 
is likely that under normal conditions, ultradian and energy-dependant rises in leptin may 
act to release the restraint that ARN NPY neurons apply to GnRH neurons and permit 
LH pulses to occur. In PCOS, where higher levels of leptin and lower levels of NPY 
occur, disruption to this signalling pathway potentially causes LH hypersecretion 
(Figure 6.1). This begs the question of whether alterations to leptin secretion, or ARN 
NPY leptin responsiveness is present in PNA-treated mice which also exhibit elevated 
LH secretion. 
	
Figure 6.1. Dysregulation of leptin signalling in PCOS may cause LH hypersecretion. Leptin 
signalling is a positive regulator of GnRH/LH secretion. A likely pathway for this to occur is through 
inhibiting leptin sensitive ARN NPY neurons, releasing the inhibitory transmission that these neurons 
apply directly to GnRH neurons, as well as excitatory afferents such as kisspeptin neurons. Women with 
PCOS, as well as PNA-treated mice, exhibit LH hypersecretion. One possible way in which this may arise 
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Along with elevated LH pulse frequency (Moore et al., 2015), others have 
demonstrated that PNA-treated mice exhibit subtle metabolic abnormalities that may 
suggest abnormal leptin signalling. While body mass and body fat mass and percentage 
are not increased, individual adipocytes within adipose tissue are larger (Caldwell et al., 
2014; Roland et al., 2010). In humans, enlarged adipocyte size correlates with increased 
circulating plasma leptin, even in people with a healthy BMI (Lönnqvist et al., 1997). In 
cultured human adipocytes, leptin mRNA expression and leptin secretion directly 
correlates with size (Lundgren et al., 2007; Skurk et al., 2007). Previous studies in PNA-
treated mice suggest that, while plasma leptin levels do not appear to be overtly 
increased, leptin levels may not reduce in a fasted state like they are typically expected 
to (Roland et al., 2010). If elevated leptin is present in states of transient fasting, this may 
lead to persistently reduced ARN NPY activity, which could contribute to the elevated 
GnRH/LH pulse frequency in these mice (Figure 6.1).  
The experiments in this chapter aimed to address the following hypotheses: 
1. PNA-treated mice exhibit altered leptin secretion profiles compared with fertile 
VEH-treated controls 
2. ARN NPY neuron leptin-responsiveness is altered in PNA-treated mice. 
These hypotheses were addressed by: 
1. Measurement of plasma leptin in fed and fasted states in VEH- and PNA-treated 
mice. 
2. Assessing the proportion of ARN NPY neurons that have induced phosphorylated 
signal transducer and activator of transcription 3 (pSTAT3) following exogenous 
leptin administration in a fasted state in VEH- and PNA-treated mice. 




Adult female mice were housed under conditions outlined in section 2.2 until the 
day prior to leptin treatment. Mice in which ARN NPY neurons were identified by green 
fluorescent protein (GFP) were generated by crossing agouti-related peptide (AgRP)-
IRES-Cre mice (Tong et al., 2008) with ROSA26-CAGS-tGFP floxed-stop reporter mice 
(Wen et al., 2011a)(AgRP-tGFP mice). PNA mice were generated using the protocol 
outlined in section 2.3, by injection of dams on days 16, 17 and 18 of pregnancy with 
200 µL of sesame oil alone (vehicle controls, VEH, n=16) or containing 250 µg of 
dihydrotestosterone (DHT, n=16). Female offspring were later studied in adulthood (60-
90 days). 
6.2.2 Leptin treatment 
Twelve hours prior to treatment (approximately 2300 h), mice in metestrus or 
diestrus had chow removed from their cages and underwent an overnight fast. The 
following morning, mice were weighed and injected subcutaneously with either 
recombinant leptin (n=8 VEH, 8 PNA; 0.02 mg/kg, National Hormone and Peptide 
Program, Torrance, CA, USA) or saline (n=8 VEH, 8 PNA), starting at 1100 h and 
staggered at 10 minute (min) intervals between mice. This time of treatment was selected 
because mid-morning leptin sensitivity is approximately halfway between peak and 
lowest leptin sensitivity within the ARN (Boucsein et al., 2019), so an increase or 
decrease in leptin response in PNA-treated mice is more likely to be observable. 
Likewise, the dosage chosen (0.02 mg/kg) was selected for the same reason, as it causes 
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a robust but not maximal response within the ARN (Kim et al., 2016). At 90 min post 
treatment, mice were killed and fixed brains were dissected as outlined in section 2.6.2.  
6.2.3 Leptin ELISA 
Plasma was collected from VEH (n=8) and PNA (n=8) mice both in a fed state, 
and after an overnight fast, using tail-tip blood collection as outlined in section 2.4. An 
enzyme-linked immunosorbent assay (ELISA) was performed to measure leptin within 
each animal in both states using a mouse leptin ELISA kit (Crystal Chem, Elk Grove 
Village, IL, USA), performed according to manufacturer instructions. Briefly, a 26.5 
ng/mL leptin stock solution was prepared, and from this, standards were generated by 
serial dilution from 12.8 ng/mL through to 0.2 ng/mL. Antibody coated plates were then 
washed (using provided 20X wash buffer diluted 1:20 in ddH2O) twice and 50 µL of 
guinea pig anti-mouse leptin was dispensed per well, followed by 45 µL of sample 
diluent solution. In each well, either 5 µL of standards or samples were dispensed in 
duplicate. Four blank wells were included, into which a further 5 µL of sample diluent 
was dispensed. The plate then incubated for 16 h at 4°C on an orbital shaker. Following 
this the plate was washed five times and 100 µL of anti-guinea pig IgG conjugated with 
horse radish peroxidase was dispensed per well, and incubated for a further 3 h at 4°C on 
an orbital shaker. Contents were removed and the plate was washed another seven times, 
and 100 µL of enzyme substrate (3, 3’, 5, 5’-tetramethylbenzidine) was dispensed per 
well, and allowed to react for 30 min at room temperature while covered. The reaction 
was then stopped by addition of 100 µL of 1 M sulfuric acid, and immediately read at 
450 nm using a VICTOR X3 2030 Multiplate Reader (PerkinElmer, Waltham, MA, 
USA), with blank correction applied by subtracting the mean absorbance measured 
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across the blank wells. The minimum sensitivity of the assay is 0.2 ng/mL of leptin. The 
intra-assay coefficient of variation was calculated as 8.25%.  
6.2.4 Immunohistochemistry 
Response to leptin treatment in ARN NPY neurons was assessed by the presence 
of pSTAT3, an intracellular signal transducer (Myers et al., 2008). Free floating IHC was 
performed on fixed 30 µm coronal brain sections throughout the ARN using the double 
label IHC protocol outlined in section 2.7.1, including the EDTA antigen retrieval step. 
Published evidence of primary antibody validation is provided in Appendix I. The 
presence of pSTAT3 was labelled using a rabbit anti-pSTAT3 (1:3000, Tyr705, #9145, 
Cell Signaling Technology, Danvers, MA, USA) and ARN NPY neurons were labelled 
via expressed tGFP reporter using a chicken anti-GFP primary antibody (1:5000; Aves 
Labs). The GFP signal was amplified using a goat anti-chicken AlexaFluor488 antibody, 
while a goat anti-rabbit AlexaFluor568 was used to label pSTAT3.  
6.2.5 Image acquisition and analysis 
Confocal microscopy was performed using a Nikon A1R multi-photon 
microscope (Nikon Instruments Inc., Melville, NY, USA) using lasers and objectives 
described in section 2.9. Two z-stacks per animal were collected from one hemisphere 
of the rARN, mARN and cARN using a 40x air objective at 2 µm z-intervals with a 
pinhole size of 1 AU. Laser power was maintained at 1.2 units, and digital gain and offset 
of red and green channels was confined to a narrow range between animals (< 5% 
variation). Images were later analysed using NIS Elements software (Nikon Instruments 
Inc.). In each image, the number of GFP-ir, and pSTAT3-ir cells were counted, as well 
as the number of double-labelled cells. Using these counts, the percentage of pSTAT3-ir 
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cells co-expressing GFP-ir and the percentage of GFP-ir cells co-expressing pSTAT3-ir 
were calculated.  
6.2.6 Statistical analysis 
Statistical analysis was performed using PRISM software (Graphpad Software 
Inc., LA Jolla, CA, USA). Comparison of body weight was performed using a two-tailed 
unpaired Student’s t-test. Comparison of plasma leptin concentration was performed 
using a repeated measures two-way ANOVA, with post-hoc multiple comparisons 
carried out using a Bonferroni’s test. When comparing the number of pSTAT3-ir cells 
and the percentage of ARN NPY neurons that were pSTAT3-ir, a two-way ANOVA was 
performed when the rARN, mARN and cARN were compared separately, and post-hoc 
multiple comparisons was carried out using a Tukey’s test. Where the whole ARN was 
grouped, a one-way ANOVA was performed and post-hoc multiple comparisons was 
carried out using a Tukey’s test. For all analyses, p-values < 0.05 were considered 
statistically significant. 
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6.3 Results 
6.3.1 Comparison of body weight and plasma leptin concentration 
To assess overt metabolic differences that might have accounted for any potential 
difference in leptin responsiveness in the ARN, body weight and plasma leptin 
concentrations were assessed in VEH- and PNA-treated mice (Figure 6.2). Body weight 
assessed just prior to sacrifice and tissue collection was virtually identical between VEH- 
(22.51 ± 0.82g, n=16) and PNA-treated mice (22.44 ± 0.82g, n=16; Figure 6.2, A). 
Plasma leptin levels were measured by ELISA from blood samples collected in fed and 
fasted states (Figure 6.2, B). There was an overall effect of feeding state as assessed by 
repeated measures two-way ANOVA (F(1, 14) = 23.79, p = 0.0002), and post-hoc 
analysis revealed a significant reduction in the concentration of plasma leptin following 
fasting within both VEH-treated mice (3.82 ± 0.87ng/mL vs. 7.50 ± 1.7ng/mL in fed 
state, n=8, p = 0.0026) and PNA-treated mice (2.20 ± 0.38ng/mL vs. 4.86 ± 1.1ng/mL in 
fed state, n=8, p = 0.023). When the effect of treatment was assessed by repeated 
measures two-way ANOVA, no overall difference between plasma leptin concentration 
between VEH- and PNA-treated mice was observed (F(1, 14) = 2.13, p = 0.17). 
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Figure 6.2. Body weight and plasma leptin concentrations are not different between VEH- and PNA-
treated mice. (A) The body weight (g) in VEH- (black, n=16) and PNA-treated mice (red, n=16). (B) 
Circulating leptin concentration (ng/mL) in plasma from VEH- (black bars, n=8) and PNA-treated mice 
(red bars, n=8) was measured under fed and fasted conditions. Results are presented as mean ± SEM. * p 
< 0.05, ** p < 0.01 assessed by Bonferroni’s multiple comparisons test. 
6.3.2 Comparison of ARN NPY neuron leptin responsiveness using induction of 
pSTAT3  
To assess the responsiveness of the ARN to leptin, as well as to examine the 
responsiveness of ARN NPY neurons specifically, IHC was performed against GFP and 
pSTAT3 (Figure 6.3). In fasted animals administered saline, very few pSTAT3-ir nuclei 
were observed, and little co-expression with GFP expressing ARN NPY neurons was 
apparent (Figure 6.3 i, iii). In contrast, fasted animals administered leptin displayed a 
large number of pSTAT3-ir nuclei scattered throughout the ARN, and a sizeable 
proportion of ARN NPY neurons were co-localised with pSTAT3 (Figure 6.3 ii, iv). 
When quantified, neither leptin administration nor PNA-treatment had a significant 
effect on the number of GFP expressing NPY neurons present across the whole ARN as 
determined by a two-way ANOVA (F(3,27) = 1.58, p = 0.22, Figure 6.4, A). When 
assessing the induction of pSTAT3 in the rostral to caudal regions of the ARN, two-way 
ANOVA revealed a significant effect of treatment group on the number of pSTAT3-ir 
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post-hoc analysis revealed that the number of pSTAT3-ir cells was greater in VEH- and 
PNA-treated mice administered leptin compared with VEH- and PNA-treated mice given 
saline; however, there were no significant differences in the number of pSTAT3-ir cells 
between VEH- and PNA-treated mice given saline, nor between VEH- and PNA-treated 
mice administered leptin.  
To determine the sensitivity of ARN NPY neurons to leptin, the percentage of 
ARN NPY neurons co-labelled with pSTAT3 was assessed. When the rostro-caudal 
regions of the ARN were grouped (Figure 6.4, C), one-way ANOVA revealed a 
significant effect of treatment of the percentage of NPY neurons expressing pSTAT3 
(F(3, 27) = 10.78, p < 0.0001). Multiple comparisons revealed that a significantly greater 
proportion of ARN NPY neurons were co-localised with pSTAT3-ir nuclei in VEH-
treated mice administered leptin (49.5 ± 5.0%) compared with both VEH- (18.9 ± 4.3%, 
p = 0.0029) and PNA-treated (24.36 ± 6.8%, p = 0.017) mice given saline. Similarly, 
PNA-treated mice administered leptin had a greater percentage of co-labelled NPY 
neurons (54.29 ± 5.2%) compared with VEH- (p = 0.0004) and PNA-treated mice (p = 
0.0026) given saline. No significant differences were revealed between VEH- and PNA-
treated mice given saline, nor between VEH- and PNA-treated mice given leptin. When 
the percentage of NPY neurons co-localised with pSTAT3 was assessed in the rARN, 
mARN and cARN separately (Figure 6.4, D), the results were similar to when the ARN 
as a whole was assessed. A two-way ANOVA revealed a significant effect of treatment 
of the percentage of co-labelled NPY neurons (F(3, 81) = 26.35, p < 0.0001), however in 
no region of the ARN were any differences between VEH and PNA mice within the same 
treatment group revealed by multiple comparisons. 
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Figure 6.3. ARN NPY neurons are co-localised with pSTAT3 VEH- and PNA-treated mice 
administered exogenous leptin. Single z-plane images of the mARN are shown from VEH-treated mice 
given saline (i) or leptin (ii) as well as PNA-treated mice given saline (iii) or leptin (iv). ARN NPY neurons 
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Figure 6.4. ARN NPY neuron responsiveness to leptin is not altered PNA-treated mice. (A) The mean 
number of GFP expressing NPY neurons in the ARN of VEH- (empty black bars, n=8) and PNA-treated 
mice (empty red bars, n=8) given saline, VEH- (solid black bars, n=8) and PNA-treated mice (solid red 
bars, n=8) given leptin. (B) The mean number of pSTAT3 immunoreactive cells per section in the rARN, 
mARN and cARN of VEH- and PNA-treated mice given saline, as well as VEH- and PNA-treated mice 
given leptin. (C) The mean percentage of NPY neurons per section positive for pSTAT3 immunoreactivity 
averaged across the whole ARN of VEH- and PNA-treated mice given saline, as well as VEH- and PNA-
treated mice given leptin. (D) The mean percentage of NPY neurons per section in rARN, mARN and 
cARN positive for pSTAT3 immunoreactivity in of VEH- and PNA-treated mice given saline, as well as 
VEH- and PNA-treated mice given leptin. Results are presented as mean ± SEM. Statistically significant 
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6.4 Discussion 
In the present chapter, I assessed whether PNA mice exhibit abnormalities to their 
leptin signalling in ARN NPY neurons, hypothesising that there is reduced leptin 
signalling, which may have subsequent implications for ARN NPY signalling to GnRH 
neurons. Despite previous findings in PNA-treated mice (Roland et al., 2010), the present 
cohort of mice did not exhibit any abnormalities to their fasted plasma leptin levels. 
Leptin responsiveness in the ARN was not different between VEH- and PNA-treated 
mice by assessing the number of cells in which pSTAT3 was induced, nor was the 
sensitivity to leptin different specifically within ARN NPY neurons. These data suggest 
that altered leptin signalling in ARN NPY neurons does not influence rapid LH pulse 
frequency that is observed in the PNA-treated mice. 
Hyperleptinaemia is frequently present in women with PCOS (Brzechffa et al., 
1996; Laughlin et al., 1997; Mantzoros et al., 1997; Rouru et al., 1997), and there is 
evidence suggesting this occurs in lean women (Chakrabarti, 2013; Yildizhan et al., 
2011). PNA-treated mice utilised within this thesis are, by overt body mass and body fat 
percentage metrics, a model of lean PCOS (Caldwell et al., 2014; Roland et al., 2010). 
Prior assessment of plasma leptin concentrations within this model suggested that leptin 
was elevated in a fasted state (Roland et al., 2010), potentially reflecting fasted 
hyperleptinaemia in women with PCOS (Chakrabarti, 2013). In contrast to these 
findings, the results presented in this chapter demonstrate that plasma leptin measured 
by a sensitive ELISA are significantly lower following an overnight fast compared with 
a fed state in PNA-treated mice; this is similar to the reduction in leptin observed in fasted 
fertile VEH-treated controls. Additionally, as reported previously (Roland et al., 2010), 
there were no significant differences in plasma leptin levels between VEH- and PNA-
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treated mice when direct comparisons were made in fed and fasted states. These 
contrasting findings are possibly due to the different approaches taken to measure plasma 
leptin. The prior study utilised a broad adipokine detection assay (Roland et al., 2010), 
while the present study used a specific and sensitive leptin ELISA, and may allow greater 
resolution of differences between fed and fasted states. Alternatively, due to the circadian 
and pulsatile variations in plasma leptin levels (Saad et al., 1998), concentrations 
measured at a single time point may make it more difficult to assess differences.  
Even in the absence of hyperleptinaemia, a lack of response to leptin in the 
hypothalamus may still have been possible in PNA-treated mice, for example in the form 
of reduction in leptin receptor expression. While this has not directly been assessed in 
the hypothalamus of women with PCOS, circulating levels of soluble leptin receptor are 
reduced, which may be caused by hyperandrogenism (Sepilian et al., 2006). At the level 
of the hypothalamus, the ARN is regarded as the area most susceptible to leptin resistance 
at the cellular level (Enriori et al., 2007; Munzberg et al., 2004). In the present chapter, I 
assessed whether leptin resistance was present in the ARN of the PNA mouse as well as 
within the ARN NPY neurons specifically. This was assessed by immunodetection of 
pSTAT3 following exogenous leptin treatment, as pSTAT3 is induced in the intracellular 
leptin signalling pathway and is frequently used to assess leptin resistance (Myers et al., 
2008). These data demonstrated that, not only is the response to leptin within the ARN 
NPY neurons of PNA-treated mice the same as VEH-treated fertile controls, there does 
not appear to be any degree of leptin resistance in the ARN of PNA mice when pSTAT3 
induction is assessed. Overall it appears that in PNA-treated mice, normal leptin 
sensitivity is present in ARN NPY neurons, suggesting that there are no alterations to the 
relay of leptin signalling to GnRH neurons. Thus, it is unlikely that leptin-NPY-GnRH 
	 	 CHAPTER SIX 
 167 
neural signalling is causing central neuroendocrine disruptions and may be ruled out as 
a cause of PCOS pathology.  
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7 DISCOVERING ALTERATIONS IN 
HYPOTHALAMIC GENE EXPRESSION IN 
THE PNA MOUSE  
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7.1 Introduction 
The results presented in the previous chapters of this thesis have so far used 
predominantly anatomical techniques to determine whether ARN NPY-to-GnRH neuron 
signalling, as well as peripheral hormone signalling to ARN NPY neurons, is altered in 
PNA-treated mice. These approaches, while useful for assessing gross alterations on the 
anatomical level, do not necessarily provide full insight into whether alterations to 
signalling are occurring at a finer molecular level. The results presented in this chapter 
examined this by assessing differences in gene transcription, to assess whether prenatal 
androgen excess impacts that expression of transmitters, or peripheral hormone receptors 
related to both ARN NPY neural circuitry and the broader hypothalamic control of 
fertility. The expression of NPY receptors was also assessed in known projection target 
areas that are also important for GnRH neuron regulation. Additionally, as alterations to 
ARN NPY neurons had not been elucidated thus far, genes important for kisspeptin 
signalling were also assessed. 
Research using animal models of PCOS have revealed a potentially neurocentric 
pathophysiology for this disorder. Specifically, evidence suggests that alterations in 
GnRH neural network signalling could underpin key features of PCOS such as the 
diminishment of steroid hormone mediated negative feedback (Moore et al., 2013; Moore 
et al., 2015), hyperactivity of GnRH neurons (Roland and Moenter, 2011; Sullivan and 
Moenter, 2004b), and ultimately elevated LH secretion (Moore et al., 2015). Anatomical 
and electrophysiological approaches to investigate the PCOS-like PNA-treated mouse 
have uncovered clear alterations to GnRH neural signalling, but so far this has only been 
identified with respect to GABA circuitry. GABAergic post-synaptic currents are 
elevated (Sullivan and Moenter, 2004b), coinciding with elevated putative GABAergic 
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innervation that likely arises from the ARN (Moore et al., 2015; Silva et al., 2018). The 
basal firing rate of GnRH neurons themselves is increased (Roland and Moenter, 2011) 
which may arise from stimulatory GABAergic input (Herbison and Moenter, 2011; Silva 
et al., 2019). Furthermore, steroid hormone sensitivity is altered with fewer cells 
expressing PR in the RP3V and ARN, and a greater number of cells express ERa and 
AR in the PeN and AVPV nuclei of the RP3V respectively (Moore et al., 2015). 
Efforts to identify alterations to other afferent signalling pathways in PNA-treated 
mice have yielded mixed results. Kisspeptin-GnRH neuron signalling is a critical 
component of LH surge generation, and is thought to form the core of GnRH/LH pulse 
generation (Clarkson et al., 2008; Clarkson et al., 2017), and has therefore drawn 
considerable interest as a potential site of altered signalling in PCOS models. While 
alterations to the number of kisspeptin neurons in the AVPV and ARN has been reported 
in the PNA mouse (Hu et al., 2018), this is not reflected at the transcript level (Caldwell 
et al., 2015). Moreover, from our own work examining the number of cells in the ARN 
expressing the peptides NPY, kisspeptin and b-endorphin, or the enzymes TH and nNOS, 
there were no apparent differences in the size of these populations between fertile female 
mice and PNA-treated mice (Marshall et al., 2017). It is possible that the approaches 
taken in these studies are limited to detecting only the most robust of changes; examining 
the total cell number within a population does not examine alterations to neuropeptides 
or neurotransmitters synthesised by individual cells. Unpublished examinations of 
transcript expression of peptides or their receptors have been carried out within our lab 
by broadly examining the anterior and posterior hypothalamus as a whole, however this 
has not elucidated any changes. This is possibly due to the limitations of the approach 
taken, in which qPCR was used that required large amounts of tissue pooled across 
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animals to obtain adequate concentrations of RNA. This may preclude the identification 
of finer alterations as a result of PNA-treatment, such as specific transcriptional changes 
within individual nuclei.  
To overcome this issue, sensitive assays for the detection of many genes in small 
tissue samples have become more readily available. One such technique, NanoString, 
utilises a single-molecule RNA counting technique for assessing differential expression 
of mRNA under variable conditions (Geiss et al., 2008; Kulkarni, 2011), allowing us to 
readdress whether alterations to gene expression are occurring within key nuclei of the 
GnRH neural network. The objective of experiments in this chapter were to assess 
whether androgen excess in PNA-treated mice alters expression of genes known to be 
important for GnRH neuron regulation, examining within the rPOA, RP3V and ARN. 
Genes examined fell into four broad classes of: peripheral hormone receptors, 
neurotransmitters and neuropeptides, neuropeptide receptors, and cytokines.   




Adult female C57BL/6 mice were generated and housed under conditions 
outlined in section 2.1. PNA mice were generated using the protocol outlined in section 
2.3, by injection of dams on days 16, 17 and 18 of pregnancy with 200 µL of sesame oil 
alone (vehicle controls, VEH, n=12) or containing 250 µg of dihydrotestosterone (DHT, 
n=12). Female offspring were later studied in adulthood (60-90 days). 
7.2.2 Tissue and RNA sample collection  
Unfixed frozen brains were collected and prepared as specified in section 2.6.1. 
Tissue containing the rPOA, RP3V and ARN was then micro dissected from the 
appropriate 250 µm coronal sections. Glass slides on which coronal slices were loosely 
affixed were kept cold on a metal block with dry ice. Using a dissecting microscope and 
modified 20 gauge needles, tissue was micro dissected as shown in Figure 7.1, and tissue 
samples were placed immediately into lysis buffer. RNA was then purified from tissue 
on the same day using the protocol outlined in section 2.8, and frozen at -80°C until later 
use. Sample quality was assessed by Otago Genomics and is provided in Appendix III. 
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Figure 7.1. Location of tissue dissected for RNA purification. Schematic coronal brain sections are 
shown reflecting the rostro-caudal orientation of the two to three 250 µm thick sections that typically 
contained regions of interest. Tissue was micro dissected from the rPOA, RP3V and AHA using a punch 
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7.2.3 NanoString design and assay 
Differential gene expression within the rPOA, RP3V and ARN was assessed by 
designing a NanoStringTM nCounter® Custom CodeSet for 17 genes of interest and 3 
housekeeping reference genes (Table 5.1). Sequence data for genes of interest were 
identified using the National Centre for Biotechnology Information’s GenBank database, 
and reference numbers provided to NanoString where probes were designed. In house 
quality control did not flag any probes for out of range RNA melting temperature, cross 
hybridization, or issues with RNA secondary structure interference. All target sequences 
(Table 5.1) were designed to detect all known isoforms of each gene. The NanoString 
assay was run by Otago Genomics, as described previously (Kulkarni, 2011). Briefly, 
sample RNA (100 ng RNA per 5 µL sample in RNase free water) is hybridised with two 
sequence-specific probes designed against each gene of interest to form a single tripartite 
structure (Figure 7.2, 1-2). This consists of a capture probe that binds individual RNA 
molecules to the assay cartridge (Figure 7.2, 3), and a reporter probe which contains a 
unique fluorescent label per gene. Captured and labelled RNA is then imaged using 
automated fluorescent microscopy, each instance of each particular tag is counted, 
generating ‘counts’ of each RNA molecule containing target sequences per sample which 
is later analysed (Geiss et al., 2008; Kulkarni, 2011) (Figure 7.2, 4). This assay is 
enzyme-free and only requires small RNA quantities, allowing detection of many genes 
in a small sample. 
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Figure 7.2. Overview of NanoString methodology. (1) In each sample well, probes complementary for 
the target genes of interest are introduced. This consists of a capture probe conjugated with biotin, and a 
reporter probe with a fluorescent ‘barcode’ that is unique to each gene of interest. (2) Capture and reporter 
probes hybridise with each target gene, forming a single tripartite structure. (3) Samples are then 
transferred to assay cartridges with streptavidin coated slides that bind to biotin on the target mRNA, off-
target mRNA is then removed with washes. (4) Bound mRNA from each sample is imaged using a 
fluorescent microscope, and each barcode is counted to assess the number of individual mRNA molecules 
encoding for each target gene that are present. These counts are later analysed to assess differences between 
samples. 
7.2.4 Differential gene expression analysis 
Raw expression counts were processed using nSolver software (NanoString 
Technologies Inc., Seattle, WA, USA). Firstly, several quality control (QC) parameters 
were assessed (QC readouts are provided in Appendix III). Binding density QC was 
assessed to ensure that samples were not too concentrated and individual tagged 
molecules were not overlapping; all samples were within the 0.1-2.25 molecules per µm2 
range suggested in the nSolver user manual. Image QC was also assessed; between 
samples a range of 93%-100% of the image field of view was usable for obtaining RNA 
counts (75% of the field of view per sample was deemed acceptable). To assess assay 
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and a linear regression is automatically performed; all samples had r2 values of 0.99-1.0 
(r2 = 0.95 was considered a QC pass for assay linearity). Finally, a limit of detection QC 
was performed where the lowest positive control probe was compared with the mean of 
spiked in negative control probes; in all samples the count generated from the positive 
control was greater than 2 standard deviations higher than counts generated from 
negative controls. Two rounds of normalisation were then applied to the raw count data. 
A positive control normalisation is first applied to account for potential differences in 
hybridization efficiency between samples, the nSolver software calculates the geometric 
mean of all positive controls in each sample and applies a normalisation factor. A second 
round of normalisation is then applied based on the geometric mean of the housekeeping 
genes (Gapdh, Actb, Sdha). Ratios for each gene in each sample were generated, 
expressed as fold change of the PNA treated group versus VEH treated. Statistical 
differences were assessed by unpaired two-tailed Student’s t-test comparing normalised 
data, where p < 0.05 was considered significant. 
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Table 7.1. Genes of interest and target sequences for NanoString capture and reporter probes. 
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Name Gene NCBI Reference Sequence (5’-3’) 
























































Blue, hormone receptors; green, neurotransmitters and neuropeptides; red, neuropeptide receptors; yellow, 
cytokines; grey, housekeeping genes. 
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7.3 Results 
7.3.1 Differential gene expression in the rostral preoptic area 
To assess differences in gene expression in the rPOA as a result of PNA 
treatment, normalised mRNA counts were compared between PNA treated mice and 
VEH controls (relative expression of each gene relative to VEH treated mice are shown 
in Figure 7.3). Out of all the genes of interest, Lepr encoding for the leptin receptor was 
the only gene with altered expression in PNA treated mice, where expression was 
significantly reduced by approximately half (0.59 ± 0.3 relative to VEH, p = 0.0057, 
Figure 7.3, A).  
7.3.2 Differential gene expression in the rostral periventricular area of the 3rd 
ventricle 
To assess differences in gene expression in the RP3V as a result of PNA 
treatment, normalised mRNA counts were compared between PNA treated mice and 
VEH controls (relative expression of each gene relative to VEH treated mice are shown 
in Figure 7.3). Out of all the genes of interest, Npy1r encoding for the Y1 receptor was 
the only gene with altered expression in PNA treated mice, where expression was 
significantly reduced by approximately 20% (0.82 ± 0.7 relative to VEH, p = 0.025, 
Figure 7.3 B).  
7.3.3 Differential gene expression in the arcuate nucleus 
To assess differences in gene expression in the ARN as a result of PNA treatment, 
normalised mRNA counts were compared between PNA treated mice and VEH controls 
(relative expression of each gene relative to VEH treated mice are shown in Figure 7.3). 
Out of all the genes of interest, Tnf encoding for tumor necrosis factor was the only gene 
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with altered expression in PNA treated mice, where expression was significantly reduced 
by approximately 25% (0.77 ± 0.1 relative to VEH, p = 0.048, Figure 7.3 A).  
	
	
Figure 7.3. Relative expression of leptin receptor, Y1 receptor, and tumor necrosis factor genes are 
altered in regions of the hypothalamus in PNA mice. The relative expression of 17 genes of interest and 
3 housekeeping genes was assessed in VEH-treated (empty bars, n=12) and PNA-treated (filled bars, n=11-
12) female mice. The relative expression of each gene is shown as a ratio relative to the expression in 
VEH-treated mice from tissue collected in the (A) rPOA, (B) RP3V and (C) ARN. Results are presented 






































































































































































































	 	 CHAPTER SEVEN 
 181 
7.4 Discussion 
The objective of the experiments presented in the chapter were to assess, at the 
transcript level, whether alterations in signalling within the afferent GnRH neural 
network were present in PNA-treated mice, in the rPOA, RP3V, and ARN, which are 
known to be key regulatory regions. Strikingly, expression of the great majority of genes 
assessed were unaltered with just one gene in each region displaying reduced expression, 
namely Lepr in the rPOA, Npy1r in the RP3V and Tnf in the ARN. Surprisingly, no 
alterations to expression of the genes Esr1, Pgr or Ar, encoding for steroid hormone 
receptors were detected. This stands in contrast to the finding that the number of cells 
expressing PR is reduced in the ARN of PNA treated mice, and that ERa and AR are 
increased in nuclei within the RP3V (Moore et al., 2015). This may indicate that 
alterations to the number of cells expressing these receptors is occurring further 
downstream than at the gene expression level, possibly by mechanisms such as post-
translational modification and receptor turnover. Consistent with our previous findings 
were the number of cells in the ARN expressing NPY, kisspeptin or VGAT are 
unchanged in PNA treated mice (Marshall et al., 2017), there were no changes detected 
in Npy, Kiss1, or Gad1 in the ARN respectively.  
7.4.1 NPY Y1 receptor gene transcription is down regulated in the RP3V of PNA 
mice 
To assess whether NPY-to-GnRH neural signalling may be altered, the Npy1r 
gene encoding for the Y1R was examined. Expression of Npy1r in the rPOA, where one 
function of this receptor is to modulate GnRH neurons, was not altered. This is perhaps 
consistent with the findings shown in the previous chapter (section 4.5) in which it was 
demonstrated that ARN NPY neural projections to GnRH neurons are unchanged in 
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PNA-treated mice. As Y1R signalling is the primary mediator of NPY-to-GnRH 
regulation in the mouse (Roa and Herbison, 2012), it therefore seems unlikely that direct 
signalling by NPY neurons to GnRH neurons is altered in the PNA mouse. Npy1r was 
similarly unaltered in the ARN of PNA mice, therefore it is unlikely that NPY-to-ARN 
kisspeptin signalling is dramatically altered, thus altering the GnRH pulse generator 
(Clarkson et al., 2017).  
Surprisingly, however, a modest but significant reduction in Npy1r mRNA 
expression was observed in the RP3V, the putative locus of LH surge generation 
(Clarkson et al., 2008; Herbison, 2008). ARN NPY neurons specifically have been shown 
to form functional circuits with kisspeptin neurons in the AVPV within this area (Padilla 
et al., 2017), which is hypothesised as a potential gating circuit where LH surge 
generation is only permitted by appropriate nutritional status detected at the level of the 
ARN NPY cell bodies. Interestingly, under conditions where E2 levels are elevated, such 
as prior to the preovulatory LH surge, application of NPY has been demonstrated to 
potently stimulate LH secretion (Sahu et al., 1987), and in mice where the NPY gene has 
been knocked out, the LH surge amplitude is diminished (Xu et al., 2000a), indicating a 
modulatory role for NPY in LH surge generation. This is likely to act via the Y1R, as 
Npy1r expression is elevated in the preoptic area and mediobasal hypothalamus prior to 
the LH surge (Xu et al., 2000b). While ARN NPY neural communication with kisspeptin 
neurons is normally inhibitory via GABA signalling (Padilla et al., 2017), a stimulatory 
role of NPY acting on RP3V kisspeptin neurons may occur depending upon the hormonal 
milieu, and compose a pathway for how NPY modulates the LH surge. Reduced 
expression of Npy1r in PNA-treated mice may therefore indicate a mechanism, alongside 
attenuated steroid hormone feedback, for why these mice do not spontaneously generate 
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LH surges. It is important to note, however, that the identity of cells with reduced Y1R 
still remains to be determined. 
7.4.2 Leptin receptor expression is reduced in the rPOA of PNA mice 
As signalling of metabolic status to the brain via leptin is a necessary permissive 
signal regulating fertility (Batt et al., 1982; Chehab et al., 1996; Swerdloff et al., 1976), 
Lepr expression was assessed in PNA mice. As the ARN is the site where leptin 
signalling fulfils its primary role in regulating feeding behaviour through NPY neurons 
(Schwartz et al., 1996; Stephens et al., 1995), it was anticipated that if Lepr expression 
was altered it would be within this region, however this was not the case. This is 
consistent with the fact that PNA mice do not undergo overt changes to their body weight 
(Caldwell et al., 2014; Roland et al., 2010), however anatomical work would still be 
necessary to tease apart whether a subset of neurons in the ARN alter their sensitivity to 
leptin.  
Surprisingly however, a robust decrease in Lepr expression in the rPOA was 
observed. GnRH neurons themselves do not express leptin receptors (Quennell et al., 
2009), so this does not reflect a direct alteration to GnRH neuron leptin sensitivity. Leptin 
sensitive neurons within this area are predominantly composed of glutamatergic 
thermoregulatory neurons that, when stimulated, ultimately increase sympathetic nerve 
activity to brown adipose tissue (BAT), raising body temperature, altering energy 
expenditure, and reducing food intake (Yu et al., 2016). In other PCOS animal models, 
there is in fact evidence of attenuated BAT function that may contribute to the metabolic 
and reproductive abnormalities in these animals. In female DHEA-treated rats, BAT 
activity is markedly reduced; remarkably however, transplantation of BAT from healthy 
control rats improved estrous cycling in these animals (Yuan et al., 2016). Similarly, 
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administration of a specific activator of BAT function improves cyclicity and restores 
normal LH secretion in DHEA-treated female rats (Hu et al., 2017). Additionally, there 
is evidence that in chronically DHT-treated mice, leptin fails to induce BAT activity 
(Nohara et al., 2014). As stated previously, the PNA-treated mouse does not display 
increased body weight (Caldwell et al., 2014; Roland et al., 2010), however BAT 
function has not been reported upon. Considering this reduction in rPOA Lepr, it would 
be interesting to conduct a more in depth metabolic assessment of these mice to assess 
whether thermogenesis and BAT function is altered. 
A subset of leptin sensitive nNOS neurons in this region are more directly 
implicated in relaying leptin signalling to GnRH neurons and subsequently regulating 
fertility (Bellefontaine et al., 2014). Exogenous application of leptin in mice leads to a 
relatively fast phosphorylation of nNOS in the rPOA, and in the same time frame causes 
an increase in plasma LH, which is blunted by nNOS blockade. Notably, specific deletion 
of leptin receptors from rPOA nNOS neurons leads to elevated LH levels with no 
subsequent change in body weight (Bellefontaine et al., 2014). As LH levels are elevated 
in the PNA-treated mouse (Moore et al., 2015) with no associated change in body weight 
(Roland et al., 2010), this raises an interesting possibility where altered leptin signalling 
to rPOA nNOS neurons contributes to infertility seen in PNA-treated mice. Future 
experiments examining the effect of exogenous leptin on the phosphorylation of nNOS 
in this region may begin to elucidate this further.  
7.4.3 Expression of the cytokine Tnf is reduced in the ARN of PNA mice 
As well as examining genes related to reproductive and neural signalling, genes 
for the cytokines Tnf and Il1b were assessed in PNA treated mice. Circulating levels of 
the proinflammatory cytokine tumor necrosis factor α (TNFα) is elevated in women with 
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PCOS, independent of obesity (Gonzalez et al., 1999), which is implicated in the insulin 
resistance seen in many women with PCOS via alterations to glucose transporters 
(Rosenbaum et al., 1993; Rui et al., 2001; Stephens and Pekala, 1992). Interleukin-1b is 
also elevated in women with PCOS, and while its role is less well defined, it is thought 
to reflect chronic, low-grade inflammation in these women (Zafari Zangeneh et al., 
2017). As glucose tolerance is impaired in the PNA mouse (Roland et al., 2010), Tnf 
expression was examined in PNA mice. In the rPOA and RP3V this was unchanged, 
however there was surprisingly a small reduction in Tnf expression in the ARN compared 
with vehicle controls. This seems contrary to the body of literature that consistently 
report circulating TNFα as being elevated, and may suggest a different role for local 
hypothalamic Tnf expression in the PNA mouse. Further research into the activation of 
local cytokine secreting cells within this region in the PNA mouse, such as microglia, 
may be necessary to further elucidate this finding. 
7.4.4 Gene expression in KNDy neurons appears to be unaltered in the ARN of 
PNA mice 
Notably, kisspeptin-GnRH neuron signalling does not appear to be altered, as 
Kiss1r expression is unchanged in the rPOA. Moreover, within the ARN, genes encoding 
for the autoregulatory peptides NKB (Tac2) and dynorphin (Pdyn) that are co-expressed 
within kisspeptin neurons are unaltered. This also applies to genes encoding for their 
respective receptors, namely Tacr3 and Oprk1. Coordinated activity of kisspeptin 
neurons leading to GnRH pulse generation (Clarkson et al., 2017) is hypothesised to 
occur via autosynaptic regulation via NKB and dynorphin (Lehman et al., 2010; Navarro 
et al., 2009). Thus, no apparent changes within the regulatory components of kisspeptin 
neurons in the ARN appears to suggest that elevated LH secretion in the PNA mouse 
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occurs independently of endogenous activity of the GnRH neural pulse generator, 
however electrophysiological experiments would need to be carried out to confirm this. 
This is consistent with what is observed in women with PCOS, where plasma kisspeptin 
levels are unaltered (Daghestani, 2018; Emekci Ozay et al., 2016), and that ‘uncoupling’ 
of pulsatile patterns of plasma kisspeptin and LH levels occurs (Katulski et al., 2018), 
again suggesting that elevated LH pulse frequency is independent of ARN kisspeptin 
neurons.  
7.4.5 Summary 
In this chapter it has been demonstrated that, at the mRNA transcript level, 
expression of genes related to signalling to and within the GnRH neural network are 
largely unaltered in the PNA mouse. In particular, the lack of alterations to genes 
associated with regulation of kisspeptin-NKB-dynorphin neurons suggest elevated LH 
secretion in the PNA mouse may not be associated with changes in the endogenous 
activity of the GnRH neuron pulse generator. A reduction in Npy1r expression in the 
RP3V may reflect impaired signalling to LH surge generating kisspeptin neurons by NPY 
neurons, and provide further insight into the lack of LH surge in PNA mice. Finally, a 
robust reduction in Lepr in the rPOA may reflect reduced leptin signalling to nNOS 
neurons in this region, which could contribute to alterations in LH pulse frequency seen 
in this model of PCOS. These data using a previously unused tool establish a platform of 
previously identified expression data indicating potential remodelling in PNA-treated 
mice that may be addressed in greater depth in future. 
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8 FINAL DISCUSSION  
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8.1 Background and summary of findings 
PCOS is an endocrinopathy in which hyperandrogenism is associated with 
elevated secretion of LH and thus elevated GnRH neural activity at the level of the 
hypothalamus (Balen et al., 1995; Franks, 1989; Taylor et al., 1997). Women with PCOS 
are not responsive to circulating ovarian hormones that typically slow LH secretion, and 
this lack of response appears to be androgen driven (Daniels and Berga, 1997; Eagleson 
et al., 2000; Pastor et al., 1998). As GnRH neurons do not express AR (Huang and Harlan, 
1993), this neuroendocrine derangement is therefore due to alterations in steroid hormone 
sensitive afferent neurons.  
Work in the PNA-treated mouse has greatly progressed our understanding of 
circuit alterations that occur as a result of the early androgen exposure hypothesised to 
generate PCOS in women. In particular, the ARN of the hypothalamus has been 
identified as a site that is particularly susceptible to remodelling by prenatal androgen 
excess. Previous work conducted by our group and others have revealed that GABAergic 
input to GnRH neurons is elevated in PNA-treated mice (Moore et al., 2015; Sullivan 
and Moenter, 2004b), providing what appears to be excitatory drive (Herbison and 
Moenter, 2011; Silva et al., 2019). This is androgen mediated, as peripubertal androgen 
blockade appears to reverse this elevation (Silva et al., 2018). Specific alterations in ARN 
GABA neurons have been identified, where in the PNA-treated mouse they increase their 
putative innervation to GnRH neurons and are less responsive to P4, an ovarian hormone 
important for negative feedback (Moore et al., 2015); this implicates ARN GABA 
neurons as a potential source of altered regulation of GnRH neurons that ultimately leads 
to elevated LH secretion and infertility.  
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A known, large subset of ARN GABA neurons are appetite regulating NPY 
neurons that have a long established role in modulating LH secretion. Given the frequent 
metabolic dysregulation that occurs in PCOS (Fogel et al., 2001; Pikee et al., 2016) 
(Ladron de Guevara et al., 2014), and apparent alterations to NPY secretion that women 
with PCOS exhibit (Romualdi et al., 2008), ARN NPY neurons have been implicated as 
a potential subset of GABA neurons that undergo remodelling in the PNA-treated mouse. 
Based upon this established work, this PhD thesis aimed to examine the ARN NPY subset 
of GABA neurons specifically to determine whether remodelling occurs in their 
communication with GnRH neurons or in their receptivity to peripheral hormone 
feedback. 
This project determined what proportion of ARN GABA neurons co-express 
NPY in both fertile male and female mice, and whether this was altered in female mice 
with PNA-treatment. This study also aimed to further dissect the molecular identity of 
ARN GABA neurons, examining kisspeptin, TH, b-endorphin, and nNOS 
immunoreactivity with this population (Chapter 3). This revealed that one third of ARN 
GABA neurons co-expressed NPY, composing by far the largest subset of ARN GABA 
neurons of all the molecular phenotypes examined (Marshall et al., 2017). In addition, 
the vast majority of ARN NPY neurons were found to be VGAT positive (>93%), 
suggesting that virtually all ARN NPY neurons use synaptic GABA neurotransmission. 
This contrasts with previous findings in the rat where just one third of ARN NPY neurons 
appear GABAergic (Horvath et al., 1997), either highlighting the sensitivity of the 
genetic reporter approach used here, or reflecting a genuine species difference in ARN 
NPY neurons. When the proportion of GABAergic NPY neurons in fertile females was 
compared with males and PNA-treated females, no differences were found. There was, 
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however, a difference in the total number of NPY neurons between males and both fertile 
and PNA-treated female mice, which is similar to findings in the rat (Urban et al., 1993). 
This suggests that masculinisation of the brain, but not necessarily androgen-mediated 
actions, program ARN NPY neuron development. Importantly, this provides further 
evidence that PNA-treatment does not masculinise the brain, but instead perturbs the 
feminised brain. Interestingly, this is in contrast to work in the ewe, where DHT treatment 
increases the number of ARN NPY neurons (Sheppard et al., 2011).  
Other key GnRH neuron regulatory afferents did not co-localise with VGAT 
reporter neurons to the same degree as NPY (Chapter 3). Notably, ARN kisspeptin 
neurons, composing the putative GnRH neuron pulse generator (Clarkson et al., 2017), 
were predominantly not GABAergic (<3% of VGAT positive cells). These findings 
demonstrate that ARN NPY neurons compose a significant proportion of the ARN 
GABA neurons that are known to be altered by androgen excess, however prenatal 
androgen exposure does not cause overt changes in the number of neurons expressing 
NPY within this region. 
To examine this distinct NPYergic subpopulation, the next study validated the 
use of AgRP-Cre mice for specific genetic targeting of ARN NPY neurons, examining 
reporter specificity and efficacy. Fibre mapping and retrograde tracing was used to 
establish the axon projection pathways of ARN NPY neurons throughout the entire brain, 
and determine what proportion of ARN NPY neurons project to the region of GnRH 
neurons, respectively (Chapter 4). It was found that coupling Cre-dependent tGFP 
reporter expression in AgRP-Cre mice generated a reporter that was both highly specific 
and efficient for identification of ARN NPY neurons (Coutinho et al., 2019). tGFP 
association with axons (Callahan and Thomas, 1994) enabled identification of over 140 
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distinct nuclei or areas that ARN NPY neurons extend their axonal projections. This 
elucidated a projection distribution that was consistent with areas of innervation 
described by established literature (Betley et al., 2013), while also revealing dense 
projections to known GnRH neuron regulatory regions such as the AVPV and intra-ARN 
projections. Using fluorescent RetroBeads injected into the rPOA to trace which ARN 
NPY neurons extend projections toward GnRH neurons, it was ascertained these neurons 
compose a small subset of cells that are scattered across the ARN, and are not an 
anatomically defined subpopulation. 
Having established AgRP-Cre mice as an appropriate model to study ARN NPY 
neurons specifically, these mice were used to address the hypothesis that prenatal 
androgen exposure leads to remodelling of this population with respect to their sensitivity 
to circulating steroid hormones, and innervation of GnRH neurons (Chapter 5). Unlike 
the broader ARN GABA neuron population, ARN NPY neurons completely lacked 
immunoreactive evidence of classical estrogen and progesterone receptors. Interestingly, 
however, ARN NPY neurons were immunoreactive for AR and a greater proportion 
expressed this receptor in PNA-treated mice. This indicates greater androgen sensitivity 
in mice that are hyperandrogenic. In contrast, absolute numbers of AR immunoreactive 
cells in the ARN were unchanged in PNA-treated mice in the present study as well as 
previous work (Moore et al., 2015), indicating possible reorganization of AR expression 
within subsets of ARN neurons following early androgen exposure.  
When I examined the close appositions that ARN NPY axons formed with GnRH 
neurons, an indication of putative innervation, it was revealed that there were no 
differences in these appositions made with GnRH neurons in PNA-treated mice. Overall, 
the results presented in this study (Chapter 5) suggest that ARN NPY neurons compose 
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a distinct subset of ARN GABA neurons that are not remodelled like the broader ARN 
GABA population (Moore et al., 2015; Silva et al., 2018), but instead undergo their own 
separate alterations in PNA mice in the form of elevated androgen sensitivity 
(summarised in Figure 8.1 and Table 8.1). 
The following chapter describes experiments examining the possible role that 
circulating leptin, and ARN NPY cellular response to leptin, may be playing in 
generating infertility in PNA-treated mice (Chapter 6). When plasma leptin was 
examined in fed and fasted states in PNA-treated mice using an ELISA, there was no 
difference in plasma levels compared with fertile controls. Interestingly, PNA-treated 
mice exhibited a reduction in plasma leptin in the fasted state, contrasting previous work 
describing persistently elevated leptin even when fasted in the PNA mouse (Roland et 
al., 2010). These data do not support the hypothesis that fasted hyperleptinaemia leads to 
suppressed ARN NPY activity in PNA-treated mice. Confirming this, ARN NPY 
neurons exhibited no alterations to their leptin responsiveness indicated by induction of 
pSTAT3 within PNA-treated mice administered exogenous leptin. The results presented 
within this chapter indicate that leptin signalling in the ARN is normal in PNA-treated 
mice, and leptin acting within this region is not likely to contribute to altered GnRH 
neuron activity or LH hypersecretion. 
Although no anatomical remodelling of the ARN NPY-to-GnRH neuron circuit 
was identified, this did not rule out other differences in neurotransmitter or receptor 
expression. This was explored at the transcript level, assessing differences in expression 
of NPY and its receptor as well as a broader range of signalling molecules and receptors 
with important roles in GnRH neuron regulation (Chapter 7). Using a highly sensitive 
NanoString assay for single molecule counting of mRNA, genes encoding for peripheral 
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hormone receptors, neurotransmitters, neurotransmitter receptors, and cytokines were 
assessed. These genes, measured in the rPOA, RP3V and ARN, were largely unchanged 
in PNA-treated mice; notably, progesterone receptor expression was unchanged in the 
ARN in contrast with the finding that fewer cells express PR in this region (Moore et al., 
2015). NPY Y1R gene expression was downregulated in the RP3V of PNA-treated mice; 
this region is where LH surge modulating kisspeptin neurons reside (Clarkson and 
Herbison, 2006b), a population that ARN NPY neurons are known to form functional 
circuitry with (Padilla et al., 2017). This loss of Y1R expressing in the RP3V may reflect 
an alteration to a bisynaptic ARN NPY to GnRH neuron circuit, relayed via kisspeptin 
neurons (outlined in Figure 8.1). Additionally, a sizable reduction in leptin receptor gene 
expression was observed in the rPOA, which may reflect a loss in leptin responsive nNOS 
neurons that reside in the immediate vicinity to GnRH neurons, exerting excitatory 
influence via gaseous transmission (Figure 8.1) (Bellefontaine et al., 2014). 
The following discussion will aim to contextualise the findings presented in this 
thesis within the broader pathophysiology of PCOS, as well as outline future directions 
to elucidate the possible role of ARN NPY neurons in this disorder. 
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Figure 8.1. Summary of GnRH regulatory signal remodelling in the PNA-treated mouse. (Top) The 
GnRH neurons (red) that govern fertility are modulated by a number of afferent neural populations 
throughout the hypothalamus. The ARN of the hypothalamus is a key region in which hormonal cues from 
the periphery are sensed and relayed to the GnRH neurons by such afferent populations. The ARN GABA 
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circuitry to the proximal regions of the GnRH neurons to modulate their activity. ARN NPY neurons also 
extend projections to other GnRH regulatory regions such as the RP3V, where the NPY Y1R is expressed, 
and kisspeptin neurons (orange) reside (Padilla et al., 2017); this suggests a bisynaptic circuit between 
ARN NPY neurons and GnRH neurons acting via kisspeptin neurons. Additionally, NPY inhibits 
GABAergic output presynaptically via Y1R (Sullivan and Moenter, 2004a). In normal, fertile mice, the 
broad ARN GABAergic population is highly sensitive to progesterone through its nuclear receptor (yellow 
nuclei), suggesting this population is important for progesterone mediated negative feedback. ARN NPY 
neurons to not express PR, however, a subset of them are sensitive to androgens, acting via the androgen 
receptor (red nuclei). Additionally, NPY neurons are highly sensitive to leptin, a metabolic cue that is a 
permissive signal in maintaining fertility. Leptin sensitive neurons in the rPOA (grey), the immediate 
vicinity to GnRH neurons, also may play a regulatory role via excitatory neurotransmitters and gaseous 
transmitters. This complex interplay of signals ultimately generates regular pulses of GnRH and LH that 
act to generate fertility. (Bottom) In the PNA-treated mouse that models PCOS, a number of alterations 
are generated that are associated with infertility. There is a loss of PR in the ARN, including within the 
ARN GABA neurons, which also extend a greater number of projections to the GnRH neurons. The ARN 
NPY neuron projections to GnRH neurons do not undergo the same remodelling, however a greater 
proportion of them express the androgen receptor. In this model, their receptivity to leptin is also 
unchanged. Outside of the ARN, on the transcription level, there is a reduction in Y1R in the RP3V, 
suggesting possible impairment of the NPY to kisspeptin to GnRH neuron bisynaptic circuit. Within the 
rPOA, where leptin sensitive regulatory neurons reside, there is a robust reduction in leptin receptor 
expression at the transcription level. These alterations may disrupt the balance of neural signalling and 
peripheral feedback leading to elevated GnRH neural activity and observed elevations in LH pulse 
frequency, thus leading to infertility in these mice with PCOS features. AR, androgen receptor; ARN, 
arcuate nucleus; GABA, g-Aminobutyric acid; GABAAR, GABAA receptor; GnRH, gonadotropin-
releasing hormone; LepR, leptin receptor; LH, luteinising hormone; nNOS, neural nitric acid synthase; 
NPY, neuropeptide Y; PNA, prenatal androgen exposure; PR, progesterone receptor; RP3V, rostral 
periventricular area of the 3rd ventricle; rPOA, rostral preoptic area; Y1R, NPY Y1 receptor. 
Table 8.1. Comparison of ARN GABA and ARN NPY alterations in PNA-treated mice. 
Alteration GABA neurons NPY neurons 
Rewiring to GnRH neurons ­1 « 
PR ¯1 Not detected 
AR ? ­ 
LepR ? « 
Cognate receptor expression «
2 
(GABAA on GnRH neurons) 
¯ 
(Y1R in RP3V) 
1(Moore et al., 2015), 2(Sullivan and Moenter, 2004b) 
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8.2 Implications of findings 
8.2.1 The remodelling of ARN GABA circuits is not stereotyped following prenatal 
androgen exposure 
A major finding established here is that the NPY expressing subset of neurons is 
not remodelled to the same degree as that of the broader ARN GABA neuron population 
in PNA-treated mice. Our current working hypothesis is that prenatal androgens alter the 
developmental course of hypothalamic circuits that potentially lead to the development 
of PCOS (Moore and Campbell, 2017; Ruddenklau and Campbell, 2019), including 
alterations seen specifically in the rewiring of ARN GABA neurons onto GnRH neurons 
(Moore et al., 2015). This is supported by evidence that androgen receptor blockade over 
the peripubertal period in mice reverses the increase in GABAergic synapses that contact 
GnRH neurons (Silva et al., 2018). It is unclear at the present stage whether androgens 
act directly onto AR expressing GABA neurons to establish this rewiring, however 
projects being conducted presently within our lab are working to assess this. Considering 
the possibility, however, that neurons expressing AR may be rewired following PNA-
treatment, it is curious that ARN NPY neurons were found to be androgen sensitive but 
not overtly rewired to GnRH neurons in the present study.  
One possible explanation for this lack of rewiring is that, in the mouse, ARN NPY 
neurons are not sensitive to androgens during the time point at which DHT treatment is 
administered (E16-18). The ontogeny of AR expression in the brain may support this; in 
male mice, AR mRNA in the hypothalamus is highest at E15 and declines from E16 to 
E18 (Young and Chang, 1998). In the ARN of female mice, AR expression is low in the 
early postnatal period, assessed at postnatal day 5, then increases over postnatal 
development until adulthood (Brock et al., 2015), however this has not been assessed in 
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the late prenatal period. There is also evidence that ARN NPY neuron circuit organisation 
is highly regulated by a postnatal leptin surge that occurs at postnatal day 10 (Abegg et 
al., 2017; Ahima et al., 1998), well after the DHT exposure window in the PNA-treated 
mouse, and that this extends NPY projections toward areas governing fertility (Caron et 
al., 2012). It is possible that ARN NPY neurons are more protected from the deleterious 
effects of embryonic androgen excess as their wiring organisation is established later. 
This may explain findings in the ewe, where prenatal T treatment induces significant 
increases in ARN NPY projections to various hypothalamic nuclei, but AR-specific DHT 
treatment does not, suggesting an ER mediated mechanism rather than AR (Sheppard et 
al., 2011). This may also explain key differences in the PNA-treated mouse and mice that 
are treated with DHT postnatally. PNA-treated mice do not exhibit increased body mass 
or body fat percentage (Roland et al., 2010), but postnatal treatment induces increased 
adiposity that is dependent on the expression of neural AR (Caldwell et al., 2014; 
Caldwell et al., 2017). This possible mechanism highlights that defining the ontogeny of 
AR in ARN NPY neurons may elucidate how androgen excess generates different 
phenotypes when given at different developmental time points. 
8.2.2 The ARN GABA neurons that undergo remodelling in PNA-treated mice have 
not yet been identified 
One of the key findings described in this thesis is that close appositions made by 
ARN NPY neurons on GnRH neurons are not altered by PNA-treatment, and that these 
neurons do not express PR (Chapter 5). An implication of this is that we have not yet 
identified the population or populations of ARN GABA neurons that undergo 
remodelling in PNA-treated mice; therefore, the question of what the identity of these 
GABA neurons are still remains. The results described in Chapter 3 also identified a 
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high degree of co-expression of both TH and nNOS with VGAT, implicating 50-60% of 
these populations as being GABAergic. Immunoreactivity for TH was used primarily to 
identify TIDA neurons that reside in the ARN, as dopamine is a well-established inhibitor 
of GnRH neurons in mice (Liu and Herbison, 2013a). Recent unpublished work within 
the Campbell laboratory, however, suggests that TIDA neurons are not likely to be the 
GABA neurons that are remodelled in PNA-treated mice. Viral-vector mediated tracing 
of the projections from TIDA neurons to GnRH neurons was conducted in dopamine 
transporter (DAT)-Cre mice. Interestingly, these neurons did not appear to form close 
appositions with GnRH neuron cell bodies or proximal dendrites, the site where 
remodelling of GABAergic innervation occurs (Moore et al., 2015; Sullivan and 
Moenter, 2004b). Similarly, nNOS neurons project to the distal dendrite of GnRH 
neurons (Chachlaki et al., 2017), thus are also unlikely to represent the remodelled 
GABAergic population. 
Another important consideration is that the identification of GABAergic 
subpopulations outlined in Chapter 3 defined, at most, 60% of the ARN GABA neurons. 
It therefore remains likely that remodelling occurs in one or more currently undefined 
populations composing the remaining 40%. A compelling candidate population that may 
be among this 40% are neurons that express the neuropeptide galanin. Within the ARN 
in rats, galanin has been reported to co-express with GAD, and to a lesser extent, TH 
(Melander et al., 1986), indicating they are GABAergic. Additionally, there is anatomical 
evidence in mice that galanin immunoreactive terminals form close appositions with 
GnRH neuron cell bodies, and these co-localise with synaptophysin indicating they are 
likely to be forming synapses (Rajendren, 2002). Furthermore, galanin can directly act 
upon GnRH neurons causing depolarisation and increasing firing rate when applied to 
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the soma in female mice (Todman et al., 2005). It is not yet clear whether galanin neurons 
specifically in the ARN innervate GnRH neurons at these proximal regions, however. 
Interestingly, there is even evidence in women with PCOS that plasma galanin is elevated 
(Baranowska et al., 1999a). Further investigation into subpopulations of ARN GABA 
neurons in PNA-treated mice may wish to assess signs of remodelling within ARN 
galanin neurons using similar techniques to those described in this thesis. 
8.2.3 Further insight into the possible mechanism of androgen blockade of 
progesterone negative feedback 
A key finding presented in this thesis is that a greater proportion of ARN NPY 
neurons express AR in PNA-treated mice (Chapter 5), which may provide insight into 
the mechanism of androgen blockade of progesterone feedback. It is well established that 
negative feedback impairment is a feature in women with PCOS (Daniels and Berga, 
1997; Pastor et al., 1998), and that long-term treatment with anti-androgenic drugs 
restores progesterone (P4) negative feedback in these women (Eagleson et al., 2000). The 
PNA-treated mouse utilised in the present thesis also exhibits a loss of P4 negative 
feedback and an associated loss of PR expression in the ARN, including specifically in 
GABA neurons (Moore et al., 2015). Electrophysiological work supports this further, as 
DHT elicits an elevation in GnRH neuron activity both in the presence and absence of 
P4, while P4 alone slows GnRH neuron firing rate (Pielecka et al., 2006). Additionally, 
P4 and DHT appear to counteract one another in their influence on GABAergic PCSs 
onto GnRH neurons (Sullivan and Moenter, 2005). Together this implicates GABA 
neurons in the ARN as a potential locus for where androgen disruption of P4 signalling 
is occurring, however the specific mechanism for how this occurs is still subject to 
debate. 
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One mechanism that has been proposed is by genomic interference of 
transcription of the Pgr gene encoding for PR by androgen-mediated actions 
(Ruddenklau and Campbell, 2019) (depicted in Figure 8.2). This is supported by 
measurements of hypothalamic PR mRNA in rats (Foecking and Levine, 2005), where 
estradiol priming induces increased PR expression in untreated rats but not in rats that 
were given implants to maintain supraphysiological levels of T. Additionally, in vitro 
work in the gonadotroph demonstrates that DHT suppresses the ability of P4 to induce 
LH secretion, which the authors attribute in part to direct suppression of PR (Turgeon 
and Waring, 1999). Furthermore, in human breast cancer cell lines, androgens also 
appear to supress PR expression (Liberato et al., 1993) and induction of PR by estradiol 
(MacIndoe and Etre, 1981). It should be noted, however, that similar work has not been 
conducted in neuron cell lines. Results presented here, however, suggest that Pgr mRNA 
expression in the PNA-treated mouse is not suppressed in tissue punches from the rPOA, 
RP3V or the ARN (Chapter 7). This is in contrast to reduced PR protein expression 
found in the ARN here (Chapter 5) and in past work (Moore et al., 2015). This raises an 
interesting possibility that PR, or PR expressing neurons, are suppressed by presently 
unidentified non-genomic actions leading to a loss of P4 mediated feedback. 
Despite not undergoing significant remodelling, a greater proportion of ARN 
NPY neurons were found to be immunoreactive for AR in the PNA-treated mouse. The 
implications of this are presently not known, however it raises an interesting possibility 
that androgens may act via a transsynaptic pathway relayed by NPY neurons to modulate 
the response to P4 in PR expressing neurons via intra-ARN circuitry (Figure 8.2). One 
way in which this could occur is by altered neural modulation of PR expressing cells. 
ARN NPY neurons, for example, are can inhibit ARN kisspeptin neurons via GABAergic 
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transmission (Padilla et al., 2017). Alterations to the ARN signalling milieu in this way 
could lead to inappropriate activity of PR sensitive cells in the presence of androgens and 
P4.  
Another interesting possibility is by altering non genomic post-translational 
modification of PRs in target neurons. PRs are regulated by a number of modifications 
via second-messengers such as phosphorylation, that are thought to influence nuclear 
trafficking of PR and receptor turnover (Daniel et al., 2009; Mani and Portillo, 2010). 
Furthermore, neurotransmitter mediated modulation of PR activity is not unheard of, as 
dopamine or agonists of the D1 receptor have been reported to influence post-
translational modification of PR [outlined in (Mani and Portillo, 2010)]. It may therefore 
be possible that neuropeptides such as NPY or AgRP influence second messenger 
pathways in PR expressing neurons to suppress their response to P4. In order to speculate 
of this further, the role of androgens acting in ARN NPY neurons needs to be elucidated 
further, both in the context of fertile mice and in the PNA-treated mouse.  
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Figure 8.2. Possible mechanisms of androgen blockade of progesterone signalling in the ARN of 
PNA-treated mice. Elevated androgens in PCOS and the PNA-treated mouse have an established role in 
disrupting progesterone mediated negative feedback, however the precise mechanism has yet to be 
elucidated. It is possible that within GABA neurons, and other PR expressing populations such as 
kisspeptin neurons, androgen signalling via AR acts to suppress transcription of the PR gene, leading to a 
loss of the receptor in these cells (Ruddenklau and Campbell, 2019). As a greater proportion of ARN NPY 
neurons express AR in PNA-treated mice, it is also possible that androgens modulate the activity of 
progesterone responsive neurons via a transsynaptic pathway relayed through ARN NPY neurons. AR, 
androgen receptor; ARN, arcuate nucleus; GABA, g-Aminobutyric acid; GnRH, gonadotropin-releasing 
hormone; LH, luteinising hormone; NPY, neuropeptide Y; PR, progesterone receptor; rPOA, rostral 
preoptic area. 
8.3 Future directions  
8.3.1 Assessment of androgen actions in ARN NPY neurons and blockade in PNA-
treated mice 
A common strategy for managing PCOS features in women is by use of a range 
of pharmacological anti-androgenic compounds. The most widely used, flutamide, is a 
competitive AR antagonist that improves menstrual cycle regularity and LH 
hypersecretion (De Leo et al., 1998; Paradisi et al., 2013), alleviates distressing features 
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improves blood lipid profiles irrespective of adiposity (Diamanti-Kandarakis et al., 
1998). While on the surface flutamide appears to improve PCOS features, there is some 
argument that hyperandrogenism, once it arises, leads to intrinsic defects in ovarian 
follicular health and viability that persists even when removed from the hyperandrogenic 
environment (Bertoldo et al., 2019). Additionally, flutamide and other anti-androgens 
have a number of well documented side effects including hepatotoxicity and disruption 
to sexual development in male foetuses [full range of side effects outlined in (Conway et 
al., 2014)], making them unsuitable for long term use and dangerous for attempting to 
improve pregnancy outcomes in PCOS. Thus, it is clear that for anti-androgens to be an 
effective treatment avenue in PCOS, more targeted approaches need to be defined and 
studied. 
I have identified that androgen signalling within the ARN NPY neural population 
is potentially altered in PNA-treated mice, where a greater proportion of this population 
expresses AR compared to fertile controls. Others have demonstrated that, in a mouse 
model of PCOS with metabolic and reproductive features, neural knockout of AR leads 
to protection from the metabolic phenotype as well as improvements to their fertility 
(Caldwell et al., 2017). This role of neural AR in generating a metabolic phenotype under 
this paradigm strongly implicates the ARN NPY neural population in having a role in the 
androgen-mediated pathophysiology in this mouse. It is unclear, however, what effect 
androgens have on ARN NPY neurons, and whether acute vs. chronic androgen exposure 
modulates ARN NPY neurons differently. Assessment of the acute effect of androgens 
on ARN NPY neural activity could be determined by administering an exogenous bolus 
of DHT followed by immunodetection of cFos in VEH and PNA-treated mice to assess 
whether androgens lead to greater neural activation in this population (Hoffman et al., 
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1993). Assessment of up- or down-regulation of the Npy gene could also be assessed 
following acute DHT treatment. One way in which this could be achieved is by 
fluorescence-activated cell sorting of ARN samples from AgRP-tGFP mice and 
subsequent single cell qPCR in NPY neurons specifically.  
Ultimately, genetic strategies would need to be employed in order to block AR 
activity within the ARN NPY neural population in order to assess the chronic role 
androgens acting upon these neurons in fertility, and the possible involvement in PNA-
treated mice. The simplest approach is to generate AR knockout within ARN NPY 
neurons by breeding existing AgRP-Cre mice (Tong et al., 2008) with an AR-floxed 
transgenic line (De Gendt and Verhoeven, 2012) to assess whether these mice are 
protected from a PCOS-like phenotype following PNA exposure, or chronic postnatal 
DHT exposure (Caldwell et al., 2017). However, to address the ongoing effects of 
hyperandrogenism upon this population an acute knockout would need to be generated. 
One way in which this could be achieved is by crossing AgRP-Cre mice with (Tong et 
al., 2008) a floxed Cas9 mouse line (Chen et al., 2017), followed by viral delivery of 
guide RNAs in adulthood. In this way, guide RNAs could knock out AR, or alternatively 
inactivate it by introducing ‘junk’ sequences into crucial sites encoding for androgen or 
DNA binding upon the receptor. If acute AR inactivation in ARN NPY neurons in 
adulthood improved fertility, this approach could be extended further to determine at 
which point during postnatal development aberrant AR signalling leads to infertility. 
8.3.2 Mapping of circuit changes within the wider GnRH neuronal network in 
PNA-treated mice 
While this thesis does not support that there are anatomical changes to the direct 
input of ARN NPY neurons to GnRH neurons, there remains the possibility that 
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projections to GnRH neural afferents in other regions of the brain may be altered in the 
PNA-treated mouse. Mapping of axon projections throughout the brain using Cre-
dependent tGFP reporter revealed projections extensively throughout hypothalamic and 
extra-hypothalamic regions, some of which contain known GnRH afferent neural 
populations (Chapter 4). Moreover, assessment of gene expression in the RP3V, 
containing GnRH afferent kisspeptin neurons (Clarkson and Herbison, 2006b; Smith et 
al., 2005a; Smith et al., 2005b), revealed a reduction in expression of the Y1 NPY receptor 
(Chapter 7), suggesting alterations to the circuit in this region. Anatomical evidence 
from the T treated ewe model of PCOS demonstrates that projection density from ARN 
NPY neurons to several regions of the hypothalamus is greater (Sheppard et al., 2011), 
demonstrating circuits generated by this population are susceptible to remodelling, 
however only a relatively narrow number of regions has been examined to date. As 
activation of ARN NPY neurons slows LH secretion (Coutinho et al., 2019) it is possible 
that remodelling of NPY neuron inhibitory inputs to kisspeptin neurons are a potential 
source of LH hypersecretion in PNA-treated mice (Figure 8.3).  
The use of the AgRP-Cre and tGFP reporter cross used in the present study (Tong 
et al., 2008; Wen et al., 2011b) would provide a useful launching point, as this 
specifically targets reporter expression to the axon allowing robust resolution of fibre 
projections. The present study has already utilised this in order to define regions that 
receive a large amount of projections from the ARN NPY neurons; with these regions 
defined it would be possible to quantify and compare the density of projections within 
each of these regions in order to assess whether this is altered in PNA-treated mice. The 
RP3V is a particular area of interest, and within this region kisspeptin immunoreactivity 
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could be used to assess whether putative innervation to this population specifically is 
altered, using a similar technique to that used in Chapter 5.  
	
Figure 8.3. Possible rewiring of ARN NPY neural inputs to kisspeptin neurons may increase GnRH 
neuron activity in PNA-treated mice. In fertile mice, ARN NPY neurons provide inhibitory drive to 
kisspeptin neurons (Padilla et al., 2017), which are the putative GnRH neuron pulse generator (Clarkson 
et al., 2017). In PNA-treated mice, remodelling of inhibitory input from ARN NPY neurons to kisspeptin 
neurons may contribute to more rapid GnRH/LH pulses.  
While using projection density would provide insight into potential regions of 
interest, one drawback of this approach would be that it would not be possible to 
distinguish between where regions are being innervated and simply containing fibres of 
passage. A way in which this could be refined within region of interest would be by use 
of a genetically targeted synaptic marker. Subcellular labelling of synaptic terminals can 
be achieved by expression of reporter tagged synaptophysin within populations of 
interest (Groh et al., 2008; Wimmer et al., 2004), and may be delivered virally within a 
Cre-dependent transgene (Carter et al., 2013). Delivery of a Cre-dependent pAAV-
synaptophysin-EGFP into the ARN of AgRP-Cre mice would allow further assessment 
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provide insight into how ARN NPY neuron input to other GnRH neural afferents is 
altered. 
8.3.3 Assessing the role of ARN NPY neurons on fertility in female mice using 
chronic inhibition 
As discussed in several sections throughout this thesis, ARN NPY neurons have 
a known but as yet poorly defined role in regulating fertility. Recent functional work 
within our lab has demonstrated that optogenetic or chemogenetic stimulation of ARN 
NPY neurons may suppress GnRH/LH secretion in vivo (Coutinho et al., 2019), however 
the downstream effects on fertility generated by this circuit has yet to be addressed. One 
way in which the importance of ARN NPY signalling to GnRH neurons may be assessed 
is by inhibition of this circuit. NPY knockout mice utilised in the past have not been 
particularly revealing as multiple redundant circuits influencing fertility may alter in 
compensatory mechanisms over development, and only subtle effects of fertility have 
been observed this way (Xu et al., 2000a). There is evidence that developmental 
compensation for loss of ARN NPY neurons is robust, as ablation of this population in 
adult mice leads to starvation, whereas ablation in neonates has little effect on feeding 
behaviour (Luquet et al., 2005).  
Acute methods of ARN NPY neural ablation or signal inhibition have been 
successfully utilised in many studies investigating feeding behaviour (Carter et al., 2013; 
Luquet et al., 2005; Padilla et al., 2016; Tan et al., 2014), however to date the 
reproductive consequences of such experiments have gone unexamined. As total ablation 
of the ARN NPY neurons causes starvation, this raises ethical and logistical concerns 
that make it unsuited for a long-term investigation on fertility. One way in which this 
may be achieved in a more targeted manner is by use of a Cre-dependent viral delivery 
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of tetanus toxin which inhibits neurotransmission in Cre-expressing neurons (Heimer-
McGinn et al., 2013) and has previously been successfully targeted to terminals to inhibit 
a subset of AgRP neurons projecting to particular regions of interest (Padilla et al., 2016). 
The scattered distribution of GnRH neurons and therefore the terminals innervating them, 
however, may make total ablation of GnRH neural afferent ARN NPY neurons difficult 
using this approach, however work within this thesis has demonstrated that targeting 
rPOA-projecting ARN NPY neurons is achievable (Chapter 4).  
Another possible avenue for assessing the role of ARN NPY neurons in fertility 
may be to apply a chronic chemogenetic approach. Recent work with our lab has 
developed a protocol for chronic excitation of ARN GABA neurons using the excitatory 
DREADD hM3Dq in concert with CNO delivered via drinking water over a course of 
two weeks (Coutinho et al., 2019; Silva et al., 2019). Using this protocol, it was 
demonstrated that chronic activation of this population that provides excitatory input to 
GnRH neurons elicits a phenotype that is similar to PNA model mice, lending support to 
the hypothesis that over-excitation of GnRH neurons leads to PCOS features. As ARN 
NPY neurons most likely contribute to overall GnRH neural inhibition (Roa and 
Herbison, 2012), a chronic inhibition via the inhibitory DREADD hM4Di (Armbruster 
et al., 2007), using a similar CNO delivery protocol may reveal a similar phenotype. 
Within these mice the direct effect on GnRH output may be examined by measuring LH 
secretion in serially collected blood samples, as well as downstream effects on fertility 
by assessing ovarian morphology, estrus cycle regularity, proestrus frequency, and 
circulating androgens. 
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8.4 Clinical relevance of ARN NPY circuitry in PCOS 
While ARN NPY neurons are not extensively remodelled in the model of lean 
PCOS utilised in the present thesis, this circuit remains physiologically relevant in 
women with PCOS. Obesity and metabolic syndrome are the most common co-
morbidities that are associated with PCOS (Ladron de Guevara et al., 2014; Pikee et al., 
2016), indicating dysregulation of hypothalamic circuits involved with feeding 
behaviour. ARN NPY neurons are principle drivers of appetite (Parker and Bloom, 
2012), and most likely play a role in relaying metabolic status to GnRH neurons. 
Evidence in rodent models suggests that NPY neurons have a role in suppressing LH 
secretion and GnRH neuron activity (Raposinho et al., 1999; Roa and Herbison, 2012; 
Xu et al., 2009), as well as inhibiting activity of excitatory afferents to GnRH neurons 
(Padilla et al., 2017). Recent evidence within our lab has established that optogenetic and 
chemogenetic activation of ARN NPY neurons slows LH secretion, suggesting 
suppression of GnRH neurons (Coutinho et al., 2019). Taken together this body of 
evidence implicates ARN NPY neurons as applying a physiological break to LH 
secretion in times of negative energy balance; or in the case of obesity and leptin 
resistance where this circuit becomes maladaptive and ARN NPY neurons are over 
activated.  
An interesting phenomenon that occurs in women with PCOS is that they appear 
to have reduced NPY secretion, indicated by reduced plasma NPY compared with 
weight-matched controls (Romualdi et al., 2008). This could be taken as a ‘lifting’ of this 
physiological break, which would be consistent with the elevated LH secretion frequently 
present in PCOS (Balen et al., 1995; Franks, 1989). Calorie restriction is a potent up-
regulator of ARN NPY expression (Hahn et al., 1998), and is also known to enhance the 
	 	 CHAPTER EIGHT 
 210 
negative feedback exerted by ovarian steroid hormones to slow LH secretion in rodents 
(Nagatani et al., 1994; Spillar and Piacsek, 1991). Weight loss, frequently achieved by 
calorie restriction, is also known to improve cycle frequency and lower circulating 
androgens in women with PCOS (Crosignani et al., 2003; Kiddy et al., 1992), however 
it is not clear whether this occurs by central or peripheral mechanisms. The precise role 
of ARN NPY neurons as a physiological break on LH secretion will be important to 
elucidate, especially in the context of PCOS. If ARN NPY neurons can be stimulated by 
calorie restriction or therapeutically, this may help to improve outcomes in women with 
PCOS undergoing treatments to alleviate their disorder, particularly with anti-androgens. 
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8.5 Concluding remarks  
Within this thesis I have presented a thorough anatomical and molecular 
interrogation of ARN NPY circuitry in PNA-treated mice that model PCOS. The data 
presented do not support the hypothesis that ARN NPY neurons are the subset of ARN 
GABA neurons previously identified within our lab as undergoing extensive remodelling 
following prenatal exposure to androgens, however other subtle alterations were 
uncovered. While ARN NPY neurons lack receptors for ovarian steroid hormones 
classically involved with negative feedback, an increase in the androgen receptor 
expression within this population was found. As androgens are involved with disruption 
of negative feedback in PCOS, this potentially opens up an avenue for future research to 
elucidate the possible role of androgens acting via ARN NPY neurons in this 
phenomenon. Direct changes to circuitry between ARN NPY neurons and GnRH neurons 
were not found, however gene expression in the RP3V revealed a possible disruption to 
NPY signalling in this area that contains important GnRH neuron afferents. When 
possible dysregulation of metabolic cue signalling was examined by assessing leptin 
responsiveness, this was not found to be changed in the PNA-treated mouse. The results 
presented herein expand upon our body of knowledge about the potential role of ARN 
GABAergic circuitry in PCOS, while presenting a new avenue of research into androgen 
mediated disruption of negative feedback in this disorder. 
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Antigen Species Dilution  Manufacturer Specificity 




(Bingham et al., 
2006) 




(Clifton et al., 1998) 




et al., 2013) 
GFP Chicken (polyclonal) 1:5000 AVES 
Immunoreactivity 
absent in wild-type 
mice (Roberts et al., 
2014) 
GFP Rabbit (polyclonal) 1:10,000 Molecular Probes 
Immunoreactivity 
absent in wild-type 
mice (Rezaï et al., 
2012) 
GnRH Guinea pig (polyclonal) 1:5000 





(Rizwan et al., 2012) 
Kisspeptin Rabbit (polyclonal) 1:5000 







nNOS Sheep (polyclonal) 1:5000 











et al., 2009) 




(Quadros et al., 
2007; Waters et al., 
2008) 




detection of pSTAT3 
but did not detect 
dephosphorylated 
STAT3 (Scott et al., 
2009) 
TH Rabbit (polyclonal) 1:5000 Millipore 
Immunoblotting with 
purified TH (Lee et 
al., 1989) 
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rons co-localized with NPY, and nearly all NPY neurons 
(>95%) co-localized with VGaT across groups. Both TH and 
nNOS labeling was co-localized with  ∼ 10% of ARN GABA 
neurons. The proportion of TH neurons co-localized with 
VGaT was significantly greater in males than either control 
or PNA females, and the proportion of nNOS neurons co-lo-
calizing VGaT was higher in control and PNA females com-
pared with males.  Conclusion: These data highlight NPY as 
a significant subpopulation of ARN GABA neurons, demon-
strate no significant impact of PNA on signal co-expression, 
and, for the first time, show sexually dimorphic co-expres-
sion patterns of TH and nNOS with ARN GABA neurons. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 The hypothalamic arcuate nucleus (ARN) is a critical 
integration point for the translation of peripheral hor-
mone cues into neuronal signaling pathways in the mam-
malian brain. This long, ventrally located nucleus resides 
immediately dorsal to the median eminence and along 
either side of the third ventricle in the medial basal hypo-
thalamus. Multiple neuronal phenotypes, typically de-
fined by classical or neuropeptidergic signaling mole-
cules, are located in the ARN and project widely through-
 Keywords 
 Hypothalamus · Polycystic ovary syndrome · Neuropeptide 
Y · Nitric oxide synthase · Tyrosine hydroxylase · Kisspeptin 
 Abstract 
 Background/Aims: Arcuate nucleus (ARN) γ-aminobutyric 
acid (GABA) neurons are implicated in many critical homeo-
static mechanisms, from food intake to fertility. To deter-
mine the functional relevance of ARN GABA neurons, it is 
essential to define the neurotransmitters co-expressed with 
and potentially co-released from ARN GABA neurons.  Meth-
ods: The present study investigated the expression of mark-
ers of specific signaling molecules by ARN GABA neurons in 
brain sections from male, female, and, in some cases, prena-
tally androgen-treated (PNA) female, vesicular GABA trans-
porter (VGaT)-ires-Cre/tdTomato reporter mice. Immuno-
fluorescence for kisspeptin, β-endorphin, neuropeptide Y 
(NPY), tyrosine hydroxylase (TH) and neuronal nitric oxide 
synthase (nNOS) was detected by confocal microscopy, and 
co-localization with tdTomato VGaT reporter expression 
throughout the ARN was quantified.  Results: GABA neurons 
rarely co-localized with kisspeptin (<2%) or β-endorphin 
(<1%), and only a small proportion of kisspeptin ( ∼ 10%) or 
β-endorphin ( ∼ 3%) neurons co-localized with VGaT in male 
and female mice. In contrast, one-third of ARN GABA neu-
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out the brain to regulate a variety of critical functions 
including, but not limited to, energy homeostasis, growth, 
reproduction, and lactation. One particular ARN popula-
tion of neurons that is frequently associated with the reg-
ulation of these homeostatic mechanisms is the γ-ami-
nobutyric acid (GABA) neurons. GABA neurons residing 
specifically within the ARN are strongly linked with the 
regulation of lactation  [1, 2] , feeding behavior  [3, 4] , and 
in the direct regulation of fertility  [5–7] .
 Fertility is dependent upon a complex neural network 
that ultimately drives the activity of the gonadotropin-
releasing hormone (GnRH) neurons and downstream pi-
tuitary-gonadal axis  [8] . Gonadal steroid hormone feed-
back to GnRH neurons is vital for the appropriate regula-
tion of reproductive function, and this occurs in large part 
through the complex of neurons afferent to GnRH neu-
rons  [9, 10] . The ARN is considered a central node in go-
nadal steroid hormone feedback, particularly the restraint 
of the GnRH axis, and direct, hormone-sensitive afferent 
inputs project from the ARN to GnRH neurons  [11] . Ear-
ly studies in the rat highlight the medial basal hypothala-
mus as a critical site of estrogen feedback signaling  [12, 
13] , and more recent studies in the mouse demonstrate 
that selective adult knockdown of estrogen receptor-α 
(ESR1) expression in the ARN disrupts chronic estrogen 
negative feedback  [14] . The specific neurochemical iden-
tity of the ARN neurons mediating steroid hormone feed-
back information to GnRH neurons has not been clearly 
defined; however, GABA signaling neurons in the ARN 
have been implicated  [15] .
 A role for ARN GABA neurons in mediating feedback 
signals to GnRH neurons has emerged from investigating 
a condition characterized by impaired steroid hormone 
negative feedback, the common endocrine disorder poly-
cystic ovary syndrome (PCOS)  [16–19] . Increased GABA 
activation of GnRH neurons  [20] and increased GABA 
innervation to GnRH neurons  [15] have been identified 
in a prenataly androgenized (PNA) mouse model of 
PCOS that exhibits impaired negative feedback of the 
GnRH axis  [15, 21] . Dense GABA projections to GnRH 
neurons, originating specifically from the ARN, are sig-
nificantly elevated in PNA mice  [15] . This population of 
ARN neurons is steroid hormone sensitive, but loses ste-
roid hormone responsiveness in the PCOS-like condition 
 [15] . These observations suggest that altered ARN GABA 
neuron activity could contribute to the neuroendocrine 
dysfunction of PCOS, and that ARN GABA neurons may 
play an important role in regulating normal fertility. 
 Virtually all GABA neurons in the brain express and 
release neuropeptides or other neurotransmitters in ad-
dition to GABA that may be involved in downstream sig-
naling. For example, increased ARN GABA innervation 
to GnRH neurons in the PCOS model may be reflective 
of increased GABA signaling, or increased signaling from 
neurotransmitters co-released from GABA neurons. To 
definitively assess the functional importance of ARN 
GABA neurons in the regulation of fertility and other 
critical homeostatic mechanisms, it is important to have 
a better understanding of potentially co-released neu-
rotransmitters.
 Although co-expression with GABA has been report-
ed for some selected populations of ARN neurons  [22, 
23] , there is currently very little assessment of the neuro-
peptides and neurotransmitters co-expressed in the ARN 
GABA neuron population as a whole. Historically, the 
identification of GABA neurons in the hypothalamus
has been challenging. While GAD (glutamate decarbox-
ylase)-65 or GAD-67 immunolabeling is achievable in
the cortex, hippocampus, and other extra-hypothalamic 
brain regions, the presumably low level of GAD present 
in hypothalamic GABA neurons has precluded our abil-
ity to confidently identify specific neurons for co-labeling 
studies. The development of a transgenic mouse line, tar-
geting Cre expression to neurons expressing the vesicular 
GABA transporter (VGaT)  [24] , has now made it possi -
ble to clearly visualize hypothalamic GABA neurons by 
crossing these mice with floxed reporter strains.
 Therefore, the aim of the current study was to define 
the neurotransmitter phenotypes of ARN GABA neu-
rons, with a focus on some of the signaling molecules 
known to emerge from the ARN and play a role in food 
intake, lactation, and/or the central regulation of fertility. 
Co-localization of markers for the following peptidergic, 
catecholaminergic, and gaseous neurotransmitters were 
assessed in male and female mice: kisspeptin, neuropep-
tide Y (NPY), dopamine, nitric oxide, pro-opiomelano-
cortin (POMC). Neurotransmitters with significant co-
localization in ARN GABA neurons were additionally 
quantified in PNA mice modeling PCOS to determine 
whether the co-expression of any of these neuronal sig-
nals is modified in a state of impaired steroid hormone 
feedback.
 Materials and Methods 
 Animals 
 In order to identify the majority of ARN GABA neurons, 
 VGaT-ires- Cre knock-in mice  [24] were crossed with Ai9 Cre-de-
pendent tdTomato reporter mice  [25] to generate VGaT-ires-Cre/
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tively in GABAergic neurons  [24] and the vast majority of GABA 
neurons express  VGaT  [26] . Adult (60–90 days) male and freely 
cycling adult female mice between 60 and 80 days old were housed 
under 12-h light cycles with food and water available ad libitum. 
All protocols used in this study were approved by the University 
of Otago Animal Ethics Committee. 
 Prenatal Androgen Treatment 
 Prenatal androgen (PNA) treatment to model PCOS was car-
ried out as previously described  [20, 21] . Briefly, homozygous male 
and female VGaT-ires-Cre/tdTomato mice were housed together, 
and female mice were frequently checked for vaginal plugs to time 
mating. On days 16–18 of pregnancy, dams were given daily s.c. 
injections of sesame oil (200 µL) either as a vehicle control (VEH 
control group) or containing 250 µg dihydrotestosterone (PNA 
group). PNA- and vehicle-treated female offspring were then stud-
ied in adulthood (60–90 days old).
 Intracerebroventricular Colchicine Injections and Tissue 
Collection 
 To investigate NPY, neuronal nitric oxide synthase (nNOS), 
and kisspeptin immunoreactivity, mice were treated with colchi-
cine prior to tissue collection to halt axonal transport and improve 
neuropeptide immunoreactivity in cell bodies. Male and freely cy-
cling female mice were anesthetized with isoflurane, delivered at
4 L/min initially to induce anesthesia and then maintained at 0.6 
L/min for the duration of surgery. Mice were secured in a stereo-
taxic frame (Stoelting), and a small hole was drilled in the skull 0.1 
mm posterior to Bregma and 0.7 mm lateral to the sagittal suture. 
A Hamilton needle containing 1 µL of colchicine (30 µg/µL in sa-
line) was lowered to a depth of 2.4 mm ventral to the skull surface. 
Colchicine was then immediately injected i.c.v. over 1 min, and the 
cannula was removed after a 5-min period. Animals were killed for 
tissue collection within 24 h.
 Mice treated with or without colchicine were overdosed with 
pentobarbital (3 mg/100 μL) and transcardially perfused with 4% 
paraformaldehyde. Untreated mice were collected on the day of 
diestrus, and all perfusions took place between 1: 00 and 4: 00 p.m. 
Fixed brains were dissected, postfixed for 1 h at room temperature 
and then transferred to 30% sucrose in Tris-buffered saline (TBS) 
overnight for cryopreservation. Brains were then cut using a freez-
ing microtome (Leica 2400, Leica Biosystems) into 3 sets of 30 µm-
thick coronal slices. 
 Single-Label Immunohistochemistry 
 Free-floating single-label immunohistochemistry (IHC) was 
performed on 1 in every 3 coronal slices containing the ARN 
(Bregma –1.22 to –2.80 mm). The following well-characterized 
primary antibodies (also detailed in  Table 1 ) were used to detect 
immunoreactivity (-ir) for the following neuropeptides or signal-
ing molecules: rabbit anti-kisspeptin (a kind gift from A. Caraty, 
1: 5,000  [27] ), anti-rabbit β-endorphin (ImmunoStar, 1: 5,000 
 [28] ), rabbit anti-NPY (Sigma-Aldrich, 1: 5,000  [29] ), rabbit anti-
tyrosine hydroxylase (anti-TH; to identify neurons capable of pro-
ducing dopamine, Millipore, 1: 5,000  [30] ), sheep anti-nNOS (to 
identify nitric oxide signaling neurons, a kind gift of P.C. Emson, 
1: 5,000  [31] ). All antibodies and sera were diluted in TBS contain-
ing 3% Triton X-100 and 0.25% bovine serum albumin. Between 
all incubations, three 10-min washes were performed in TBS. Brain 
slices were first incubated in either 5% normal goat serum (NGS, 
for NPY, kisspeptin, TH, and β-endorphin immunolabeling) or 
5% normal donkey serum (NDS; for nNOS immunolabeling) for 
30 min at room temperature. Following this, slices were incubated 
with one of the primary antibodies listed above and outlined in 
 Table 1 for 48 h at 4   °   C, along with either 2% NGS or 2% NDS. 
Where IHC was performed against NPY or kisspeptin, brain slices 
were incubated with a polyclonal goat anti-rabbit AlexaFluor488 
antibody (1: 200, Molecular Probes, Invitrogen) for 2 h at room 
temperature. Where IHC was performed against TH or β-endor-
phin, brain slices were first incubated with biotinylated goat anti-
rabbit IgG (1: 400, Vector Laboratories Inc.), followed immediate-
ly by incubation with streptavidin AlexaFluor488 (1: 400, Molecu-
lar Probes, Invitrogen), each for 2 h at room temperature. Where 
IHC was performed against nNOS, brain slices were first incubat-
 Table 1.  Primary antibodies used in immunohistochemistry
Antigen Immunogen Source, host species, cat. No., clone or lot No., RRID Concentration
NPY Synthetic porcine NPY conjugated to 
keyhole limpet hemocyanin
Sigma-Aldrich, rabbit polyclonal, cat. No. N9528, 
RRID:AB_260814
1:5,000 dilution
Kisspeptin YNWNSFGLRY-NH2 coupled to bovine 
serum albumin with glutaraldehyde
A. Caraty; INRA – French National Institute for 
Agricultural Research, rabbit polyclonal, cat.: AC566, 
RRID:AB_2314709
1:5,000 dilution
nNOS Rat brain nNOS P.C. Emson; Babraham Institute, sheep polyclonal, 
cat. No. nNOS, RRID:AB_2314957
1:5,000 dilution
TH Synthetic peptide corresponding to
amino acids 32 – 47 of rat TH
Millipore, rabbit polyclonal, cat. No. AB5986, 
RRID:AB_92190
1:5,000 dilution
β-Endorphin Synthetic human β-endorphin coupled
to keyhole limpet hemocyanin by a 
carbodiimide linker




















   
   
   
   
   
   
   
   
   
   
   
























ed with biotinylated donkey anti-sheep IgG (1: 500, Vector Labo-
ratories Inc.), followed by incubation with streptavidin AlexaFlu-
or488 (1: 1,000, Molecular Probes, Invitrogen) then a 2-min 
Hoechst nuclear label (1: 100, Hoechst 33258, Sigma-Aldrich). For 
each label, negative controls were obtained by omitting the pri-
mary antibody. In some experiments, a blue fluorescent Hoechst 
counter-stain was used to aid in identifying individual cells (blue 
label is not shown on representative images). 
 Confocal Microscopy 
 To detect specific immunoreactivity and endogenously ex-
pressed tdTomato fluorescence, confocal z-stacks were obtained 
using a Zeiss710 confocal microscope or a NikonA1R confocal mi-
croscope. Using the Zeiss710, image stacks of the unilateral ARN 
were collected at 20× magnification with 2.12-µm z-intervals from 
two representative slices in the rostral, middle, and caudal ARN 
(rARN, mARN, cARN) of each animal. For each phenotype la-
bel, one representative high-power image stack from the rARN, 
mARN, and cARN was taken at 40× magnification with 2× digital 
zoom for representative purposes. Tissue labeled for nNOS was 
imaged using a NikonA1R confocal microscope, at 40× magnifica-
tion with 2-µm z-intervals. 
 Analysis 
 Images collected using the Zeiss710 microscope were analyzed 
using ImageJ software (version 1.48, National Institutes of Health, 
USA), while images collected using the NikonA1R microscope 
were analyzed using Nikon NIS Elements software (version 4.0, 
Nikon Instruments Inc.). The numbers of cell bodies expressing 
tdTomato (GABA neurons) and single- or double-labeled cells
expressing phenotype markers (kisspeptin/β-endorphin/NPY/
nNOS/TH) were quantified within the field of view (a unilateral 
hemisphere of the ARN) in each confocal stack by a researcher 
blinded to treatment group. Percentages of phenotype-labeled 
cells co-expressing tdTomato (GABA) and percentages of tdTo-
mato-expressing (GABA) cells co-labeled with phenotype markers 
were determined. Statistical analysis was performed using PRISM 
software (GraphPad). Differences in mean co-expression of tdTo-
mato and each respective label between male, control female, and 
PNA female groups were compared in each region of the ARN us-
ing a two-way ANOVA, with specific differences detected by a 
Tukey’s multiple comparison’s test. All data are presented as mean 
± SEM. A  p value of  ≤ 0.05 was considered statistically significant.
 Results 
 Identifying ARN GABA Neurons and Co-Expressed 
Signals 
 Endogenous tdTomato reporter expression  of VGaT 
was detected in neuronal cell bodies throughout the ARN 
( Fig. 1 ). VGaT/tdTomato reporter expression was found 
abundantly throughout the rostral to caudal extent of the 
ARN, and found densely packed in the ventromedial as-
pect of the ARN. Immunofluorescence for each signaling 
molecule marker investigated (kisspeptin, β-endorphin, 
NPY, TH, and nNOS) was detectable in distinct cell bod-
ies and fiber processes ( Fig. 1 ). Primary antibody omis-
sion resulted in a complete absence of labeling in specific 
neuronal structures in every co-labeling experiment.
 Average counts of total ARN neurons positive for 
VGaT/tdTomato reporter expression and each immuno-
reactive marker is shown in  Figure 2 . Total VGaT/tdTo-
mato reporter-positive cells counted across experiments 
were not different between groups or throughout the 
ARN ( Fig. 2 a), nor were kisspeptin ( Fig. 2 b) or β-endor-
phin-ir cells ( Fig. 2 c). Conversely, two-way ANOVA in-
dicated an overall effect of sex and treatment on the total 
number of NPY-ir cells ( Fig.  2 d; F(2, 66) = 11.68,  p < 
0.0001), TH-ir cells ( Fig. 2 e; F(2, 35) = 11.43,  p = 0.0002), 
and nNOS-ir cells ( Fig. 2 f; F(2, 42) = 7.3,  p = 0.0019). Spe-
cifically, the number of NPY-ir cells was higher in males 
compared with VEH females ( p = 0.0242) in the rARN, 
and higher in males compared with both VEH- ( p = 
0.0006) and PNA-treated ( p = 0.0192) females in the 
mARN. The average number of TH-ir cells was lower in 
males compared with PNA-treated females ( p = 0.0098) 
in the rARN, and higher in PNA-treated females com-
pared with both males ( p = 0.002) and VEH-treated fe-
males ( p = 0.0233) in the mARN. The total number of 
nNOS-ir cells detected in males was significantly lower 
than PNA-treated females, but not different to VEH fe-
males in the caudal ARN.
 Very Limited Co-Localization of Kisspeptin and 
β-Endorphin-ir in ARN GABA Neurons 
 Kisspeptin-ir neurons were detected in a scattered dis-
tribution throughout the ARN ( Fig. 1 a,  2 a). β-Endorphin-
ir cells were more numerous than kisspeptin ( Fig. 2 b), but 
also found in a scattered distribution ( Fig. 1 b). Amongst 
both populations of cells, co-localization with VGaT/td-
Tomato-expressing neurons was rarely detected ( Fig. 1 a, 
b,  3 ). In males ( n = 4), less than 1% of VGaT neurons were 
co-localized with kisspeptin-ir throughout the ARN 
 Fig. 1. Signaling molecule immunoreactivity and VGaT-tdTomato 
expression throughout the ARN. Representative confocal z-stacks 
(6.36 µm thickness) of kisspeptin ( a ), β-endorphin ( b ), NPY ( c ), 
TH ( d ) and nNOS ( e ) (green) immunoreactivity with tdTomato 
expression (red) throughout the rostral, middle, and caudal re-
gions of the ARN. Scale bars = 50 µm.  Insets High-power z-stacks 
(5.12 µm thickness) corresponding to the areas highlighted in ( a–
e ), with open arrowheads indicating single-labeled immunore-
active neurons, and filled arrowheads indicating double-labeled 
cells. Scale bars, 10 µm ( a–d ) and 5 µm ( e ). 3V, third ventricle; 
ARN, arcuate nucleus; c, caudal; m, middle; nNOS, neuronal nitric 
oxide synthase; NPY, neuropeptide Y; r, rostral; TH, tyrosine hy-
droxylase; VGaT, vesicular GABA transporter. 
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( Fig. 3 a). Similarly low co-expression was detected in fe-
males ( n = 4) in the rostral and middle regions of the 
ARN. Two-way ANOVA indicated an overall effect of sex 
throughout the ARN (F(1, 18) = 13.14,  p = 0.0019) with 
co-localization statistically higher in females than in 
males in the caudal ARN (Tukey’s multiple comparisons, 
 p = 0.0053). Approximately 10–15% of ARN kisspeptin 
neurons were identified as GABAergic ( Fig. 3 b). An over-
all effect of sex was indicated by two-way ANOVA (F(1, 
18) = 5.437,  p = 0.0315); however, post hoc  analysis de-
tected no specific differences between males and females 
in any region of the ARN.
 Throughout the ARN, the percentage of VGaT/tdTo-
































































































































 Fig. 2. Average number of neurotransmitter- or enzyme-immuno-
reactive cells across the ARN. The mean total number of cells 
counted within each coronal section expressing tdTomato (indi-
cating VGaT-expressing GABA neurons), kisspeptin ( a ), β-en-
dorphin ( b ), NPY ( c ), TH ( d ) or nNOS ( e ) VGaT ( f ), immunore-
activity throughout the ARN. ARN, arcuate nucleus; c, caudal; ir, 
immunoreactive; m, middle; nNOS, neuronal nitric oxide syn-
thase; NPY, neuropeptide Y; PNA, prenatal androgen-treated; r, 
rostral; TH, tyrosine hydroxylase; VEH, vehicle-treated; VGaT, 
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was also very small (less than 1%) and not different be-
tween males ( n = 4) and females ( n = 5) in the rostral, 
middle or caudal regions (F(1, 21) = 0.0043,  p = 0.9485). 
Likewise, the percentage of β-endorphin neurons ex-
pressing VGaT/tdTomato was very low ( Fig. 3 d) and not 
different between males and females in any part of the 
ARN (F(1, 21) = 0.0018,  p = 0.9669).
 GABA and NPY Are Highly Co-Expressed in the ARN  
 NPY-ir neurons were mainly confined to ventrome-
dial regions throughout the ARN ( Fig. 1 c), and a high de-
gree of co-localization with VGaT/tdTomato ( ∼ 33%) was 
identified at higher magnification ( Fig. 1 c inset). No dif-
ferences in the percentage of VGaT/tdTomato neurons 
expressing NPY ( Fig. 4 a) were found between males ( n = 
5), and VEH ( n = 6) or PNA-treated ( n = 4) females in any 
area of the ARN (F(2, 36) = 0.3079,  p = 0.7369). The vast 
majority of NPY-ir neurons were co-labeled with the 
VGaT/tdTomato reporter in all of the groups investigated 
( Fig. 4 b), and there were no differences between groups.
 Co-Localization of TH-ir in ARN GABA Neurons Is 
Sexually Dimorphic  
 Labeling for the rate-limited enzyme TH was used to 
detect ARN GABA neurons that have the cellular ma-
chinery to express dopamine. TH-ir cells were located 
most abundantly in the rostral and middle regions of the 
ARN, primarily in the dorsomedial and ventrolateral ar-
eas of each coronal section ( Fig. 1 d). At high magnifica-
tion, both single- and double-labeled TH-ir neurons were 
visible in both dorsal and ventral regions ( Fig. 1 d, inset). 
Approximately 10–15% of ARN GABA neurons co-local-
ized with TH-ir, and this was not different between males 
( n = 5), VEH-treated females ( n = 6), and PNA-treated 
females ( n = 5) ( Fig. 4 c) in any region of the ARN (F(2, 







































































 Fig. 3. Percentage of co-localization of kisspeptin and β-endorphin 
with VGaT in male and female mice. The mean percentage of 
VGaT neurons co-localized with kisspeptin ( a ) as well as the per-
centage of kisspeptin neurons co-localized with VGaT ( b ) was cal-
culated in males (n = 4, black bars) and females (n = 4, white bars). 
The mean percentage of VGaT neurons co-localized with β-en-
dorphin ( c ) as well as the percentage of β-endorphin neurons co-
localized with VGaT ( d ) was calculated in males ( n = 4) and fe-


















   
   
   
   
   
   
   
   
   
   
   
























 The percentage of TH-ir neurons expressing VGaT/
tdTomato ( Fig. 4 d) was consistently higher in males than 
either female group (F(2, 35) = 41.51,  p < 0.0001). In the 
rostral ARN, the percentage of TH-ir cells expressing 
VGaT/tdTomato was significantly higher in males com-
pared to both VEH-treated ( p = 0.0001) and PNA-treated 
( p = 0.0246) females. This was also the case for the middle 
ARN, with the proportion of TH-ir GABA neurons high-
er in males compared to VEH-treated ( p = 0.0002) and 
PNA-treated females ( p = 0.0227), and the caudal ARN, 
with male levels elevated compared with VEH-treated
























































































































 Fig. 4. Percentage of co-localization of NPY, TH, and nNOS with 
VGaT in males as well as VEH-treated and PNA-treated females. 
The proportions of co-localization relative to the total population 
of cells immunoreactive for each neuropeptide/neurotransmitter/
enzyme were assessed in males, VEH-treated females, and PNA-
treated females throughout the regions of the ARN. The percent-
age of VGaT neurons co-localized with NPY ( a ), TH ( c ), and 
nNOS ( e ) is shown, as well as the percentage of neurons immuno-
reactive for NPY ( b ), TH ( d ), and nNOS ( f ) that co-localize with 
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 GABA and nNOS Co-Expression Is Sexually 
Dimorphic in the ARN  
 Cells immunoreactive for nNOS were found scattered 
throughout the rostral to caudal extent of the ARN 
( Fig. 1 e), with both single- and double-labeled cells de-
tected ( Fig. 1 e, inset). Approximately 10% of ARN GABA 
neurons co-localized with nNOS-ir in both female groups, 
and this was significantly lower in males ( Fig. 4 e). Two-
way ANOVA indicated an overall effect of sex and treat-
ment (F(2, 42) = 12.87,  p < 0.0001) in the percentage of 
VGaT/tdTomato neurons co-localized with nNOS-ir 
throughout the ARN in males ( n = 5) and VEH- ( n = 6) 
and PNA-treated females ( n = 6). In the rostral ARN, the 
percentage was lower in males compared with VEH-
treated females (6.66 ± 2.6% vs. 12.3 ± 1.1%) (male vs. 
VEH female:  p = 0.0316) but not PNA-treated females 
(9.91 ± 1.3%). Similarly, in the middle ARN, the percent-
age was lower in males compared to VEH-treated females 
(6.43 ± 1.8% vs. 12.5 ± 1.4%) (male vs. VEH female:  p = 
0.0204) but was not different to PNA-treated females 
(10.6 ± 1.8%). In the caudal ARN, the percentage in males 
was lower compared with both VEH- and PNA-treated 
females (2.70 ± 0.7% vs. 9.34 ± 1.1 vs. 9.32 ± 1.2) (male vs. 
VEH female: p = 0.0101; male vs. PNA female:  p = 0.0104).
 The percentage of nNOS-ir cells co-localized with 
VGaT/tdTomato in the ARN was approximately 20% in 
males, 50% in VEH-treated females and 43% in PNA-
treated females ( Fig. 4 f). Two-way ANOVA showed an 
overall effect of sex and treatment (F(2, 42) = 32.12,  p < 
0.0001), with post hoc analysis revealing a significantly 
lower percentage of nNOS-ir cells positive for VGaT/td-
Tomato in males compared to VEH- and PNA-treated 
females in the rARN (male vs. VEH female:  p < 0.0001; 
male vs. PNA female:  p = 0.0135), in the mARN (male vs. 
VEH female:  p = 0.0014; male vs. PNA female:  p = 0.0049), 
and in the cARN (male vs. VEH female:  p < 0.0001; male 
vs. PNA female:  p = 0.0009) ( Fig. 4 d).
 Discussion 
 This study describes and quantifies the co-localization 
of specific neuropeptides and neurotransmitters in 
VGaT/tdTomato-positive GABA neurons residing in the 
ARN of male, control female, and PNA female mice 
(summarized in  Fig.  5 ). A VGaT-ires-Cre/tdTomato 
transgenic mouse was employed to clearly identify neu-
rons in the ARN that use GABA neurotransmission  [24] . 
This approach overcomes the difficultly of assessing 
GABA neurons in the hypothalamus with immunolabel-
ing of GAD enzymes or in situ hybridization and made it 



























 Fig. 5. Summary of neuropeptides and enzymes co-localized with 
GABA in the ARN. Schematic diagrams representing the male 
(left) and female (right) ARN. Each bubble represents the total 
population of the cell type labeled, with filled regions indicating 
the mean proportion of co-localization in the middle ARN for each 
cell type. The right hemisphere on each diagram represents the 
total GABAergic population in the middle ARN and the relative 
proportion of that population that co-localizes with kisspeptin, 
β-endorphin, NPY, TH, and nNOS. The left hemisphere repre-
sents the total kisspeptin-, β-endorphin-, NPY-, TH-, and nNOS-
immunoreactive population, and the proportion of each popula-
tion that co-localizes with GABA. The size of each bubble repre-
sents the population size of each marker/signaling molecule. ARN, 
arcuate nucleus; β-endo, β-endorphin; GABA, γ-aminobutyric 
acid; kiss, kisspeptin; nNOS, neuronal nitric oxide synthase; NPY, 
neuropeptide Y; PNA, prenatal androgen; TH, tyrosine hydroxy-


















   
   
   
   
   
   
   
   
   
   
   
























with immunohistochemical identification of markers of 
interest, including kisspeptin, NPY, TH, β-endorphin, 
and nNOS. Prior colchicine treatment ensured that neu-
ropeptides were detectable in neuronal cell bodies. The 
distribution patterns reported here for GABA and other 
neuronal markers are similar to mRNA expression pat-
terns previously reported by the Allen Brain Institute 
(http://www.brain-map.org), and our findings are in line 
with previous reports of the immunoreactive detection of 
kisspeptin  [32] , NPY  [33, 34] , TH  [34, 35] , β-endorphin 
 [35] , and nNOS  [36] in the mouse. In conjunction with 
the previously reported characterization of these antisera 
and the absence of labeling in primary antibody omission 
controls here, these data support our ability to accurately 
identify the neuronal expression of these peptidergic, cat-
echolaminergic, and gaseous neurotransmitters in the 
mouse brain.
 Co-localization of kisspeptin and β-endorphin with 
VGaT/tdTomato-reporter was extremely small, com-
prising roughly 1% of the ARN GABA population. Evi-
dence of GABA transmission was found in approximate-
ly 10–15% of the ARN kisspeptin neurons and in less 
than 5% of the β-endorphin-ir neurons, and this was not 
different between sexes. The proportion of GABAergic 
kisspeptin neurons identified here was similar to a previ-
ous report identifying GABA by VGaT expression  [37] , 
but significantly less than the 50% co-expression that was 
identified through co-localization of GAD-67 mRNA 
with reporter expression of kisspeptin  [38] . Immunode-
tection of kisspeptin neurons in the ARN is notoriously 
difficult, even with colchicine, and therefore GABA co-
expression proportions here may underrepresent the full 
ARN kisspeptin population. Nevertheless, optogenetic 
studies have recently shown that target actions of ARN 
kisspeptin input are predominantly glutamatergic as op-
posed to GABAergic  [39, 40] . Kisspeptin is a potent and 
critical regulator of GnRH neurons  [41] , and there is an 
ongoing hypothesis that the ARN kisspeptin population 
is involved in mediating gonadal steroid hormone nega-
tive feedback to GnRH neurons  [42] . While there is no 
question that ARN kisspeptin neurons are involved in 
driving GnRH/LH release  [43] , the present data suggest 
that ARN kisspeptin neurons are almost entirely distinct 
from the previously reported ARN GABA neurons that 
send dense, plastic projections to the GnRH neuron cell 
bodies  [15] . This is in line with evidence demonstrating 
that ARN kisspeptin neurons do not project to GnRH 
neuron cell bodies in the rostral forebrain, and are more 
likely to regulate GnRH neurons at dendronic or termi-
nal levels  [44] .
 β-Endorphin labels POMC neurons, well known for 
their role in the regulation of food intake behavior and 
metabolism  [45] . The cleavage products of POMC, in-
cluding β-endorphin and α-MSH, and highly co-ex-
pressed cocaine and amphetamine-regulated transcript, 
have all been shown to have direct but limited effects on 
GnRH neuron excitability  [46] . The present findings sug-
gest that the majority of POMC neurons do not express 
VGaT and can be ruled out as a co-transmitter in ARN 
GABA neurotransmission to GnRH neurons. However, 
there is good evidence that ARN POMC neurons release 
and signal with the neurotransmitter GABA and that ap-
proximately 40% on POMC neurons express the GAD 
enzymes  [47] . Therefore, there is clearly a small popula-
tion of ARN neurons that are GABAergic but do not nec-
essarily require VGaT. Our data are specific for those 
ARN GABAergic neurons that express VGaT and do not 
necessarily represent the entire population of GABAergic 
neurons in the ARN.
 NPY was by far the most abundantly co-localized neu-
rotransmitter in ARN GABA neurons, and this propor-
tion did not vary between groups. The present study 
found that NPY-ir neurons make up one-third of the 
ARN GABA population, and that NPY-ir neurons are al-
most entirely GABAergic. These findings are similar to 
those in the rat, where co-localization with glutamic acid 
decarboxylase, a rate-limiting enzyme for GABA produc-
tion, identified at least one-quarter of GABA neurons ex-
press NPY  [48] . There is long-standing functional and 
anatomical evidence that ARN NPY neurons use GABA 
neurotransmission in the regulation of circuits mediating 
food intake behavior  [49] , and more recent approaches 
suggest that co-released GABA actions at postsynaptic 
targets are essential for normal feeding behavior  [3, 4, 50] . 
Although the co-expression of GABA in virtually all NPY 
neurons is well accepted, the present study defines, for the 
first time, the specific proportion of ARN GABA neurons 
that co-localize and presumably co-release NPY in the 
mouse. Of interest, NPY cell counts were significantly 
greater in males than either female group in the present 
study. Although sexually differentiated expression of 
NPY has not been reported previously in the mouse, NPY 
content near GnRH somata is reported to be elevated in 
masculinized female rats  [51] . NPY neurons are known 
to project to GnRH neurons, and NPY boutons in contact 
with GnRH neurons demonstrate asymmetric synapses 
suggestive of GABAergic neurotransmission  [52] . The 
majority of GnRH neurons are modulated directly by 
NPY, and NPY has complex effects on GnRH neuron ex-
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 A large proportion of TH-expressing neurons were 
identified here as GABAergic (50–75%), and TH-positive 
neurons were identified in roughly 10–15% of ARN 
GABA neurons. These findings are in agreement with
recent optogenetic studies showing that stimulation of 
ARN TH-expressing neurons results in GABA currents 
in neighboring neurons  [2] . TH labeling identifies both 
dorsal A1 tuberoinfundibular dopamine (TIDA) neurons 
and ventrolateral A12 growth hormone-releasing hor-
mone neurons that do not contain dopamine  [2] . GABA 
co-expression patterns appeared similar across both dor-
sal and ventral populations, suggesting similar co-expres-
sion proportions for both TIDA and A12 neurons. Dopa-
mine has been shown to have potent inhibitory effects on 
GnRH neuron excitability  [53] , and there is substantial 
ultrastructural evidence for dopamine synaptic inputs
to GnRH neurons  [54–56] ; however, it is questionable 
whether this input arises from the ARN  [57] . Interest-
ingly, the present study found that TH-positive neurons 
in males were more likely to be GABAergic than in fe-
males, a sex difference that has not been previously re-
ported in the ARN.
 Although previous studies have identified co-expres-
sion of nNOS and GABA in the hippocampus and olfac-
tory bulb  [58, 59] , this is the first study to identify co-ex-
pression of nNOS and GABA in the hypothalamus. In 
contrast with ARN GABA/TH neurons, the population of 
ARN GABA/nNOS neurons was significantly lower in 
males compared with either female group. This was large-
ly in the absence of differences in the mean number of 
nNOS-ir cells between groups, suggesting that only the 
cell population co-expressing GABA and nNOS in the 
ARN is sexually dimorphic. Preoptic area nitric oxide-
producing neurons are known to play a role in the control 
of reproductive function [for review see  60 ], but the spe-
cific role of ARN nNOS neurons remains undefined.
 No differences were identified in GABA co-expression 
patterns in the PNA female group compared to males or 
control females, suggesting that these proportions remain 
unaltered by androgen signaling in late pregnancy. It was 
identified, however, that ARN dopamine neuron number 
is significantly elevated in this model of PCOS. Altered 
hypothalamic dopamine tone has been previously report-
ed in women with PCOS  [61] ; however, the specific role 
of ARN dopamine neurons in the PCOS phenotype and 
in the regulation of reproductive function remains to be 
determined. Intriguingly, there is evidence for deranged 
NPY signaling  [62, 63] in women with PCOS, and expres-
sion of agouti-related peptide in ARN NPY neurons is 
significantly elevated in a sheep model of PCOS  [64] . Al-
though we found no evidence of altered NPY expression 
or co-expression in PNA animals, due to the large co-
expression between NPY and GABA it will be of interest 
to determine whether NPY/AgRP-expressing GABA pro-
jections to GnRH neurons are altered in the PCOS-like 
condition. The current study did not investigate the co-
expression of VGaT-tdTomato reporter with kisspeptin 
or β-endorphin in PNA females given the very low co-
expression found in males and females. While we can-
not rule out that the co-expression of GABA with either 
kisspeptin or β-endorphin changes in PNA animals, it 
would be surprising given the lack of changes detected in 
the total number of GABA neurons and other phenotyp-
ic subpopulations.
 The distribution of nNOS-ir, NPY-ir, and TH-ir cells 
throughout the ARN suggest no overlap between these 
populations, in line with previous findings  [65, 66] . This 
suggests that these represent distinct GABA subpopula-
tions that likely make up greater than 55% of the total 
ARN GABA population ( Fig. 5 ). While transgenic report-
er expression for hypothalamic GABA neurons is advan-
tageous to alleviate the need for in situ hybridization and 
provide a robust means to identify co-expressed proteins, 
this particular VGaT-tdTomato reporter is most concen-
trated around the nucleus, posing some challenges in as-
sessing co-localization with cytoplasmic labels. Given this 
technical limitation, and that some GABA signaling neu-
rons are known to lack VGaT, the co-expression propor-
tions reported here may underrepresent the actual pro-
portion of co-labeled GABA neurons.
 It will be important to determine in future studies the 
role of the specific NPY, TH-positive/dopamine, and ni-
tric oxide-expressing GABA subpopulations, and the dis-
tinct contributions of these signaling molecules, in regu-
lating steroid hormone feedback to GnRH neurons in fer-
tile and PCOS-like mice. 
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APPENDIX III: NANOSTRING ASSAY 
QUALITY CONTROL 
	  















Limit of Detection 
QC (Threshold 0.5 
fM) 
3455-
01 8.9 0.99 0.19 1 10.38 
3455-
02 8.9 0.95 0.21 1 23.72 
3455-
03 8.8 0.97 0.2 1 19.75 
3455-
04 7.8 0.98 0.22 1 17.49 
3455-
05 9.1 0.98 0.18 1 21.75 
3455-
06 8.9 0.98 0.19 1 19.33 
3455-
07 8 0.97 0.24 1 20.16 
3455-
08 9.4 0.93 0.22 1 19.03 
3455-
09 8.3 0.93 0.23 1 21.56 
3455-
10 8.6 0.96 0.28 1 25.86 
3455-
11 8.6 0.98 0.22 1 25.03 
3455-
12 9.2 0.97 0.24 1 20.35 
3455-
13 9 0.97 0.22 1 20.85 
3455-
14 10 0.98 0.19 1 19.7 
3455-
15 8 0.98 0.16 1 21.15 
3455-
16 7.7 0.98 0.16 1 13.9 
3455-
17 0 N/A N/A N/A N/A 
3455-
18 7.8 0.98 0.17 1 25.11 
3455-
19 8.2 0.98 0.21 1 21.18 
3455-
20 8.7 0.97 0.21 1 14.76 
3455-
21 9.1 0.98 0.25 1 18.72 
3455-
22 4.3 0.99 0.16 1 21.96 
3455-
23 8.1 0.96 0.18 1 20.36 
3455-
24 9.9 0.98 0.26 1 21.99 
3455-
25 8.3 0.98 0.19 1 23.49 
3455-
26 3.9 0.98 0.23 1 23.98 
3455-
27 8.8 0.98 0.24 1 20.14 















Limit of Detection 
QC (Threshold 0.5 
fM) 
3455-
28 8.6 0.97 0.26 1 21.87 
3455-
29 9 0.98 0.24 1 20.02 
3455-
30 8.5 0.98 0.22 1 28.48 
3455-
31 9 0.97 0.28 1 21 
3455-
32 8.8 0.97 0.23 1 24.95 
3455-
33 7.2 0.95 0.22 1 14.76 
3455-
34 8.8 0.97 0.24 1 17.16 
3455-
35 9.3 0.96 0.24 1 28.54 
3455-
36 8.7 0.97 0.26 1 20.11 
3455-
37 8.1 1 0.17 1 5.75 
3455-
38 9.1 0.99 0.19 1 20.24 
3455-
39 8.5 0.99 0.21 1 26.57 
3455-
40 4.9 0.99 0.15 1 29.19 
3455-
41 8.2 0.99 0.22 1 26.55 
3455-
42 7.8 0.99 0.17 1 15.3 
3455-
43 8.9 0.99 0.24 1 25.2 
3455-
44 8.7 0.94 0.25 1 28.04 
3455-
45 10 0.93 0.18 1 18.4 
3455-
46 9.8 0.94 0.24 0.99 25.49 
3455-
47 8.6 0.98 0.18 1 24.76 
3455-
48 10 0.99 0.2 1 19.09 
3455-
49 9.1 0.99 0.21 1 12.23 
3455-
50 9.3 0.99 0.17 1 16.21 
3455-
51 7.7 0.99 0.16 1 13.97 
3455-
52 7.2 0.98 0.2 1 21.07 
3455-
53 9.5 1 0.16 1 18.81 
3455-
54 6.7 0.99 0.17 1 24.18 















Limit of Detection 
QC (Threshold 0.5 
fM) 
3455-
55 7.3 0.98 0.16 1 20.93 
3455-
56 5.7 0.98 0.13 1 21.5 
3455-
57 8.4 0.99 0.14 1 18.95 
3455-
58 9.8 0.98 0.21 1 14.78 
3455-
59 7.6 0.98 0.18 1 20.4 
3455-
60 9.9 0.99 0.19 1 16.55 
3455-
61 8.8 0.99 0.15 1 9.17 
3455-
62 10 0.99 0.17 1 20.13 
3455-
63 10 0.98 0.19 1 19.18 
3455-
64 8.4 0.98 0.2 1 15.58 
3455-
65 3.2 0.99 0.15 1 18.59 
3455-
66 8.9 0.98 0.18 1 19.06 
3455-
67 8.1 0.98 0.18 1 12.64 
3455-
68 7.1 0.98 0.17 1 10.87 
3455-
69 7.6 0.98 0.18 1 11.95 
3455-
70 7.1 0.98 0.2 1 16.31 
3455-
71 9.2 0.98 0.19 1 18.74 
3455-
72 10 0.98 0.17 1 14.31 
	
